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ABSTRACT
Hyperthyroidism caused by toxic nodular goitre, is the commonest endocrine disease of the
domestic cat. Despite this, little is known about feline thyroid physiology, pathophysiology, nor
the pathogenesis of the disease. Since L-triiodothyronine (T3) is the hormone responsible for the
major clinical manifestations of thyrotoxicosis, investigations are here reported into the hepatic,
renal and thyroidal expression of type 1 iodothyronine deiodinase (IDI), the selenoenzyme
responsible for conversion of L-thyroxine (T4) to T3 in these tissues. Studies were carried out
into the possible role of thyroid stimulating immunoglobulins, selenium status and somatic
mutations of the thyrotropin receptor (TSHR) in the pathogenesis of the disease. Finally, data are
presented on a previously unreported method of presurgical management of the disease using a
combination of potassium iodate and propranolol.
While feline liver and kidney were found to express IDI at similar concentrations, and the feline
enzyme is able to metabolise T4 at a similar rate to that of rats, feline IDI is unusual in that it has
little ability to metabolise reverse triiodothyronine which is the preferred substrate for this enzyme
in rats and humans. Additionally, unlike all other carnivores and omnivores studied thus far, cats
were not found to express thyroidal IDI.
Using feline thyrocytes, Chinese hamster ovary cells expressing human TSHR (JP09) and the
rat thyrocyte cell line FRTL-5, no populations of immunoglobulins were detectable in the sera of
hyperthyroid cats which stimulated cAMP production, displaced TSH binding from its receptor or
induced growth compared to euthyroid cats.
The plasma selenium status of cats from areas with high (Edinburgh and Sydney) and low
(Denmark and Perth) incidences, respectively, of hyperthyroidism was not significantly different
from each other. Cats however, have plasma selenium concentrations and red blood cell
glutathione peroxidase activities which are approximately 10 times that of selenium replete rats
and humans.
In 11 hyperthyroid cats, the DNA for the TSHR region between codons 480 and 640 (the most
common site for somatic mutations in human toxic nodular goitre) was not found to contain any
such mutations.
The mainstay of presurgical treatment for hyperthyroidism is the use of carbimazole, a drug
which is not well-tolerated by approximately 8 per cent of affected cats. A combination of
propranolol and potassium iodate was found to normalise heart rates, serum T3, and to a lesser
extent T4 concentrations in a significant number of cats and may be used as an alternative
presurgical treatment in those cats which cannot tolerate carbimazole.
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1.00 INTRODUCTION
1.01 THE FELINE THYROID GLAND, THYROID HORMONES AND CONTROL
OF THYROCYTE GROWTH AND FUNCTION
a) ANATOMY AND FUNCTION OF THE THYROID GLAND IN CATS.
The cat has two separate thyroid lobes, regarded by anatomists as a single gland, located on
either side of the trachea each covered by a connective tissue sheath. Like in the dog, it is not
usually connected by an isthmus as it is in other species such as humans, equids and bovids
(Dyce, Sack, and Wensing, 1987). The thyroid glands receive their blood supply via the cranial
thyroid artery which arises from the common carotid artery. A caudal or inferior thyroid artery
may also supply the glands but is not present in most cats (Nicholas and Swingle, 1924). There
are four parathyroid glands in cats, a pair associated with each thyroid gland (one internal, one
external for each gland) which share their blood supply with the thyroid glands.
The basic unit of the thyroid gland is the follicle, surrounded by the basement membrane (Capen,
1996). The follicular lumen is filled with colloid which contains thyroglobulin, a large glycoprotein
molecule that is the precursor of all thyroid hormones.
b) GENERAL STRUCTURE OF THYROID HORMONES
The main secretory products of the thyroid gland in rats and humans are L- 3,5,3',5'
tetraiodothyronine (L-thyroxine, T4), L-3-5-3'-triiodothyronine (T3), and L-3-3'-5' triiodothyronine
(reverse T3, rT3). All three are iodinated derivatives of two tyrosine residues coupled by an ether
bond and are known as iodothyronines (Figure 1.01). The phenolic ring is regarded as the outer
ring and the tyrosyl ring is regarded as the inner ring. Reverse T3 differs from T3 as it has only a




c) SYNTHESIS AND SECRETION OF THYROID HORMONES
Little is known regarding the specifics of synthesis, secretion or metabolism of thyroid hormones
in the domestic cat. What is presented here is a review of general concepts of these areas from
studies involving humans and rats.
The functional unit of the thyroid gland is the follicle which is made up of a cluster of follicles
surrounding a colloid filled lumen. Colloid consists mainly of thyroglobulin. This is a high
molecular weight protein synthesised by thyrocytes and exported and stored in the follicular
lumen. Synthesis of thyroid hormones requires iodination of tyrosyl residues on thyroglobulin
followed by coupling of these iodinated derivatives. These reactions take place within the
follicular lumen at the surface of the apical membrane.
Iodide is actively taken up by thyroid follicular cells via a sodium/iodide cotransport system (the
NaV'iodine pump") (Taurog, 1996). This action is stimulated by thyroid stimulating hormone
(thyrotropin, TSH) via activation of a cyclic adenosine monophosphate (cAMP) mediated second
messenger pathway. Iodide is oxidised to a reactive intermediate by thyroid peroxidase (TPO)
before being incorporated onto tyrosine residues of acceptor proteins, mainly thyroglobulin.
lodinated tyrosine residues (monoiodotyrosine [MIT] and diiodotyrosine [DIT]) combine to form
iodothyronines: either T4 or T3. This reaction takes place in the follicular lumen. The reaction
requires the generation of hydrogen peroxide (H202) in high concentrations. The production of
H202 is the rate limiting step in thyroid hormone synthesis when iodine supply is adequate.
Without H202 TP0 has no activity (Taurog, 1996). The thyrocyte is therefore exposed to large
quantities of toxic H202. Production of H202 is increased by the calcium /phosphoinositol (PIP)
cascade but in some animals, cAMP may also be involved (Taurog, 1996). The selenoenzymes
glutathione peroxidase and thioredoxin reductase are important in protecting the thyrocyte
against oxidative damage.
Two DIT residues coupled to thyroglobulin form T4, and the coupling of one MIT and one DIT
form T3 or the biologically inactive isomer rT3.
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Thyroglobulin is then transported back into the follicular cell by pinocytosis to be hydrolysed in
lysosomes, releasing T4 and T3 which pass out of the thyrocyte into the blood stream mainly by
diffusion. Intrathyroidal production of T3 accounts for approximately 20% of circulating T3 in rats
and humans. Most of the iodotyrosines are metabolised in the thyroid by deiodination and iodide
can then be re-used in thyroid hormone synthesis. Small amounts of thyroglobulin are also
released in to the circulation during this process (Figure 1.02).
d) TRANSPORT OF THYROID HORMONES
In humans, thyroid hormones circulate in plasma largely protein bound (99.95 per cent) in order
of affinity, by thyroid hormone-binding globulin (TBG) (the existence of TBG remains in doubt in
cats), transthyretin (TTR)(previously known as thyroxine-binding prealbumin) and albumin
(Chopra, 1996; Beckett and Wilkinson, 1998; Hard, 1998). Less than 0.05 per cent and 0.1 per
cent of T4 and T3 respectively, circulate unbound ('free') in plasma but it is these concentrations
which have biological effects and initiate negative feedback mechanisms (Chopra, 1996).
e) BIOLOGICAL ROLE OF THYROID HORMONES
Thyroxine is the most abundant iodothyronine in thyroglobulin being about 10 to 20 times more
abundant than T3, and 30 to 100 times more abundant than rT3 (Chopra, 1996). Triiodothyronine
is several times more potent, and is less avidly bound in serum, than T4 (Chopra, 1996). The
peripheral deiodination of T4 to T3 is discussed in detail in Chapter 1.01 (g,h and i). Reverse T3
has no metabolic activity and is rapidly deiodinated to 3, 3' diiodothyronine (T2).
Besides T4, T3 and rT3, several other iodothyronines are found in sera. These include three
diiodothyronines (3,3'-T2, 3,5-T2 and 3',5'-T2), two monoiodothyronines (3'-T1 and 3-T1), two
acetic acid residues of T4 (tetrac) and T3 (triac) and the sulphate and glucuronide conjugates of
T4, T3 and rT3 (Chopra, 1996). Cats have poor glucuronidation ability.
Thyroxine acts mainly as a prohormone, although there is still some debate regarding possible
roles in metabolism and the regulation of the thyroid gland. The importance of T4 and T3 is tissue
specific. The brain requires plasma T4 but not T3 for development whilst in the kidney, plasma
3
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T3 and not T4, provides the most important source of T3 acting at nuclear receptors (Beckett and
Wilkinson, 1998). Reverse T3 has been shown to have thyroidal agonistic and antagonistic
activity in different systems. Other iodothyronines including tetrac and triac also have biological
activity, although this is approximately 11 and 21 per cent the calorigenic activity of T4
respectively (Chopra, 1996). However, these two thyroid hormone derivatives are more potent
than T4 in other respects. Tetrac is far more potent than T4 in suppressing TSH release from rat
pituitary cells (Beckett and Wilkinson, 1998) Tetrac and triac are approximately 10 to 20 times
more potent than T4 in stimulating tadpole metamorphosis (Chopra, 1996).
Thyroid hormones enter cells mainly by active transport. Once inside the cell, both T4 and T3
bind to soluble intracellular proteins. The main site of action is the nucleus. Thyroid hormones are
necessary for maintaining the metabolism and level of activity of most organs and ensuring
development of most tissues in the body including the brain (Uyttersport, Allgeier, Baptist et a!.,
1997; Mitchell, Nicol, Beckett etal., 1998).
f) GENERAL CONTROL OF THYROID FUNCTION
Thyroid hormone synthesis and secretion are regulated by extrathyroidal (TSH) and intrathyroidal
mechanisms (Dumont, Maenhaunt, Pison et at., 1991). TSH secretion is modulated by thyroid
hormones via a classical negative feedback mechanism (Uyttersport, Allgeier, Baptist et a!.,
1997). At the level of the pituitary, 50 per cent of the inhibition of TSH secretion occurs by T3
produced from the local monodeiodination of T4 and 50 per cent from circulating T4 (Table 1.01).
The 'thermostat' mechanism of thyroid hormone secretion is the TSH-feedback loop which is
modulated by thyrotropin releasing hormone (TRH) from the hypothalamus (Figure 1.03).
Release of TRH is under the control of poorly understood mechanisms from higher brain centres
(Uyttersport, Allgeier, Baptist et at., 1997).
In most euthyroid animals, the hypothalamic-pituitary-thyroidal axis regulates the control of
thyroid hormone production by extrathyroidal (TSH, deiodinases), and intrathyroidal factors
(extracellular glutathione peroxidase, E-GPX; hydrogen peroxide, H202 concentrations). TSH
results in increased thyroid hormone synthesis and secretion. Negative feedback on the pituitary,
mainly from free T3 (FT3) and free T4 (FT4) reduce TRH secretion. Intrathyroidal regulatory
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mechanisms include the Wolff-Chaikoff effect (the inhibition of thyroidal iodine organification by
excess iodine intake), decreased TSH receptor sensitivity and alterations in ratios of T4 to T3
production (Nagataki and Yokoyama, 1996).
g) METABOLISM OF THYROID HORMONES-THE IODOTHYRONINE
DEIODINASES
The thyroid gland is the sole source of circulating T4 which is regarded largely as a prohormone
and is a precursor to all other iodothyronines. In selenium replete humans and rats,
approximately 20% of circulating T3 originates from the thyroid gland, whilst 80% of T3 in plasma
appears to arise from 5'-mono-deiodination of T4 in a number of tissues especially the liver and
kidney (Silva and Larsen, 1986; Kohrle, 1994; St Germain, 1994). T4 has little biological activity
and requires 5' monodeiodination to produce the metabolically active hormone T3. Thyroid
hormones are metabolised by the sequential removal of iodine atoms from the phenolic (3' or 5'
positions) and tyrosine (3 or 5 positions) rings. Deiodination of T4 and other iodothyronines is
catalysed by the family of iodothyronine deiodinases (ID) all of which are selenoenzymes.
Current evidence suggests that these enzymes provide an autoregulatory role in many tissues to
maintain intracellular T3 in response to altered thyroidal secretion of thyroid hormones (St
Germain and Croteau 1989; Kohrle, 1994). In addition, the deiodinases appear to be of critical
importance during development, ensuring there is a regulated and co-ordinated exposure of
specific tissues to thyroid hormones (St Germain and Galton, 1997; Mitchell, Nicol, Beckett et al.,
1998; Richard, Hume, Kaptein et al., 1998). Three selenoenzymes are involved in the
deiodination of thyroid hormones, namely iodothyronine deiodinase types I, II and III (IDI, IDII,
IDIII). IDI is the major isoenzyme found in liver and kidney and under normal circumstances this
enzyme appears to provide the major proportion of T3 found in plasma.
The categorisation of these three selenoenzymes was originally derived from their tissue
distribution, substrate specificity and sensitivity to propylthiouracil (PTU) and aurothioglucose
(AuG). In recent years, each has been cloned and found to have different sequence homologies
The characteristics of these three enzymes is presented in Table 1.01. The pathways of thyroid
hormone metabolism are illustrated in Figure 1.04. The substrate specificity and kinetic data are
illustrated in Table 1.02.
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The importance of peripheral deiodination in local hormone control is evident from studies which
demonstrate that there are clear tissue differences in the source of T3 which is bound to nuclear
T3 receptors (Table 1.03). In the brain, approximately 80% of T3 residing on the nuclear
receptors appears to arise from deiodination of T4 within this tissue. By contrast, in the kidney,
approximately 90% of nuclear T3 arises from plasma T3 (Silva and Larsen, 1986). Thyroxine
may also undergo 5-monodeiodination in many tissues to yield the metabolically inactive
molecule rT3. The observation that different tissues have widely different thyroid hormone
concentrations appears to suggest that different tissues have different requirements for thyroid
hormones (St Germain and Galton, 1997). It has also been speculated that deiodination plays an
important role in illness where circulating thyroid hormone concentrations are markedly altered.
Deiodination of thyroid hormones thus plays a crucial role in the regulation of T3 supply to both
tissue and blood.
Compared to humans and rats, relatively little is known regarding thyroid hormone metabolism in
cats. A multicompartmental model investigating T4 and T3 metabolism in the cat demonstrated
that the majority of T3 is generated by peripheral metabolism of T4. However, the rate of T3
production appeared to be twice that of the rat and 10 times greater than that reported in humans
(Hays, Broome and Turrel, 1988). There is little reported difference in clearance or metabolism of
thyroid hormones between euthyroid and hyperthyroid cats (Broome, Hays and Turrel, 1987). In
euthyroid and thyrotoxic humans, markedly different thyroid hormone kinetics have been
reported (Rosenthal, 1981).
Non-deiodinating pathways of thyroid hormone metabolism include ether bond cleavage,
metabolism of the alanine side chain, sulfoconjugation, glucuronidation and O-methylation and




Table 1.01: Characteristics of the iodothyronine deiodinases in the rat (Types I, II and III).
Type I Type II Type III
Deiodination site 5 and 5' 5' 5
Reaction kinetics Ping-pong Sequential Sequential
Substrate preference rT3>T4>T3 T4>rT3 T3 (sulphate) >T4












Role Provides plasma T3 Local T3 production
(BAT - plasma T3)
Important roles in
foetal development
Propylthiouracil Inhibits No effect No effect
lopanoic acid Inhibits Inhibits Inhibits
Aurothioglucose Yes No No
Selenoenzyme Yes Yes Yes
Subunit molecular




Hyperthyroidism Increase Decrease Increase
Low T3 syndrome Decreased No change No change











CNS, central nervous system; BAT, brown adipose tissue.
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Table 1.02: Kinetic data of IDI deiodination with various substrates
Substrate Product Deiodination Km* Vmax* Vmax/Km
t4 t3 phenolic 5'-D 2.3 30 13
t4s t3s phenolic 5'-D ND ND ND
t4 rt3 tyrosyl 5-D 1.9 18 9
t4s rT4S tyrosyl 5-D 0.3 526 2020
rt3 3,3'-T2 phenolic 5'-D 0.06 559 8730
rT3S 3,3'-T2S phenolic 5'-D 0.06 516 8600
t3 3,3'-T2 tyrosyl 5-D 6.2 36 6
t3s 3,3'-T2S tyrosyl 5-D 4.6 1050 230
3,3'-T2 3-t, phenolic 3'-D 8.9 188 21
3,3'-T2S 3-T,S phenolic 3'-D 0.3 353 1040
*
Km is expressed in pmol/L and Vmax in pmol/min/mg of protein.
Adapted from Visser, Vanbuuren, Rutgers et at. (1990).
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From Beckett and Arthur (1994)
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i) IODOTHYRONINE DEIODINASE - 1 (IDI)
Type I 5' deiodinase is defined by its substrate specificity and the ability of PTU and AuG to
inhibit catalysis (Leonard and Kohrle, 1996). In rodents, fish and many higher vertebrates, the
highest concentrations of IDI are found in the thyroid followed by the kidney, liver and pituitary
and much lower activities in skeletal muscle, heart, spleen, lung, intestine, lactating mammary
glands, placenta, salivary glands, brain, white adipose tissue, intestines, skin and nucleated red
blood cells (Leonard and Kohrle, 1996). IDI catalyses many reactions such as the outer ring
deiodination (ORD) of T4, producing T3, as well as the clearance of plasma T4 by inner ring
deiodination (IRD) to produce the inactive metabolite, rT3 (Visser, Kaptein, Terpstra et al., 1988).
The site of deiodination by IDI is dependent on the substrate. Thyroxine-sulphate (T4-sulphate)
and T3-sulphate undergo preferential tyrosyl ring deiodination, whereas the non-sulphated
iodothyronines (T4, rT3) and sulphated 3,3'-diiodothyronine (T2-sulphate) undergo preferential
phenolic ring deiodination (St Germain and Galton, 1997).
IDI is expressed in high concentrations in the thyroid of some species such as humans, dogs and
rodents but many animal species including goats, cattle and sheep fail to express the enzyme, or
at least express it at very low concentrations within the gland (Beckett, Beech, Nicol et al., 1993).
In rats and humans, IDI appears to show a substrate preference for rT3, although it can readily
act on T4 (Visser, Kaptein, Terpstra et al., 1988).
The current concept of thyroid hormone metabolism is that circulating hormone is transferred to
the interstitial space, followed by uptake into cells mainly by active transport. The hormone/ID
complex is transported to nuclear receptors where it exerts it thimometic action. Although the
subcellular location of IDI is likely to differ from organ to organ, the enzyme is an integral part of
the cellular membrane. The localisation of the enzyme to a particular subcellular organelle is
largely operational (Leonard and Kohrle, 1996). IDI is often associated with the endoplasmic
reticulum in rat liver, whereas in the rat kidney, a plasma membrane localisation of IDI has been
reported (Leonard and Kohrle, 1996).
Thyroidal IDI activity increases in selenium depletion unlike hepatic IDI activity which is
decreased to approximately 5% of its original value in selenium replete rats (Beckett, Beddows,
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Morrice etal., 1987; Beckett, Russel, Nicol et al., 1992; Beckett, Beech, Nicol et al., 1993; Beech,
Walker, Beckett et al., 1995).
A number of methods have been employed to assay for IDI expression and activity. Expression
of the enzyme is usually assessed with an affinity labelling technique using 125l-bromoacetyl
derivatives of rT3, T3 or T4 (Kohrle, Rasmussen, Ekenbarger et al., 1990; Schoenmakers,
Pigmans and Visser, 1992). Activity is measured by assessing the ability of IDI to metabolise T4
or rT3 in the presence of an active thiol agent such as dithiothreitol (DTT) (Leonard and
Rosenberg, 1978; Visser, and Overmeeren-Kaptein, 1981; Moreno, Berry, Horst et al., 1994). IDI
and IDII show very different sensitivities to inhibition by the addition of PTU and AuG. IDI activity
with rT3 or T4 as substrate is readily inhibited by both these agents, whilst IDII is relatively
resistant to inhibition by PTU or AuG (St Germain, 1994). These inhibitors are thus often used to
indicate which isoenzyme is expressed by tissues (Table 1.02).
Previous studies have suggested that IDI has similar properties in all species investigated. The
main differences reported have been confined to small variations in molecular mass
(Schoenmakers, Pigmans and Visser, 1992), differences in turnover number of approximately
10-fold between species (Santini, Chopra, Hurd et al., 1992; Schoenmakers, Pigmans and
Visser, 1992) and differences in sensitivity to inhibition by AuG (Santini, Chopra, Hurd et al.,
1992). However there have been reported clear species differences concerning the degree of IDI
expression by the thyroid (Beckett, Beech, Nicol etal., 1993; Beech, Walker, Beckett et alA 993).
Kinetic reactions of IDI within and between different species have yielded widely different results.
Some of the reasons for this include failure to measure deiodination under optimal conditions
(substrate, time and pH dependent factors), the use of different co-factors and at different
concentrations, the failure to establish the stability of reaction products and the lack of
appropriate conditions to examine a multisubstrate reaction (Leonard and Kohrle, 1996).
However, despite these variations between laboratories, investigations into differences between
deiodination by different species within laboratories are still valid.
As the removal of iodine atoms is accompanied by the replacement with hydrogen atoms (a
reduction reaction), cofactors are necessary to facilitate this transfer. Early studies demonstrated
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that removal of the cytosolic component from an homogenate decreases IDI activity. The return
of the cytosolic fraction to the microsomal fraction, or addition of NADPH, reduced glutathione,
reduced monothiols or dithiols (such as dithiothreitol) restore activity (Leonard and Kohrle, 1996).
The deiodination reaction mechanism is referred to as a classic "ping-pong" reaction, where the
first half of the reaction involves the removal of an iodine atom and the subsequent formation of
an oxidised enzyme intermediate. The second half of the reaction then involves reduction of the
second substrate by a reduced thiol co-factor enabling the enzyme to enter another deiodinating
cycle (Leonard and Kohrle, 1996). The inhibition of this reaction by PTU and AuG involves the
formation of a catalytically inactive, mixed selenosulfide (Leonard and Kohrle, 1996)(Figure 1.05).
Thiouracils are competitive inhibitors with respect to the cofactors and non-competitive inhibitors
with respect to the substrate (iodothyronines) (Leonard and Kohrle, 1996). A decrease in
concentration of cofactor or increase in concentration of thiouracils results in reduction of Km
(Michaelis constant) and Vmax (the limiting velocity of the reaction) (Leonard and Kohrle, 1996).
Prior to cloning, it seemed that a third 5' deiodinase enzyme existed. It appeared that the liver
and kidney expressed two types of enzymes depending on the concentration of cofactor. When
DTT was used at 20mM, a high Km enzyme (values in the micromolar range) was observed.
When glutathione, or a reconstituted thioredoxin system were used as cofactors, a low Km
enzyme (values in the nanamolar range) was observed (St Germain and Galton, 1997).
However, it was subsequently demonstrated that the rat G21 IDI cDNA encoded for both types of
enzymes depending on the cofactor used (St Germain and Galton, 1997). Therefore, there is
only one IDI enzyme with kinetics that vary considerably, depending on the cofactor used.
The cDNA and mRNA for IDI in humans, dogs, mice, chicks and tilapia have been cloned
illustrating several important features (St Germain and Galton, 1997). The cDNA for IDI encodes
a selenocysteine insertion sequence (SECIS) in the 3' untranslated region of the mRNA (Berry,
Banu, Chen et al., 1991). There are two essential histidines at amino acid residues 158 and 174
(Berry, 1992). The phenylalanine at residue 65 of the human IDI is of critical importance in the
ability of the enzyme to catalyse the 5' deiodination of rT3 and T2-sulphate (Toyoda, Harney,
Berry et al., 1994). The cDNA sequence for IDI is highly conserved except for dog IDI which has
a leucine for phenylalanine substitution at amino acid 65 making it inefficient in catalysing 5'
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deiodination of rT3 and T2 sulphate (St Germain and Galton, 1997). The IDI of tilapia is relatively
resistant to inhibition by PTU and AuG although the structural characteristics responsible for this
difference are unknown (St Germain and Galton, 1997). The selenocysteine residue is critical for
the catabolism of thyroid hormones as site-directed mutagenesis studies confirm by replacing the
selenocysteine residue with a cysteine residue (Berry, Kieffer, Harney et al., 1993).
Sulphation of T3 and 3,3'-T2, but not rT3, markedly enhances the catabolism of these
iodothyronines (Visser, Kaptein, Terpstra et al., 1988; Visser, Vanbuuren, Rutgers et al., 1990;
Rutgers, Heusdens and Visser, 1991). Substitution of the alanine side-chain of T3 and 3,3'-T2
with acetic acid resulting in 3,3',5-triiodothyroacetic acid (TA3) and 3,3'-diiodothyroacetic acid
(3,3'-TA2) enhances deiodination 16- and 3-fold respectively (Rutgers, Heusdens and Visser,
1991). The IRD of TA3 and the ORD of 3,3'- TA2 are further stimulated about 50 times by 4'
sulphation. In fact, TA3-sulphate is the preferred substrate for IDI (Rutgers, Heusdens and Visser,
1991).
ii) IODOTHYRONINE DEIODINASE TYPE 2 (IDII)
IDII is not expressed by liver or kidney, but the enzyme appears to provide an important
intracellular source of T3 in many other tissues including the central nervous system, pituitary,
thyroid and brown adipose tissue of some species including the rat. IDII catalyses only 5'-
monodeiodination, has T4 as its preferred substrate over rT3 and has a sequential mechanism of
reaction, as opposed to the ping-pong mechanism of IDI. Like IDI, IDII has an absolute in vitro
requirement for reduced thiols (Leonard and Kohrle, 1996). The physiological cofactor has yet to
be determined. Like IDI, IDII has a highly conserved TGA selenocysteine codon but for reasons
which are unknown, it is not inhibited by AuG or PTU.
Hi) IODOTHYRONINE DEIODINASE TYPE 3 (IDIII)
IDIII performs only 5-monodeiodination, acts on T3 in preference to T4 and also has an absolute
in vitro requirement for reduced thiols. High concentrations are found in the central nervous
system, placenta and skin. IDIII shares 70% sequence homology with IDI and contains a highly
conserved TGA selenocysteine codon at the active site (Leonard and Kohrle, 1996). In recent
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years, IDIII has been shown to have an important role in the development of the neonate. IDIII
activity is highest in the newborn especially in the brain where it serves to protect the neural
tissue from T3 (St Germain and Galton, 1997). IDIII is also highly expressed in the placenta,
again acting as a barrier to protect the foetus against T4 and T3 (St Germain and Galton, 1997).
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1.02 CONTROL OF GROWTH AND FUNCTION OF THYROCYTES
IN HEALTH
a) THE THYROTROPIN RECEPTOR AND CELL SIGNALLING WITHIN THE
THYROID GLAND
i) Structure of the TSH receptor
Generally, three major types of receptor exist: channel linked, catalytic and G-protein linked. The
TSH receptor belongs to the large family of G-protein linked receptors. These group of receptors
consist of seven hydrophobic transmembrane segments, three extracellular loops, three
intracellular loops, an extracellular amino terminus and an intracellular carboxyl terminus
(Paschke, Parmentier and Vassart, 1994; Uyttersport, Allgeier, Baptist et at., 1997). TSH,
luteinising hormone (LH) and follicle stimulating hormone (FSH) are coupled mainly to the
generation of cAMP through membrane-bound adenylate cyclase (Paschke, Parmentier and
Vassart, 1994). It is estimated to have a non-glycosylated Mr of 82KDa (Ludgate, and Vassart,
1995).
The TSH receptor was first cloned in 1989 (Parmentier, Libert, Maenhaunt, 1989). Although its
sequence is generally quite homologous, TSH receptors vary morphologically between species.
The TSH receptor is encoded by 10 exons which spread over 60 kb on chromosome 14. The
large extracellular domain is encoded by nine exons, whereas the intracellular and extracellular
loops, the transmembrane segments and the C terminus are encoded by exon 10 (Paschke,
Parmentier and Vassart, 1994). The extracellular domain is important for the binding of TSH
(Ludgate and Vassart, 1995) and therefore subsequently the generation of cAMP (Paschke,
Tonacchera, Van Sande et at., 1994) (Figure 1.06). The TSH receptor is characterised by a very
long intracellular N terminal domain and a short third intracellular loop and is very homologous to
both LH and FSH receptors (Uyttersport, Allgeier, Baptist et at., 1997).
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ii) G protein signalling
The TSH receptor is one of almost 2000 G protein-coupled receptors that have been reported.
They are divided into approximately 100 families which are classified according to sequence
homology, ligand structure and receptor function. Significant G protein sequence homology
occurs within families, but between families there is little or no homology. (Ji, Grossman and Ji,
1998).
G proteins are trimers whose function [to transmit signals from transmembrane receptors to
intracellular enzymes and ion channels (liri, Farfel and Bourne, 1998)], depends upon the ability
of the protein to dissociate into an a monomer and By dimer. The dissociation is triggered by the
activation of an associated receptor (Figure 1.07).
All G proteins have seven transmembrane segments with the amino terminus in the extracellular
space, three extracellular loops, three intracytoplasmic loops and a cytoplasmic carboxyl
terminus. Regardless of the subclass of G-protein they commonly promote exchange of GDP for
GTP on the a subunit. The GTP bound a subunit then activates adenylate cyclase. The Gs
protein eventually acts as a GTPase converting GTP to GDP, which terminates the adenylate
activity. A receptor may be coupled to one or more G proteins (Vassart, Desarnaud, Duprez et
at., 1995).
G proteins are classified into many different classes for example, Gs, GiT Gq and G12. The TSH
receptor mainly binds to Gs (leading to cAMP accumulation) although at high concentrations of
TSH, will bind Gq activating the inositolphosphate diacylglycerol cascade (Laurent, Mockel, Van
Sande et al., 1987; Vassart, Desarnaud, Duprez et at., 1995; Dhanasekaran, 1998;
Dhanasekaran, Tsim, Dermott et al., 1998). The classes of some G proteins, their effectors and
actions are listed in Table 1.04.
16
Introduction Chapter 1
Table 1.04: Classification of G-proteins, the action of their effectors and second messenger
activation.
Class Effector function Second messenger
s Stimulates adenyl cyclase t cAMP
i Inhibits adenylate cyclase I cAMP
Opens K+ channels t membrane potential
o Closes Cat+ channels i membrane potential
q Activates phospholipase c TIP3, DAG
t Stimulates cGMP I cGMP
cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanine monophosphate; DAG,
diacylglycerol; IP3, inositol phosphate
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iii) Second messenger systems in the thyrocyte
Second messenger systems transform extracellular signals into intracellular ones. The
importance of each second messenger pathway within the thyroid gland is dependent on the
species involved and the affector being studied. Exposure to, and reactions with, cytokines may
also alter the response of second messenger pathways.
In the thyroid gland, at least three distinct second messenger pathways have been well defined:
(1) the hormone receptor-adenylate cyclase-cAMP protein kinase system, (2) the hormone
receptor-tyrosine protein kinase pathway and (3) the hormone-receptor-phospholipase C
cascade (PIP) (Dumont, Takeuchi, Lamy etal., 1981; Dhanasekaran, 1998) (Figure 1.08).
In all species studied to date (dog, rat, mouse, sheep, pig, bovine, horse and human), TSH and
forskolin (a diterpene compound that activates adenylate cyclase) induce cAMP accumulation
through stimulation of adenylate cyclase via G protein activation (Raspe, Reuse, Maenhaut et at.,
1989). Although TSH increases cAMP accumulation in many species, its effects on thyroid
function, differentiation and proliferation are species-specific. In dog thyrocytes and FRTL-5 cells,
TSH at physiological concentrations will stimulate only the cAMP cascade. At three times these
concentrations, TSH will also activate the PIP cascade through Gq binding (Vassart and Dumont,
1992). In human thyrocytes, TSH activates the cAMP cascade and the PIP cascade at 10 times
the concentration of TSH required for cAMP activation alone (Vassart and Dumont, 1992;
Ludgate, and Vassart, 1995; Uyttersport, Allgeier, Baptist et at., 1997; Hard, 1998). The functions
of TSH in the control of thyrocyte function in different species are therefore species specific. In
thyrocytes where only the cAMP cascade is activated, TSH effects are mediated only through
cAMP, which enhances functional characteristics of thyrocytes including iodide transport,
thyroglobulin synthesis, iodide oxidation and thyroid hormone synthesis within thyroglobulin, and
the endocytosis and digestion of thyroglobulin with release of thyroid hormones (Raspe, Reuse,
Maenhaut etal., 1989; Corvilain, Laurent, Lecomte et ai, 1994). In the human thyroid where TSH
activates both cAMP and PIP, the latter cascade also stimulates iodination and thyroid hormone
synthesis (Vassart and Dumont, 1992; Hard, 1998).
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The non-physiological concentrations of TSH required to stimulate phospholipase activation have
cast doubt over the relevance of this pathway in TSH action. However, it has been shown that
after cAMP activation occurs, the TSH receptor down regulates its cAMP response and
phospholipase activity is increased. In addition, fibroblast growth factor (FGF) causes
downregulation of TSH induced cAMP accumulation (Burrow and Eggo, 1994). There is
therefore, significant cross talk between the tyrosine kinase, PIP and cAMP pathways in
thyrocytes (Burrow and Eggo, 1994; Hard, 1998). In the dog thyrocyte, TSH has not been
demonstrated to activate the PIP cascade, although it activates all classes of G proteins
(Uyttersport, Allgeier, Baptist et a!., 1997; Hard, 1998). There is no present explanation for the
discrepancy between activation of Gqand lack of PLC activity.
TSH leads to a marked increase in protein deiodination in the dog, mouse, and bovine but this
effect is weak in the rat, pig and horse (Raspe, Reuse, Maenhaut et ai, 1989). In all species,
TSH increases thyroid hormone secretion through stimulation of adenylate cyclase and not
through the Ca++ - PIP cascade. However, not all effects of TSH are mediated through cAMP
which may be the consequence of different populations of TSH receptors or effectors
(Uyttersport, Allgeier, Baptist et al., 1997), but is more likely to be the result of different species
affinity for G-proteins that are associated with the TSH receptor (Vassart and Dumont, 1992).
Like other receptors, the TSH receptor down-regulates its response following stimulation by
thyrotropin. Because of the ubiquitous nature of steroid receptors such as the TSH receptor, and
the close similarity of the sequence of steroid hormones, activation of steroid receptors is
sometimes non-specific. For example, stimulation of the TSH receptor can occur with TSH,
human chorionic gonadotrophin (HCG) and LH (Yoshimura, Hershman, Pang et al., 1993).
The thyrocyte is also regulated by several neurotransmitters (noradrenaline through a and (3
receptors, acetylcholine through muscurinic receptors) that modulate adenylate cyclase and or
phospholipase C through their receptors (Dumont, Takeuchi, Lamy et at., 1981). The roles of
neurotransmitters vary between species and a physiological role has yet to be determined
(Uyttersport, Allgeier, Baptist et al., 1997).
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b) CONTROL OF THYROCYTE GROWTH
The development of primary cultures from a number of species has lead to the understanding
that a number of factors influence the growth of thyrocytes (Burrow and Eggo, 1994). Cell growth
can be mediated by receptors that belong to families such as G-protein coupled receptors,
receptor tyrosine kinases, cytokine receptors, cell adhesion receptors and antigen receptors
(Dhanasekaran, 1998).
Proliferation of thyroid follicular cells is controlled by many intracellular cascades with significant
cross talk as described previously. These include cAMP, phorbol-ester-PKC, inositol 1,4,5-
triphosphate (IP3)/Ca27diacylglycerol (DAG), the growth-factor-tyrosine kinases (PTK) and
mitogen activated protein kinases (MAP kinases) that are activated by a distinct group of
extracellular signals and receptors (Ledent, Denef, Cottecchia et at., 1997; Uyttersport, Allgeier,
Baptist et al., 1997). The importance and contribution of each of these pathways is highly
species-specific. Indeed, these signals may differ within the thyroid gland of an animal depending
on the degree of natural heterogeneity of thyroid cells. The cAMP cascade promotes proliferation
and differentiation whilst PKC and PTK promote proliferation and loss of differentiation
(Uyttersport, Allgeier, Baptist et al., 1997).
Thyroid cells grow mainly in adolescence and then slow down to divide approximately five times
during adult life (Dumont, Takeuchi, Lamy et al., 1981) It may be that not all cells divide, and
there may be small subpopulations of cells which slowly divide to replace dying cells. Although
thyrocytes do not divide greatly in adult life they certainly retain the propensity for growth in times
of iodine deficiency (Uyttersport, Allgeier, Baptist et al., 1997) and in the presence of goitrogenic
substances (for example thiouracil, sulfonamides and Brassica species of plants) (Dumont,
Maenhaut, Pison et al., 1991).
i) TSH-induced growth
It is now generally accepted that TSH is one of the major mitogens for thyrocytes. However, It
has not always been possible to demonstrate TSH-induced growth in all species using in vitro
techniques. Whilst the thyrocytes of some species will grow in response to TSH acting primarily
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through the cAMP pathway (Burrow and Eggo, 1994), this effect (at least in vitro) is not
maintained and begins to slow with time, suggesting that the TSH receptor eventually becomes
desensitised to growth but not necessarily other functions (Dumont, Maenhaut, Pison et a!.,
1991; Hard, 1998). Thyrocytes also go some way to controlling the growth of neighbouring
thyrocytes through release of cytokines (Dumont, Maenhaut, Pison et ai, 1991). Thyrocytes can
grow independently of TSH, for example, in anencephalic animals (Dumont, Maenhaut, Pison et
al., 1991). Growth can also be inhibited or enhanced by paracrine or autocrine factors but these
factors have species-specific effects (Dumont, Maenhaut, Pison et al., 1991; Brown, 1995). For
example, the extracellular matrix (ECM) also exhibits controlling effects on growth and may
explain some of the differences in results between laboratories studying growth effects .
TSH is mitogenic for thyrocytes in a number of species (dogs, humans, and rats) and FRTL-5
cells, but not in others (porcine, bovine and ovine) (Ollis, Davies, Munro et al., 1986; Dumont,
Maenhaut, Pison et al., 1991). In those species where it acts as a mitogen, it may do so only in
the presence of other growth factors such as IGF-1 or insulin. The lack of growth stimulation in
response to TSH may be due to inaccessibility of the TSH receptor in in vitro models, lack of an
essential factor in the culture medium, lack of growth potential in cell preparations or true
unresponsiveness to TSH.
ii) EGF-induced growth effects
EGF acts through its own receptor (EGFR) via an independent, tyrosine kinase second
messenger system. It is known to influence the growth and function of most mammalian cells
(Nilsson, 1995). It is likely that the majority of its actions are mediated in a paracrine or autocrine
manner (Nilsson, 1995; Hard, 1998). EGF is mitogenic for human, canine, porcine, ovine, and
bovine thyrocytes in vitro. In addition, in vivo it is mitogenic for thyrocytes in ovids and mice
(Dumont, Maenhaut, Pison et al., 1991). It does not produce growth in FRTL-5 cells as some
strains lack EGF receptors (Burrow, and Eggo, 1994). EGF also results in poor differentiation
and receptor expression and function and inhibits TSH-mediated thyroid functions (Hard, 1998).
In many species, differences occur in thyrocyte response to EGF. In porcine, unlike canine
thyrocytes, EGF increases intracellular calcium accumulation (Raspe, Reuse, Maenhaut et al.,
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1989). EGF also leads to induction of certain oncogenes such as c-fos and c-myc (Raspe,
Reuse, Maenhaut et al., 1989) which are associated with cell proliferation (Brown, 1995).
iii) IGF-I, IGF-II and FGF
IGF-1 stimulates growth in porcine cells. Both IGF-I and II increase growth in ovine and human
thyrocytes, and FRTL-5 cells (Dumont, Maenhaut, Pison et al., 1991). FGF acts through the
tyrosine kinase and phospholipase pathways to induce growth. FGFs have been found to be
produced by FRTL-5 cells and human thyrocytes (Hard, 1998) although FGF is not mitogenic for
human thyrocytes (Burrow, and Eggo, 1994).
It is generally accepted that more than one factor, and more than one intracellular signal, are
responsible for the proliferation of thyrocytes (Tramontano and Villone, 1994). Many of these
effects occur through G-protein signalling (point mutations in the Gas (gsp oncogene)
(Dhanasekaran, Tsim, Dermott et al., 1998) and Ras gene expression, a universal signalling
pathway through which many of the signals that direct cells to divide act (Burrow and Eggo,
1994). In addition, thyrocytes also control their own growth by the release of paracrine factors
such as IGF-I and II, FGF, transforming growth factor-p (TGF-B), glucagon, and IL-6 (Dumont,
Maenhaut, Pison et al., 1991).
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1.03 THYROID STIMULATING IMMUNOGLOBULINS
a) CATEGORIES OF THYROID STIMULATING IMMUNOGLOBULINS
The best example of thyroid disease induced by an autoantigen is Graves' disease. Autoantigens
in Graves' disease are directed against thyroglobulin (Tg), thyroid peroxidase (TPO) and the TSH
receptor. The latter is the primary autoantigen involved in the pathophysiology of the condition
(Davies, 1996). Long-acting thyroid stimulator (LATS) was first reported in 1956 (Adams and
Purves, 1956). Later it was discovered that this stimulus existed in the immunoglobulin (Ig) G
(IgG) fraction and would inhibit TSH from binding to its receptor. Since that time, substantial work
has allowed the subclassification of these immunoglobulins.
Considerable confusion exists regarding antibodies that bind to the TSH receptor, resulting
mainly from the differing nomenclature used by various groups (Ludgate and Vassart, 1995).
Antibodies that bind to the TSHR may not initiate an intracellular signal transduction process. The
four main types of antibodies are: thyroid stimulating immunoglobulins (TSIs) which stimulate the
production of cAMP and are characteristic of Graves' disease, TSH binding inhibitory
immunoglobulins (TBIls) which inhibit the binding of TSH to its receptor, thyroid blocking
antibodies (TBAB) which inhibit the accumulation of cAMP and are the probable cause of
hypothyroidism in some cases of idiopathic myxoedema (Ludgate and Vassart, 1995) and thyroid
growth stimulating immunoglobulins (TGIs). In human Graves' patients, TSIs are sometimes
subclassified into LATS or LATS-protector (LATS-P). LATS stimulate thyroid activity in several
species whereas LATS-P are thyroid stimulators specific for human thyroid tissue (Smith and
Hall, 1974). Graves' IgG is a classic TSI that also has growth promoting activity in vivo and in
vitro depending on the reporter cell used. The role of stimulating immunoglobulins in Graves'
disease is well understood, whilst the role of TSIs or TGIs in forms of 'non-immunogenic'
thyrotoxicosis, such as toxic nodular goitre, are more controversial.
The difference in functional characteristics of these immunoglobulins in Graves' disease may
relate to their molecular binding characteristics allowing activation of specific second messenger
pathways (Davies, 1996). It is possible that a number of non-immunogenic forms of
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thyrotoxicosis have as part of their pathogenesis and/or pathophysiology, the presence of
humoral factors which bind to the TSHR, altering function and/or growth of thyrocytes. These
humoral factors may be endocrine, paracrine or apocrine in nature, initiate the disease, or appear
after the main pathological process has begun.
b) DIFFICULTIES IN INTERPRETING DATA REGARDING HUMORAL
STIMULI FOR GROWTH AND FUNCTION OF THYROCYTES
The difficulties in detecting these humoral stimuli result from several factors which include the
type of disease investigated, the population of patients studied and their iodine status, the cell
reporter systems used, the methods of purification of immunoglobulins, the experimental
conditions and the end point of detection of 'stimulus' (e.g. second messenger, growth
stimulation).
What follows is a brief discussion of the problems in scientific method, and evidence for and
against the presence of a chronic low grade growth stimulator (presumably IgG) leading to the
formation of goitre in humans and felids. Particular attention is paid to growth stimulation.
i) Specificity of cell types
The TSH receptor has low specificity across species and, therefore, different thyroid cell types
(both primary cultures and manipulated cell lines) can be used to infer mechanisms of actions in
other species (Dumont, Takeuchi, Lamy et al., 1981). Immortal cell lines and, perhaps to a lesser
extent primary cell types, have been manipulated and function in an abnormal way when
compared to normal thyroid follicles. The other disadvantage of using immortalised cells are that
they represent an in vitro situation and any mechanism of action must be implied because of the
lack of many other possible contributing growth factors. Additionally, most cell systems employ
monolayer cells, which are not true representations of the three dimensional structure of normal
thyroid tissue (i.e. the follicle).
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ii) Purification of immunoglobulins
The method of purification of immunoglobulins is important for two reasons. Firstly, impurities
(such as IL-1, EGF, and IGF-1) may have some inherent thyroid stimulating activity (Zakarija and
McKenzie, 1987) resulting in false positive results, and, secondly, the immunoglobulin may be
inactivated during preparation causing it to lose its stimulating potential (Brown, Kertiles and
Kleinmann, 1986).
According to Brown, Kertiles and Kleinmann (1986), the most desirable methods for IgG
purification are anion exchange with diethylaminoethyl (DEAE) cellulose or protein A affinity
chromatography, both for their purity of extract and, consequently, inhibition of TSH binding.
However, even protein A affinity chromatography results in elution of IgA and IgM in small
quantities and cannot be considered 100 per cent specific for IgG. Protein G affinity
chromatography may be more specific.
Hi) Thyroid stimulating immunoglobulins and cAMP accumulation as a marker
TSH receptor antibodies (TRABs) prevent TSH binding to its receptor. Various studies have
shown that TRABs positive sera from Graves' patients cause stimulation of adenylate cyclase
assayed by cAMP accumulation (Kasagi, Konishi, lida et at., 1982; Kasagi, Hatabu, Tokuda et
at., 1988). A number of factors affect the sensitivity and specificity of these assay systems and
are discussed in more detail in Chapter 5. Briefly, the degree of stimulation is dependent on the
TRABs titre and whether sera were unpurified, whether immunoglobulins of all classes were
isolated (by polyethylene (PEG) or ammonium sulphate precipitation) or pure IgG was extracted.
The response is also dependent on the cell system used and on the experimental conditions.
Low sodium chloride (NaCi) concentrations increase the sensitivity of the cAMP assay (Kasagi,
Konishi, lida eta!., 1982; Kasagi, Hidaka, Hatabu et al., 1989; Kosugi, Mori and Imura, 1989)
acting through a number of mechanisms as described in Chapter 5.
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iv) Methods to determine growth
The difficulty in interpreting evidence for and against the existence and significance of TGIs lies
in the variability of the methods used to detect them in vitro (Zakarija and McKenzie, 1990). The
methods employed to study growth include [3hl]-thymidine ([3H]-TDr) incorporation into DNA,
mitotic arrest assays, direct cell counting, and cytochemical assays such as Feulgen
densitometry and glucose-6-phosphate dehydrogenase. The variability and insensitivity and non-
specificity of each method has been reported previously (Drexhage, Bottazzo, Doniach et ah,
1980). Major investigations into humoral factors causing growth in non-immunogenic forms of
thyrotoxicosis are summarised in Table 1.05.
The use of [3H]-TDr incorporation into DNA is commonly used as an indicator of cell growth.
Unfortunately this technique is not specifically associated with cell growth alone and can reflect
DNA repair without increase in cell number (Zakarija and McKenzie, 1990). Sources of error
have been reviewed by Maurer (1981) and are summarised below:
The chemical and physical properties of [3H]-TDr
• Impurities that bind to macromolecules within the cytoplasm may lead to false positives if
methods such as autoradiography are used to detect [3H]-TDr incorporation into DNA.
• Radiation from [3H]-TDr can sometimes result in aberrations to the cell and even cell death
without incorporation into DNA, leading to false negative results.
Factors influencing labelling of nuclear DNA
• The most commonly used [3H]-TDr is in the form of [3H]-methyl-5-TDr which can degrade
over periods of days and transfer its methionine group to proteins other than DNA.
• Cells may synthesise DNA at a reduced rate if already in S-phase.
Thymidine incorporation into cells as a marker for cell division, therefore, results mainly in false
positives. The method is useful as a screening test but should be used in conjunction with more
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direct assessment of cell proliferation such as cell counting or cytochemical methods if a growth
response is demonstrated.
Cytochemical assays such as the Feulgen reaction to identify cells in S-phase may be more
sensitive. This assay was developed for use in guinea pig thyroid cells which reach a peak S-
phase activity in 3 to 5 hours (Zakarija and McKenzie, 1990). However, most mammalian cells do
not reach S-phase for 8 to12 hours and division may not be detected.
Wilders-Truschnig, Drexhage, Leb et at. (1990) demonstrated cell growth in FRTL-5 cell lines in
response to purified IgG from human endemic goitre patients, using a mitotic arrest assay. A
mitotic spindle poison was added to cells to accumulate metaphases. These cells were then
stained with Giemsa and cells in metaphase were counted and expressed as an index of mitosis.
This method is more time-consuming but possibly more specific for growth.
A combination of [3H]-TDr incorporation and direct cell counting was used as confirmation of
growth in FRTL-5 ceils by Brown, Keating, Livingstone et at. (1992) following growth stimulation
by purified IgG from the sera of hyperthyroid cats. Of all methods used, it would appear that the
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c) ARGUMENTS AGAINST THE ROLE OF AUTO-ANTIBODIES IN NON-
IMMUNOGENIC HYPERTHYROIDISM
Graves' disease is known to result from the presence of humoral factors which lead to the
stimulation of growth and function of thyrocytes and is regarded as a classic example of an
autoimmune disease. The existence of immunoglobulins which affect thyrocyte growth, but not
function, in diseases other than Graves' disease has lead to much debate and will be
summarised here. These conditions include endemic and sporadic goitre and nodular toxic and
non-toxic goitre. The pathophysiology and pathogenesis of toxic nodular goitre in humans and
cats is discussed in more detail in Chapter 1.04.
i) Human studies
The role of autoantibodies in non-immunogenic forms of thyrotoxicosis (such as Hashimoto's
thyroiditis, toxic and non-toxic multinodular goitre) was investigated by Drexhage, Bottazzo,
Doniach et at. (1980). They confirmed the existence of thyroid stimulating immunoglobulins in
vitro in sera from human patients with Graves' disease and Hashimoto's thyroiditis which
inhibited binding of radiolabeled TSH to its receptor. Later, using nucleic acid cytophotometry
and [3H]-TDr uptake to monitor growth, they failed to show any significant response to sera from
'non-autoimmune thyroid disease' (adenomas and toxic nodular goitre).
Using [3H]-TDr uptake and intracellular cAMP accumulation, Valente, Vitti, Roteila et at. (1983)
demonstrated that TGIs from Graves' disease and Hashimoto's thyroiditis stimulated growth, but
IgG from Graves' disease in remission, nodular goitre, sub-acute thyroiditis or atrophic thyroiditis
did not. They showed that three distinct Graves' disease groups existed: those with potent cAMP
stimulation along with growth promoting activity, those with potent cAMP stimulation but low
grade growth activation and those with potent growth promotion but low level cAMP production.
They speculated that these immunoglobulins could act at different sites of the TSH receptor
selecting for growth or cAMP production independently.
Peter, Gerber, Studer et at. (1986) reported that when nodules from human toxic nodular goitre
patients were transplanted into nude mice, they continued to grow and remain functional. They
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concluded that if humoral stimulants were involved, they were not necessary for the maintenance
of the condition and a continuous potent humoral stimulation, as found in Graves' disease, was
therefore not occurring in toxic nodular goitre. Once transformed, a lack of regulatory control or a
positive stimulus must be exerted in these cells for them to continue to hypersecrete thyroid
hormones.
Evidence for a lack of a regulatory element was suggested by Van Sande, Lamy, Lecocq et at.
(1988), who reported the presence of a protein substrate (20KD) which was phosphorylated in
the presence of TSH in tissue adjacent to nodular tissue but not in nodular tissue from
autonomous thyroid nodules from human patients. They postulated that the absence of the 20KD
protein could represent a lack of a negative controlling element and, hence the development of
autonomy.
ii) Feline studies
Peter, Gerber, Studer et at. (1987), using their model from human studies, transplanted goitres
from cats into nude mice and showed that they continued to grow and remain functional.
Additionally, feline goitre cells behave differently in cell culture compared to normal feline thyroid
tissue. Cells from toxic nodular goitres do not take up and organify 131| in response to TSH, as
occurs in normal thyroid tissue. This suggests an intrinsic alteration at the cellular level which
leads to autonomy (Peter, Gerber, Studer et al., 1991).
Neither Peterson, Livingstone and Brown (1987) or Kennedy, Thoday and Mooney (1989) found
any evidence for the existence of TSIs in cats with hyperthyroidism using FRTL-5 cells and
cAMP accumulation as a marker. Peterson, Livingstone and Brown (1987) measured intracellular
cAMP as an indicator of second messenger stimulation in response to purified IgG from
hyperthyroid cats. This group reported that no rise in cAMP occurred when comparing
hyperthyroid cats to controls, concluding that TSIs were not involved in stimulating intracellular
cAMP, and hence, the disease was not analogous to Graves' disease of humans. Using
unpurified sera from hyperthyroid cats, Kennedy, Thoday and Mooney (1989) also found no
increase in ^11 uptake when comparing hyperthyroid cat sera to sera from healthy feline
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controls in FRTL-5 cells. By contrast, sera from six Graves' patients consistently increased iodine
uptake.
d) ARGUMENTS FOR THE EXISTENCE AND SIGNIFICANCE OF THYROID
GROWTH STIMULATING IMMUNOGLOBULINS IN NON-IMMUNOGENIC
HYPERTHYROIDISM
ii) Human studies
Weiner and van der Gaag (1985) reported the existence of TGIs in a patient with Plummer's
disease (localised thyroid autonomy) and suggested that autoimmune thyroid disease should be
regarded as a spectrum where each patient was unique. This lead to speculation that TGIs exert
a chronic but mild stimulation, perhaps priming the thyrotoxic event or selecting out populations
of cells that have enhanced growth potential.
Similarly, van der Gaag, Drexhage, Wiersinga et at. (1985), using primary cultures of guinea-pig
thyroid and purified IgG, found that TGIs in patients with euthyroid non-endemic goitre stimulated
growth (measured by DNA cytophotometry). However, approximately 10 times more IgG was
required to reach maximal responsiveness when compared to Graves' disease IgG.
ii) Feline studies
Brown, Keating, Livingstone et al. (1992) provided evidence that the serum of some hyperthyroid
cats contained an immunoglobulin that binds to the TSH receptor and stimulated thyroid cell
growth. This group purified IgG using the batch DEAE cellulose method. Sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) confirmed that the preparation was
pure IgG. Using both [^H]-TDr incorporation into DNA and direct cell counting, test sera, as a
group, stimulated FRTL-5 cell growth by a factor of 15 over that from control animals.
Brown's group used two methods to demonstrate that this purified IgG was binding to the TSH
receptor. Firstly, the IgG growth stimulating activity was inhibited completely by the addition of a
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potent TSH receptor blocking antibody from a patient with Hashimoto's thyroiditis. Secondly, the
purified immunoglobulin significantly inhibited binding of ^5| . bovine TSH to porcine thyroid
membranes. No rise in intracellular cAMP was demonstrated, suggesting that another second
messenger pathway, possibly the PIP cascade, may have been responsible for growth.
The majority of these studies in both humans and cats have tested the hypothesis that
stimulatory immunoglobulins bind at or near the TSH receptor and activate it, causing thyroid cell
growth and hyperfunction. Although this is true of the potent TSIs found in Graves' disease and
Hashimoto's thyroiditis, the chronic low grade stimulation produced by immunoglobulins in other
'non-immunogenic' thyrotoxicoses may not be demonstrated by the relatively insensitive or
inappropriate methods so far employed. Furthermore, it is likely that even if there is a role for
TGIs in mitogenesis of cells in non-immunogenic goitrous disease, these are likely to be low




1.04 INTRODUCTION TO FELINE THYROTOXICOSIS
a) GENERAL INTRODUCTION
Feline hyperthyroidism is the most commonly diagnosed endocrine disease of cats (Thoday,
1988; Thoday and Mooney, 1992a) and in some areas appears to be the commonest disease of
old cats per se. The clinical syndrome is well-characterised and documented in the veterinary
literature. Despite cats being the only non-human species to develop spontaneous
hyperthyroidism with any frequency, the close clinical and pathological resemblance to human
toxic nodular goitre has been largely ignored and few investigations into possible causal triggers,
or the pathogenesis of the disease, have been carried out.
After the two initial reports of the condition (Cotter, 1979; Peterson, Johnson and Andrews, 1979)
the prevalence of feline hyperthyroidism increased rapidly, probably beyond what may be
explained by improved awareness of, and diagnostic techniques for, the condition, prompting
suggestions that this may truly be a new disease (Broussard, Peterson and Fox 1995). A
retrospective survey of 500 cats from the Animal Medical Center, New York, from 1970 to 1984
found that less than 2 per cent of cats had gross evidence of thyroid enlargement at post-mortem
examination. The present incidence at the same institution is approximately 3.3 per cent of cats
at post-mortem examination (Broussard, Peterson and Fox 1995) but this increase is likely to be
artificially low as most cats are now successfully treated.
The disease occurs exclusively in middle to old aged cats. The age at presentation varies from 6
years (Hoenig, Goldschmidt, Ferguson et ai, 1982; Peterson, Kintzer, Cavanagh et at., 1983;
Thoday and Mooney, 1992a) to 22 years (Theran and Holzworth, 1980; Theran,1981; Peterson,
Kintzer, Cavanagh et ai., 1983), with a mean age of 12.8 years (Peterson, Kintzer, Cavanagh et
at., 1983) to 13 years (Thoday and Mooney, 1992a). There is no female sex predisposition
(Peterson, Kintzer, Cavanagh et al., 1983; Thoday and Mooney, 1992a) as there is with the three
most common causes of hyperthyroidism (Graves' disease, toxic multinodular goitre and toxic
solitary thyroid nodule) in humans (Toft, Campbell and Seth, 1981).
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Only one epidemiological study has been published investigating risk factors that may be causal
for feline toxic nodular goitre (Scarlett, Moise and Rayl, 1988). There was a significant
association with the disease and exposure to flea sprays and powders, herbicides, consumption
of canned food and an indoor lifestyle. Siamese cats had a ten-fold reduced incidence of the
disease (Scarlett, Moise and Rayl, 1988). Feline immunodeficiency virus (FIV) was studied as a
possible risk factor in a New Zealand study, although no correlation between a positive FIV
status and development of hyperthyroidism was found (Jones, Hodge and Davies, 1995).
b) CAUSAL PATHOLOGY
Two main forms of thyrotoxicosis occur in humans, with Graves' disease accounting for
approximately 60 per cent and nodular and multinodular goitre 30 per cent. The remaining 10 per
cent result from viral thyroiditis, Hashimoto's thyroiditis and other, rarer forms. Despite some
debate over classification of the histological changes in the thyroid of affected cats, 98 to 99 per
cent are reported as "thyroid adenomas (adenomatous hyperplasia)" (Peterson and Becker,
1983). These cases thus closely resemble clinically and pathologically toxic nodular or
multinodular goitre of humans, where adenomatous functioning nodules hypersecrete thyroid
hormones independently of TSH production (Studer and Gerber, 1991). Thyroid
adenocarcinomas do not result in thyrotoxicosis in humans (Braverman and Utiger, 1991). In
contrast to this, although an uncommon disease, feline thyroid adenocarcinoma causes 1 to 2
per cent of cases of feline hyperthyroidism (Peterson, Kintzer, Cavanagh et ai, 1983). Graves'
disease has not been reported in cats although comparable histological changes have been
described (Peter, Gerber, Studer et al., 1986).
c) THYROID AUTONOMY AND THE PATHOGENESIS OF HUMAN TOXIC
NODULAR GOITRE
Given that TSH positively controls the function, expression of differentiation, and growth (in some
species) of thyrocytes, it is not difficult to imagine that somatic mutations of the TSHR or its
coupled G protein activating subunit (GsCC) would result in development of a monoclonal group of
thyrocytes or "toxic adenoma" (Vassart, Desarnaud, Duprez et al., 1995).
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Seventeen such "gain-of-function" somatic mutations have been described in adenomas from
human toxic nodular goitre (Ledent, Parma, Dumont eta/., 1994; Parma, Van Sande, Swillens et
at., 1995; Van Sande, Parma, Tonacchera et a!., 1995; Tonacchera, Van Sande, Cetani et al.,
1996; Tonacchera, Van Sande, Parma et al., 1996; Duprez, Hermans, Van Sande et al., 1997;
Holzapfel, Fuhrer, Wonerow et al., 1997; Parma, Duprez, Van Sande et al., 1997; Uyttersport,
Allgeier, Baptist et al., 1997) 13 of which occur within codons 480 to 640 of the TSHR. Activating
mutations of the TSHR constitute the major cause of adenomas, accounting for about 80% of
cases (Parma, Van Sande, Swillens et al, 1995). The variability in location and frequency of
these mutations is dependent on scientific methods and the population studied (Tonacchera,
Cetani, Van Sande et al., 1996). The most important sites for functional mutations appear to be in
the first and second extracellular loops, the third intracellular loop, and the third, sixth and
seventh transmembrane segments (Parma, Van Sande, Swillens et al., 1995). A particular
mutation of alanine 293 confers a constitutively active receptor. This demonstrates that the wild
type TSHR is kept in a constrained configuration with a low cAMP turnover (Dremier, Delange,
Vassart et al., 1996). Another hot spot for mutation appears to be Phe 631 (Paschke, Van Sande,
Parma et al., 1996). When transfected into COS-7 cells, these TSHR mutations lead to an
increase in TSH-independent cAMP production over wild type (Duprez, Parma, Van Sande et al,
1994; Paschke, Tonacchera, Van Sande et al., 1994; Paschke, Van Sande, Parma et al., 1996).
The mutation thereby increases not the maximal, but the basal, activity of the receptor (Dremier,
Delange, Vassart et al., 1996). This is compatible with the observation that both in vivo and in
vitro, thyroid hyperfunctioning adenomas can be stimulated (to varying degrees) by exogenous
TSH and that in vitro, the ratio of maximally enhanced to basal cAMP is lowered (Dremier,
Delange, Vassart et al., 1996). The mutations do not usually (Van Sande, Parma, Tonacchera et
al., 1995) but may also activate the PIP pathway (Parma, Van Sande, Swillens et al., 1995;
Ledent, Denef, Cottecchia et al., 1997). Mutations in the extracellular loops seem active in this
latter respect. The activation of the receptor is highly individual. Some TSHR mutations appear
maximally activated, whilst others respond similarly to stimulation by TSH compared to that of the
wild type cell.
Mutations of the TSHR and its associated G-protein lead to autonomy from TSH. Other
mechanisms that lead to autonomy, and hence increased function or growth of the thyrocyte,
may result from any factor which leads to increased accumulation of cAMP within the cell. This
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may be caused by increased production or decreased breakdown of cAMP. Autonomy may also
result from non-genetic mechanisms and still be hereditary. This mechanism is known as
epigenicity (Dremier, Delange, Vassart et at., 1996). This occurs when cells secreting autocrine
or paracrine factors lead to increased cAMP accumulation by themselves or neighbouring cells.
As thyrocytes also have a minimal constitutive activity unlike other endocrine cells, an increase in
thyroid mass may also lead to autonomy.
Autonomy leads to hyperfunction only if the volume of adenoma is large enough, and/or the
iodine concentration of the diet is adequate or excessive. A second consequence of autonomy is
decreased sensitivity to the inhibitory effects of iodide. Indeed, administration of iodide to patients
with hyperfunctioning adenoma may sometimes lead to hyperthyroidism (Cooper, 1996).
d) PATHOGENESIS OF FELINE THYROTOXICOSIS
Peter, Gerber, Studer et at. (1987) demonstrated that feline nodular goitres are truly autonomous
when transplanted into nude mice. For this reason, it would appear that a humoral signal is not
important for the continuation of the disease. Thyroid growth stimulating immunoglobulins could,
however, initiate the disease, perhaps by selecting out faster growing or more autonomous
thyrocytes, which eventually reach 'critical mass' when thyroid hormones are produced in excess
of the animal's requirements and thyrotoxicosis then ensues. As in the human literature, the
presence and significance of TGIs has been debated. This has been previously discussed in
Chapter 1.03.
Somatic TSHR mutational analysis in the pathogenesis of feline toxic nodular goitre is described
in this thesis in Chapter 6 and has been published separately (Pearce, Foster, Imrie et a!., 1997).
e) PATHOPHYSIOLOGICAL EFFECTS OF THYROTOXICOSIS IN THE
DOMESTIC CAT
Clinical signs mimic those of human thyrotoxicosis. Most cats exhibit moderate to severe weight
loss despite polyphagia, tachycardia, irritability and restlessness, intermittent vomiting and
diarrhoea, and polydipsia and polyuria (Thoday and Mooney, 1992a). In 88 (Hoenig,
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Goldschmidt, Ferguson et at., 1982) to 98 per cent of cases (Peterson, Kintzer, Cavanagh et at.,
1983; Thoday and Mooney, 1992a), palpable goitre is present. Weight loss, which may be
profound, is caused by a number of pathophysiological mechanisms. There is an intermittent
decreased food intake due to vomiting, rapid gastrointestinal motility leads to malabsorption and
metabolic rate increases as a direct effect of thyrotoxicosis. Behavioural changes such as
irritability, restlessness and aggression are mainly due to increased sympathetic drive. Polyuria
and polydipsia may result from a number of causes including increased metabolic and glomerular
filtration rates (reviewed by Thoday and Mooney 1992a).
As in human thyrotoxicosis, the effects of thyroid hormone excess are expressed in numerous
body systems. Cardiac disease is common and many cats present with tachycardia (a heart rate
of 240 beats per minute or greater), gallop rhythms, arrhythmias and murmurs. Reversible
hypertrophic cardiomyopathy associated with thyrotoxicosis is a common feature. Cats may
present in congestive heart failure (Thoday and Mooney, 1992a). These effects are thought to
result from a variety of mechanisms including interactions between thyroid hormones and the
sympathetic nervous system, direct effects of thyroid hormones on the heart, and a cardiac
response to increased tissue demand for oxygen (reviewed by Thoday and Mooney, 1992a).
Common gastrointestinal tract manifestations include polyphagia with intermittent short periods of
anorexia (Peterson, 1984). Vomiting, diarrhoea, and increased frequency of defaecation
(Peterson, 1982) are seen frequently. Thyroid hormones are thought to have a direct emetic
action on the chemoreceptor trigger zone (Rosenthal, Jones and Lewis, 1976) but other
contributory factors may include rapid overeating (Peterson, Kintzer, Cavanagh et at., 1983) and
increased intestinal motility (Papasouliotis, Muir, Gruffydd-Jones et at., 1993). This may be a
possible mechanism for diarrhoea and increased frequency of defaecation as well as contributing
to the weight loss seen with this disease.
As the effects of thyrotoxicosis are expressed in many body systems, biochemical changes occur
commonly and include elevations in serum alkaline phosphatase (SAP), alanine
aminotransferase (ALT), aspartate aminotransferase (AST), urea and creatinine. ALT is
considered liver specific in cats and the serum increase in hyperthyroidism reflects a mild
hepatopathy due to increased metabolic rate and hepatic lipidosis in these animals. An increase
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in total SAP may reflect elevations in a number of serum iso-enzymes although the bone and
liver iso-enzymes predominate in humans (Thoday and Mooney, 1992a).
f) DIAGNOSIS OF FELINE THYROTOXICOSIS
In most cats, the definitive diagnosis of feline hyperthyroidism rests on the detection of elevated
serum concentrations of circulating total T4 (TT4). Serum total triiodothyronine (TT3)
concentrations are variably elevated. In addition, the T3 suppression test or thyrotropin releasing
hormone (TRH) stimulation test are sometimes used to confirm cases with reference range or
slightly elevated serum TT4 concentrations. TSH assays are not currently available for the cat.
g) TREATMENT OF FELINE THYROTOXICOSIS
Hyperthyroidism requires treatment to prevent severe weight loss and cardiac disease which
may result in fatal cardiac failure. There are currently three therapeutic options for cats with
thyrotoxicosis: long term use of an antithyroid drug, surgical thyroidectomy and radioactive iodine
(,31l) treatment. Management with radioactive iodine is very effective but its use is restricted to
specialised licensed centres only four of which are, at present, available in the U.K. Long-term
medical management often results in inadequate control, frequently associated with poor owner
compliance (Mooney, Thoday and Doxey, 1992). The treatment of choice for most veterinary
practitioners, therefore, is surgical thyroidectomy.
As hyperthyroid cats are poor anaesthetic risks, the induction of euthyroidism by prior short-term
medical therapy dramatically reduces peri-surgical mortality (Peterson, Kintzer, Cavanagh et at.,
1983; Birchard Peterson and Jacobson, 1984; Peterson and Turrel, 1986). The drugs of choice
are carbimazole (CBZ)(NeoMercazole, Roche) available in Europe and methimazole (Tapazole,
Eli Lilly) available in the U.S.A. In both humans (Jansson, Dahlberg and Lindstrom, 1983) and
cats (Peterson and Aucoin, 1993), CBZ is converted to methimazole, by which it exerts its effects
in vivo. Methimazole is subsequently concentrated within the thyroid gland and inhibits thyroid
peroxidase-catalysed reactions, subsequently blocking iodide oxidation, thyroglobulin iodination
and coupling of iodinated residues (Trepanier, 1990). Propylthiouracil (PTU), a pyrimidine from
the thioureylene family, is no longer used in cats due to the high incidence of haematological
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complications (Peterson, Hurvitz, Leib et al., 1984). These drugs do not result in ablation of
thyroid tissue and do not interfere with uptake of iodine by the thyroid gland or the release of
preformed hormones (Kintzer, 1994). For this reason, the hyperthyroid state returns within 24 to
72 hours of drug withdrawal. These drugs are also known to have immunomodulating effects in
humans reducing anti-thyroid antibody titres. As there is no conclusive evidence that there is an
immune component to thyrotoxicosis in cats, the relevance (if any) of immunomodulating effects
by this class of drugs in this species is unknown.
Mild clinical adverse reactions (anorexia, vomiting and lethargy) requiring drug withdrawal occur
with CBZ and methimazole. However, CBZ appears to be slightly better tolerated with a
withdrawal requirement of approximately 8 per cent of treated cases (Mooney, Thoday and
Doxey, 1992) compared with approximately 15 per cent of cases treated with methimazole
(Peterson, Kintzer and Hurvitz, 1988). Mild and transient leucopenia and lymphocytosis, not
requiring drug withdrawal, have been reported in 5 per cent of cats treated with CBZ (Mooney,
Thoday and Doxey, 1992). Additional, potentially life-threatening effects such as
thrombocytopenia and agranulocytosis, have been reported in up to 3 per cent of cats treated
with methimazole (Peterson, Kintzer and Hurvitz, 1988) but, not to date, in cats treated with CBZ.
Other reported adverse effects of methimazole include mild haematological abnormalities
(eosinophilia, lymphocytosis, and slight leucopenia), usually occurring within the first 2 months of
therapy, and the development of positive antinuclear antibodies (ANA) in 16.4 per cent and 21.8
per cent of treated cats respectively. Positive antinuclear antibodies was not associated with the
development of immune-mediated disease.
Other drugs that have been used to treat feline hyperthyroidism include stable iodine (127l), beta-
adrenoreceptor blocking agents, either alone, together or in combination with the thioglyoxalines
(reviewed by Thoday and Mooney, 1992b; Mooney and Thoday, 1999) and calcium ipodate
(Murray and Peterson, 1997).
Stable iodine was the earliest agent used to effectively treat human thyrotoxicosis. Large doses
dramatically decrease thyroid hormone synthesis (the Wolff-Chaikoff effect) by reducing
peroxidase-catalysed organification of iodide (Wolff and Chaikoff, 1948). Thyroid hormone
release is also decreased as a result of inhibition of thyroglobulin endocytosis. Unfortunately, the
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failure of thyroid function of most patients to normalise (Emerson, Anderson, Howard et al., 1975)
and the rapid escape from its inhibitory control (Cooper, 1991) means that iodine cannot be used
as sole therapy for long-term management of thyrotoxicosis. In humans, stable iodine may also
reduce the vascularity and friability of the thyroid gland allowing more easy manipulation at the
time of surgery in patients previously treated with thioureylenes (Chang, Wheeler, Woodcock et
al., 1987) or with beta-adrenoreceptor blocking agents (Feek, Sawers, Irvine et al., 1980) but not
when used alone (Coyle and Mitchell, 1982). It has been previously recommended for this
purpose prior to surgical thyroidectomy in cats (Thoday and Mooney, 1992b).
Pharmaceutical preparations of both potassium iodide and iodine are currently unavailable in the
U.K. Potassium iodate (85mg tablets yielding 50mg free iodine; Cambridge Self-Care
Diagnostics) is now used as the source of stable iodine in human medicine and has the
advantage of a longer shelf-life.
It is currently believed that an excess of thyroid hormones causes an increase in the number of
beta-adrenoceptors or an amplification of the adrenergic signal at the cell membrane level
(Trepanier, 1990) and that many of the signs of hyperthyroidism are due to subsequently
enhanced catecholamine activity with increased sympathetic drive. Thus, the beta-
adrenoreceptor blocking drugs very effectively ameliorate many of these signs and some studies
(Feely and Peden, 1984; Lennquist, Jorsto, Anderberg et al., 1985; Alderberth, Stenstrom and
Hasselgren, 1987) have reported them to be as effective as the thioureylenes in the pre-surgical
management of human patients awaiting thyroidectomy. However, the negative nitrogen balance,
increased cardiac output and elevated rate of oxygen consumption of thyrotoxicosis are seldom
normalised by beta-blockade (O'Malley, Abbott, Barnett et al., 1982) and patients remain
hyperthyroid.
Propranolol, the beta-adrenoreceptor blocking drug most frequently used in hyperthyroid cats,
has been employed as the sole agent for presurgical stabilisation (Carlson, 1986). It is a non¬
selective (3,- and (J2-adrenoreceptor blocking agent with no direct effects on the thyroid gland.
However, like some other beta-adrenoreceptor blockers, propranolol also decreases peripheral
monodeiodination of T4 to T3 (Feely and Peden, 1984). Nevertheless, serum TT3 concentrations
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fall by a maximum of 30 per cent, serum TT4 concentrations are usually unaffected and
euthyroidism is not restored (Lotti, Delitala and Devilla, 1977; Wiersinga and Touber, 1977).
Feek, Sawers, Irvine et al. (1980) showed that a combination of propranolol and potassium iodide
(as a source of stable iodine) induced clinical and biochemical euthyroidism in all 10, human
Graves' disease patients prior to thyroidectomy. In successfully treated patients, both the serum
TT3 and TT4 concentrations fell to their reference ranges within means of 5 and 8 days
respectively. There was also a significant fall before surgery, and a transient rise after surgery, of
rT3. A secondary rise or 'escape' of thyroid hormones was seen in only two (20 per cent) of
patients. The authors suggested that there may be a previously unrecognised synergism
between the drugs and that the combination may be the optimal preoperative preparation for
patients with Graves' disease.
It is clear, therefore, that an alternative method of preparation for surgery is required for a
relatively small percentage, but, because of the high incidence of the disease, a very significant
number, of hyperthyroid cats. In the study described in Chapter 8, two groups were chosen to
examine, initially, the independent action of both propranolol and potassium iodate and
subsequently their combined effect.
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1.05 SELENIUM AND SELENOENZYMES
a) SELENIUM
Selenium was discovered 180 years ago because of its toxicological properties in livestock
(Foster and Sumar, 1997). Most forms of selenium are metabolised to selenite or are further
reduced to selenides (Foster and Sumar, 1997). Animals receive selenium in food as
selenoamino acids (selenomethionine and selenocysteine) and as methylated/nonmethylated
selenium. Selenomethionine and selenocysteine are absorbed across the gut using the amino
acid transport proteins. Organic forms of selenium (e.g. selenomethionine and selenocysteine)
are more readily retained by tissues (Foster and Sumar, 1997), and increase plasma selenium
more quickly and reaches higher concentrations than inorganic forms (selenite and selenate)
(Neve, 1998). In contrast to this, platelet glutathione peroxidase (GPX) activity is increased more
rapidly by inorganic than organic forms of selenium (Neve, 1998). Cellular uptake of selenium
occurs by a number of mechanisms which vary depending on the form of selenium ingested.
Absorption of selenium from the digestive tract is not a limiting factor in bioavailability (Daniels,
1996). It appears that selenium is absorbed better with a high protein diet (Daniels, 1996) but for
unknown reasons, the availability of selenium from absorption in fish, especially tuna, is lower
than other foods (Daniels, 1996).
Selenium is contained in most bodily tissues at an average concentration of 0.2pg/g associated
with tissue proteins either loosely bound or as selenium analogues of sulphur and amino acids
which form selenoproteins (Foster and Sumar, 1997). The first selenoprotein to be identified was
cytoplasmic GPX (cGPX). It functions (with vitamins A, C and E) as a cellular protector against
oxidative damage by catalysing the breakdown of H202 and fatty acyl lipid peroxides in the
presence of reduced glutathione.
Regions of the world with low soil selenium include Denmark, eastern Finland, areas of
northeastern and south central China and parts of the United Kingdom (Aberdeenshire). Less
severe deficiencies occur in areas of Canada, western Australia, New Zealand and the U.S.A.
(Foster and Sumar, 1997).
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b) ASSESSMENT OF SELENIUM STATUS
Measurement of selenium concentration in whole blood or its fractions, and measurement of its
functional action [such as GPX activity in erythrocytes (RBCs)] are the most commonly used
measures of selenium status. Selenium supplementation results in increases in activity of RBC
GPX activity up to a plateau that serves as a measure of the optimal daily requirement (Neve,
1998). Because of this, RBC GPX is of no value in monitoring high intakes of selenium. Only
whole blood or plasma selenium concentrations are reliable for this. The discovery of other forms
of GPX (plasma GPX [p-GPX], phospholipid hydroperoxidase [phGPX] and gastrointestinal) and
other selenoenzymes ID and thioredoxin reductase (TR) may serve as new areas of investigation
regarding the re-assessment of the amounts of selenium required for optimal daily intake (Neve,
1998). Nail and hair selenium status may also be a reasonable indicator of long-term selenium
supplementation. Because of the relatively long half-life of RBCs, plasma selenium concentration
measurements are also far more sensitive than the RBC selenium concentration to acute
changes in selenium status (Neve, 1998). RBC GPX is therefore used to indicate medium-term
selenium status and plasma GPX, short-term selenium status.
Intakes of selenium for humans range from 20 to 30 pg/day in low selenium areas (in Keshan
intake is less than 11pg/day), to in excess of 1500pg/day in high selenium areas. The
recommended daily allowance for selenium intake in humans (55pg/day and 70pg/day for
females and males respectively) may reflect an underestimation of selenium requirement
considering that some functional characteristics of selenium status have not been reached at
these levels of intake (Neve, 1998). At intakes of 800pg/day, discolouration of the nails occurs
(Neve, 1998) and therefore 400pg/day is considered the maximal safe dietary intake.
c) SELENIUM DEFICIENCY
Selenium deficiency has been linked to a number of disease states in humans such as cancer,
muscular dystrophy, malaria, cardiovascular disease (Keshan disease), alopecia areata, and
pregnancy hypertension syndrome (Foster and Sumar, 1997; Ximin, Zhongxi, Wenkang et ah,
1998) as well as increasing the virulence of viruses (Beck, Shi, Morris et a!., 1995). Keshan
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disease is a well-characterised disease of selenium deficiency and is associated with the
development of chronic cardiac insufficiency, cardiomegaly, gallop rhythm and arrythmias.
Increased risk of atherosclerosis has also been associated with selenium deficiency. This has
been postulated to occur through the poor expression of free radical scavenging selenoproteins
which detoxify oxidised lipids (such as low density lipoproteins) and lipid peroxides (Foster and
Sumar, 1997). In animals, selenium deficiency has been associated with white muscle disease in
pigs, and other livestock (Oldfield, 1987). Other diseases reported include pancreatic atrophy in
chickens, and abnormalities of spermatozoa and cataract formation in rats (Oldfield, 1987).
d) SELENIUM TOXICITY
The dietary concentrations required to cause selenium toxicity in animals vary due to the type of
selenium ingested, type of diet and species (Foster and Sumar, 1997). Selenosis in animals can
result in disease of the integument (hoof rot and alopecia). In humans, toxicity has been reported
to induce hair and fingernail loss and peripheral neuropathies (Foster and Sumar, 1997).
e) SELENOENZYMES REGULATING THYROCYTE GROWTH AND
FUNCTION
There is considerable evidence in a number of species to suggest that selenium status may
modify thyroid function and peripheral thyroid hormone metabolism (Delange, 1996; Beech,
Walker, Beckett et al., 1995; Howie, Walker, Akesson et al., 1995). Conversion of T4 to the more
metabolically active hormone T3 is catalysed by the selenoenzyme IDI. Synthesis of T4 may also
be regulated through modified expression of the selenoenzyme E-GPX (Howie, Walker, Akesson
et al., 1995). There is evidence to suggest that expression of certain selenoproteins also appears
to correlate with thyroid cell growth both in vivo and in vitro and protect from oxidative damage
(Howie, Arthur, Nicol et al., 1998).
When there is adequate iodine supply, the rate limiting step in thyroid hormone synthesis is the
amount of H202 present at the apical membrane of the thyrocyte. Degradation of H202 in the
follicular lumen is regulated by E-GPX, and intracellular GPX detoxifies H?02 and thus protects
the thyrocyte from its harmful oxidant effects. It has been suggested that E-GPX is an important
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regulator of thyroid hormone synthesis in the human thyrocyte (Howie, Walker, Akesson et al.,
1995). In humans, stimulation of the PIP pathway increases H202 synthesis and decreases
secretion of E-GPX into the follicular lumen thus leading to increased H O concentrations in this
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space. E-GPX is a glycoprotein which comprises four identical subunits each having a molecular
mass of 24 000 and is functionally, immunologically and structurally different from cGPX. In rats
and humans the major source of E-GPX in plasma is the renal proximal tubules but other tissues
have been identified as excretors such as the placenta and bronchoepithelial tissues (tissues
under high oxidative stress) (Sunde, 1994).
i) Selenium and iodine status reflect thyroidal pathology - endemic goitre
In areas of the world where goitre is described as 'endemic' (greater than 10 per cent of children
are affected), two forms of endemic cretinism (myxoedematous and neurological) exist. In these
areas, the incidence of the disease may be as high as 15 per cent of the population (Delange
and Ermans, 1996). Endemic cretinism is by far the most serious complication of iodine
deficiency (Delange, 1996). Affected individuals have subnormal intellect and physical
development. Myxoedematous cretinism is used to describe severe hypothyroidism and stunted
growth with a low incidence of goitre. Plasma T4 and T3 concentrations are low with an elevated
plasma TSH concentration (Delange, 1996). Neurological cretinism is more common and
describes mental deficiency which may be accompanied by neurological problems including
hearing and speech deficits.
The pathogenesis of cretinism is only partially understood but involves iodine deficiency
(Delange, 1996). Combined selenium and iodine deficiency appears to favour the development of
myxoedematous cretinism. The proposed mechanism for this is that iodine deficiency results in
stimulation of the thyroid by TSH which results in increased production of H202. In addition, there
is a large increase in TSH secretion in the neonatal period which further enhances the production
of H202. Selenium deficiency results in loss of cGPX expression and thus a loss of protection
from the accumulation of H202. The end result is thyroid necrosis and fibrosis (Sunde, 1994;
Contempre', Dumont, Denef et al., 1995; Delange, 1996). There is still some debate about
selenium- and iodine-deficiency being the only factors involved in the pathogenesis of
myxoedematous cretinism as it is not the most predominant form of cretinism in some areas with
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combined deficiency (Moreno, Suetens, Mathieu et al., 1998). During iodine deficiency with
adequate selenium intake, cGPX expression is induced in preference to phGPX. cGPX is much
more efficient in metabolising H202 than other forms of glutathione peroxidase (Mitchel, Nicol,
Beckett et al., 1996).
ii) Thioredoxin reductase
Thioredoxin reductase (TR) is a dimeric selenoprotein comprising subunits of Mr 55 to 60 KDa,
each having a selenocysteine residue near the carboxyl terminus (Holmgren, 1985; Beckett,
Howie, Nicol et al., 1998). Thioredoxin reductase reduces oxidised thioredoxin (a small
multifunction and ubiquitous protein) (TRx-S2) to reduced thioredoxin [TRx-(SH)J using an
NADPH-dependent reaction. Both TR and thioredoxin have been shown to have growth
regulating effects on cells (Berggren, Gallegos, Gasdaska et al., 1996; Gallegos, Gasdaska,
Taylor et al., 1996; Gasdaska, Berggren, Berry et al., 1999). Reduced thioredoxin is a powerful
protein disulphide reductase [e.g. Trx-S2 + NADPH + H+ Trx(SH) 2 + NADP ; Trx(SH) 2+ protein-
S2 o Trx-S2 + protein(SH)J. TR can also detoxify lipid hydroperoxides and hydrogen peroxide
(Beckett, Howie, Nicol et al., 1998).
TR appears to have a greater capacity to detoxify H202 and lipid peroxides than GPX and is
induced by the same second messenger pathways that induce HO production. This may
suggest that one important function of TR (at least in thyrocytes) is to protect the thyrocyte from
oxidative damage from H202. The leucocyte, which produces H_02i does not express TR but has
a short life span, presumably as a result of oxidative damage.
Labelling experiments of human thyrocytes with 75Se-selenite have demonstrated that at least
eight major selenoprotein bands are expressed. Most have a Mr of between 14 and 31 KDa. The
expression of human thyroidal TR has been shown to be increased by PMA and the calcium
ionophore A23187 (Beckett, Howie, Nicol et al., 1998; Howie, Arthur, Nicol et al., 1998).
However, in FRTL-5 cells, PMA has little effect on TR expression, but the addition of PMA and
A23187 produces a marked increase in TR expression. Addition of 8-bromo-cAMP and TSH
have no effect on TR expression in human thyrocytes, suggesting that the calcium-PIP but not
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the cAMP pathway are involved in the regulation of TR expression in humans (Howie, Arthur,
Nicol etal., 1998).
TR also appears to have an important role in cell proliferation. TR has been shown to act as an
intracellular growth factor for both normal and tumour cells in culture (Berggren, Gallegos,
Gasdaska et al., 1996; Gallegos, Gasdaska, Taylor et al., 1996) by activating transcription
factors that lead to cell division (Powis, Gasdaska, Gasdaska et al., 1997). To date, no TR
binding sites have been found on the surface of cancer cells. TR also acts in an autocrine
manner by enhancing the cellular response to other growth factors (Berggren, Gallegos,
Gasdaska et al., 1996; Gasdaska, Kirkpatrick, Monfort etal., 1996; Powis, Gasdaska, Gasdaska
etal., 1997).
Selenium status can also modify TR expression/activity. TR activity is inhibited by high
concentrations of selenite (Bjornstedt, Kumar and Holmgren, 1995) and, in vivo ,TR activity in rat
liver, lung and kidney undergoes transitory increased expression when these animals are fed a
high selenium diet (Berggren, Mangin, Gasdaska et al., 1999). Changes in selenium status may,
therefore, result in altered expression of this enzyme resulting in altered growth characteristics or
changes in detoxifying capacity which may leave them exposed to oxidative damage. This may
be particularly important in the thyrocyte where protection from harmful H202 is particularly
important.
A number of TR enzymes have been sequenced from human placenta (Gasdaska, Gasdaska,
Cochran et al., 1995), Jurkat T cells (Gladyshev, Jeang and Stadtman, 1996) and lung
adenocarcinoma cells (Tamura and Stadtman, 1996), rat neuroblastoma (Zhong, Arner, Ljung et
al., 1998) and bovine liver neuroblastoma (Zhong, Arner, Ljung et al., 1998). Recently, it has
been suggested that multiple forms of TR exist. A novel isoform of TR (named TR-fS) has been
cloned and shown to have 54 per cent identity to previously cloned human TR (Gasdaska,
Berggren, Berry et al., 1999). Similarly, two isoforms of TR from rat liver have also been cloned
and sequenced (Lee, Kim, Kwon etal., 1999).
A number of human primary cancers such as lung, colon, cervical and liver tumours have been
shown to over-express thioredoxin. Transfection with reduced thioredoxin can increase tumour
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growth and inhibit apoptosis (Gasdaska, Berggren, Berry et al., 1999). The thioredoxin reductase
system thus plays an important role in cell growth and death (Gasdaska, Berggren, Berry et al.,
1999).
f) HIERARCHY OF SELENIUM SUPPLY
In rats and humans, the thyroid contains more selenium (per gram weight) than any other tissue
suggesting an important role for the trace element in this organ. There is an important hierarchy
of selenium supply to tissues such that in selenium deficiency, the thyroid, brain and skin retain
the trace element, whilst it is rapidly lost from the liver, kidneys and muscle (Arthur, Nicol and
Beckett, 1993; Beckett, Beech, Nicol et al., 1993; Calomme, Vanderpas, Francois et al., 1995;
Larsen and Berry, 1995). Thyroidal IDI activity is maintained in times of selenium deficiency in
the rat, whilst hepatic IDI activity falls (Beech, Walker, Beckett et al., 1995). In addition, there is
also an important hierarchy of selenium supply to different selenoenzymes within tissues.
Thyroidal cGPX expression diminishes in times of selenium deficiency whereas thyroidal IDI
expression increases (Howie, Arthur, Nicol et al., 1998). This suggests that thyroidal IDI-I has an
important role in the generation of T3 in certain species and this has to be retained in selenium
deficiency.
g) SELENIUM STATUS IN CATS
Concentrations of selenium in some commercial cat foods is recommended at 0.01 to 0.04
mg/400KCal (personal communication 1999, Waltham). The selenium status of domestic cats
has not been previously studied. It is, therefore, difficult to determine if selenium status or
selenoenzymes play a role in feline hyperthyroidism and whether selenium status may be
manipulated in order to prevent this important disease. As high selenium intake can regulate
apoptosis and selenoenzymes such as TR can modify growth of cells, it is possible that the
selenium status of cats may be an important factor in the development of feline thyrotoxicosis.
Because of the marked geographical distribution of hyperthyroidism in cats, it is possible that an
environmental toxin or lack of an environmental or dietary protector (such as selenium), may
result in effects within the feline thyrocyte that lead to autonomy of the thyroid gland and the
disease which we describe as feline toxic nodular goitre. Additionally, selenium has been shown
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to promote apoptosis and it is this mechanism which is thought to be involved in the cancer-
protective effects of this trace element (McCarthy, 1998).
h) IODINE STATUS IN CATS
Whilst daily iodine requirements of cats have been published, they are based purely on
speculation as no specific studies have been conducted. The iodine content of cat food has been
shown to be very variable. Mumma, Rashid, Shane et al. (1986) showed that it could contain up
to 10 times the recommended daily intake, possibly due to the inclusion of thyroid glands from
slaughtered animals. In another study, Johnson, Ford, Tartellin et al. (1992) reported that two
brands of commercial cat food contained excess amounts of iodine whilst nine contained less
than the recommended intake. They speculated that a wide variation in iodine intake may be
responsible for thyroid dysfunction in the cat. One major pet food company regulates iodine
content in cat foods to provide adult cats with approximately 0.1 to 4.5mg of iodine per cat per
day (personal communication 1999, Waltham).
In a related study, Tartellin, Johnson, Cooke et al. (1992) observed that an increase in dietary
iodine resulted in increased urinary excretion of iodine and a reciprocal drop in serum FT4
concentration. This study confirmed that the Wolff-Chaikoff effect occurs in cats. The
experimental period was too short to draw any conclusions on the long term effects of iodine
over-supplementation.
The only short to medium term published study investigating chronic dietary iodine deficiency or
excess in cats did not show any significant differences in serum FT4 concentrations over a 5
month period (Kyle, Tartellin, Cooke et al., 1994). Unfortunately, this group did not measure any
other indicators of thyroid status (e.g. T3, rT3, or TSH concentrations) so it is impossible to
speculate as to the significance of their findings regarding other aspects of thyroid function.
Additionally, the study was probably not long enough to make any conclusions regarding iodine
deficiency as it would take longer than 5 months to deplete a cat of iodine.
In addition to iodine causing suppression of thyroid hormone synthesis (Wolff-Chaikoff effect),
iodine has effects on thyrocyte growth and immunity. Iodine deficiency leads to increased
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thyrocyte growth in vitro (endemic goitre). In humans with Hashimoto's thyroiditis, the
administration of excess dietary iodide may result in hypothyroidism (due to permanent Wolff-
Chaikoff inhibition) in greater than 60 per cent of patients (Roti and Vagenakis, 1996). When
patients from iodine deficient areas are given iodine supplementation an increase in
hyperthyroidism occurs. This is not noted in nonendemic euthyroid goitre areas. Most of these
patients were considered to have pre-existing, clinically silent, multinodular goitre and it appears
that the administration of iodine unmasked thyroid autonomy (Roti and Vagenakis, 1996). Iodine
intake also regulates the pathological type of thyroid disease that occurs in humans. In iodine
deficient areas, the percentage of cases of autonomously functioning thyroid nodules is
increased compared to that of iodine replete areas (Hay and Morris, 1996). Patients with Graves'
disease are easier to control in times of iodine deficiency (Roti and Vagenakis, 1996). High iodine
intake is also known to modify the action of growth factors such as transforming growth factor-p
(Roti and Vagenakis, 1996).
Studies in animals suggest that iodine has an important role in the development of autoimmune
thyroid disease. Iodine administration has been shown to induce lymphocytic thyroiditis in
hamsters, beagles, mice, certain strains of rats and chickens (Roti and Vagenakis, 1996). The
pathogenesis of this autoimmune thyroiditis may include changes in the immunogenicity of
iodine-rich thyroglobulin, cellular damage from free radicals, direct cytotoxic effects of iodine or
changes in regulation of the MHC class I (Roti and Vagenakis, 1996). In contrast to this, Wistar
rats made iodine deficient have been shown to develop autoimmune thyroiditis (Roti and
Vagenakis, 1996). Controversy occurs in the relationship of iodine intake and the development of
Hashimoto's thyroiditis, some studies have reported an increase in incidence with increased
iodine intake, other studies demonstrate no correlation (Roti and Vagenakis, 1996).
In vitro, FRTL-5 cells show inhibited growth with the addition of pharmacological concentrations
of iodine (Roti and Vagenakis, 1996), whereas feline thyrocytes isolated from cats with
multinodular goitre do not show any change in growth characteristics (Aeschimann, Gerber, Von
Grunigen et al., 1988).
There is, therefore, a strong possibility that dietary factors such as selenium and iodine may play
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2.00 MATERIALS AND GENERAL METHODS
2.01 CHEMICAL SUPPLIERS
The following products were purchased from the suppliers listed below.
Amersham International pic, Buckinghamshire, UK.
myo- [3H]-lnositol 1.0mCi/ml (81 .OCi/mmol; 435mCi/mg); [Methyl - 3H]-Thymidine 1mCi/ml
(25Ci/mmol; 102mCi/mg).
Bio-Rad Laboratories, Bio-Rad House, Maylands Avenue, Hemel Hempstead,
Hertfordshire, U.K.
Glass plates, low range molecular weight markers; N,N,N,'N'-tetramethyl ethylenediamine
(TEMED).
Bio-stat diagnostics, Cheshire, UK.
Reverse -T3 radioimmunoassay kit (125 tubes).
Boehringer Manheim, Lewes, East Sussex, UK.
Trypsin, Dispase (type II).
Calbiochem Novabiochem, Beeston, Nottingham, UK.
Insulin, sodium, bovine; Somatostatin -14.
DPC, Caernarvon, UK.
Total T4 Radioimmunoassay kit 100 tubes.
Gibco, Life Technologies, Paisley, U.K.
Earle's balanced salt solution (EBSS); Hank's balanced salt solution (HBSS).
Lockertex, Loker Wire Weavers Ltd, P.O Box 161, Church Street, Warrington, Cheshire,
U.K.
Nylon gauze (100 and 30 pm).
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MERCK, Leicester, U.K.
Acetic acid, dimethylformamide; ethanol, ethylenediaminetetraacetic acid (EDTA); glass fibre
filters 25mm; hydrochloric acid (HCI); microcrystalline cellulose; polyethylene glycol (PEG);
potassium phosphates (KP04, KH2P04); sodium hydroxide (NaOH); trichloroacetic acid (TCA).
Millipore, Watford, U.K.
Centricon 10 centrifuge filters.
National Institute for Biological Standards and Control (NIBSC), Hertfordshire, U.K.
Bovine pituitary thyrotropin stimulating hormone (bTSH); insulin-like growth factor 1 (IGF-1).
NEN Life Sciences Products, Boston, USA
[125l-rT3], L-3,3',5'- triiodothyronine (reverse T3) specific activity > 28Mbq/|ig.
Pharmacia Biotech, St Albans, U.K.
HiTrap protein G columns, 1 and 5ml; methylene bis-acrylamide.
Sigma Aldrich Co Ltd, Poole, Dorset, UK.
Acetic anhydride, ammonium persulphate; ampicillin sodium; apo-transferrin (human);
aurothioglucose; bovine serum albumin powder (BSA); Brij; bromoacetic acid N-
hydroxysuccinamide ester; bromophenol blue; Coon's F-12 modification powdered media; D-
glucose; dialysis tubing cellulose membrane; DL-dithiothreitol; epidermal growth factor (EGF)
(mouse); radiographic film Kodak X-OMAT; glycerol; gly-his-lys acetate; glycine hydrochloride;
haemoglobin standard (18g/dl); Ham's F-12 Nutrient mixture; hydrocortisone; Igepal CA-630; 3-
isobutyl-1-methylxanthine (IBMX); 2-mercaptoethanol; micrcrystalline cellulose; newborn calf
serum heat inactivated; phorbol 12-myristate 13-acetate (PMA); propylthiouracil (6-n-propyl-2-
thiouracil, PTU); RPMI-1640 Medium 10x; scintillant (Ultima gold); Sephadex (G25, LH20);
sodium bicarbonate solution (7.5%); sodium dodecyl sulphate (lauryl sulphate, SDS); sucrose; L-
thyroxine (T4); 3,3',5'-triiodo-L-thyronine free acid (rT3); triethylamine; Trypsin-EDTA solution 1 x;
Trizma (2-amino-2-hydroxymethyl propane-1,3-diol) hydrochloride.
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2.02 MATERIALS OBTAINED FROM NON-COMMERCIAL SOURCES
i) Human serum and feline tissues
Euthyroid human serum (determined by a reference FT4 and FT3 and negative TRABs titre,
used as negative controls and to stop reaction in the deiodinase assay was kindly supplied by Mr
A. Jordon (Scottish Blood Transfusion Service, Royal Infirmary of Edinburgh). Feline tissues,
thyroid glands obtained from hyperthyroid cats following thyroidectomy for the treatment of the
disease and euthyroid cats euthanased for reasons other than thyrotoxicosis, and organs for IDI
assay following euthanasia were obtained from colleagues at The University of Edinburgh's
Small Animal Clinic and from the staff of veterinary clinics in Edinburgh and the rest of the United
Kingdom as listed in the acknowledgements.
ii) Cell lines
FRTL-5 cells were purchased from the European Collection of Cell Cultures, Porton Down,
Salisbury, UK. They were also kindly donated by Dr Steve Bidey of The University of Sheffield.
Chinese hamster ovary cells (JP09 and JP02) were the kind donation of Professor Tony
Weetman of the Rowett Research Institute, Aberdeen, UK.
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2.03 GENERAL METHODS
2.031 Assay of IDI Activity In Tissue Homogenates and Microsomal
Fractions By Release Of 125l from 125l-rT3.
i) Preparation of tissue homogenates and microsomal fractions
Tissues were homogenised in 100mMKH2P04/1mMEDTA buffer pH 7.4, at a concentration of
20% w/v and subsequently centrifuged at 1500g for 10 minutes at 5°C. The supernatant was
removed and 2ml sored at -80°C until assay was performed on this fraction. The rest of the
supernatant was centrifuged at 12 OOOg for 20 minutes. The resulting supernatant was then
centrifuged at 105 OOOg for 60 minutes to isolate the microsomal fraction. The microsomal pellet
was resuspended in assay buffer and recentrifuged at 105 OOOg to wash the microsomes and
resuspended in assay buffer to a concentration of 1pg/pl
ii) Assay procedure for tissue homogenates
For assay using crude tissue homogenates, 200(j.l of sample was incubated with 1000pl of
purified tracer at an activity of 0.5pCi/ml in the presence of 5mmol/l dithiothreitol (DTT).
Sequential experiments in which the reaction was stopped after 15minutes, 30 minutes,
60minutes, 5hours, and 24hours by the addition of 0.5ml of human sera (which binds rT3 and
T2), were carried out and the protein was precipitated with 40% TCA. The sample was then
centrifuged at 1500g for 10minutes and 0.8ml of supernatant removed. The total counts in 0.8ml
of the the supernatant, remaining supernatant and pellet were determined and the percentage of
125l released from 125l-rT3 was calculated as follows :
[ s -r (s+p) ] x 100% corrected for blank. (Where p = pellet; s = supernatant)
1% conversion was considered to represent 4.6 fmols of deiodinated rT3
2.032 Assay of IDI Activity In Tissue Homogentates Using T4 as Substrate
50mg of T4 was diluted in 10ml absolute ethanol and a working solution of T4 made by diluting
1ml of stock T4 in 100ml of 0.25M sucrose/0.05M Tris/1mM EDTA buffer pH 7.4 with 3% BSA.
Tissue homogenates were prepared as discussed previously in the aforementioned buffer with
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20mM DTT added. Homogenates were spun at 1500g for 10 minutes to remove cell debris. 2ml
of the resulting supernatant was then preincubated for 10 minutes to reach 37°C. 200gJ of T4
was added to start the reaction. At each designated time point, 200pl of sample was removed in
duplicate and placed into tubes containing 400pl of absolute ethanol and centrifuged at 1500g for
5 minutes. T3 in the supernatant was then assayed by chemiluminescence after dilution of the
sample 1:10 with buffer without DTT. Controls were buffer with no T4, homogenates with no T4,
and homogenates with T4 at time zero.
2.033 Affinity Labelling of IDI-1 in Microsomal Liver Fraction With N-
bromoacetyl [125l]-rT3
200pl of 125l-rT3 was evaporated to dryness under a stream of dry nitrogen and 20pl of 1,5mg/ml
bromoacetic acid n-hydroxy-succinamide ester in dimethylformamide was added to the dried
tracer. To this, 5pJ of 10% (v/v) triethylamine in dimethylformamide was subsequently added and
the mixture left at room temperature for 50 minutes. The iodinated affinity label was then purified
by passing it through a LH20 Sephadex column (2ml) equilibrated with 0.1mol/L HCI. The label
was eluted with 95% ethanol and stored at -20°C until used (within 7 days).
Microsomes from tissues were isolated as above (2.031) and diluted to 1mg/ml protein in 50mM
TrisHCI, 3mM EDTA, 3mM DTT. A 50pl aliquot (50gg protein) of this fraction was added to
0.6pCi of N-bromoacetyl - [125l]rT3 affinity label (stored in ethanol), which had been evaporated to
dryness under a steam of dry nitrogen and reacted for 15 minutes.
Samples were then diluted 1:3 with 'boiling mix' consisting of SDS (35mmol/L), glycerol
(1.4mmol/L), 2-mercaptoethanol (0.3mmol/L) and bromophenol blue (15mmol/L) and heated for
10 minutes at 90°C.
To study the inhibition of BrAc[125l]rT3 labelling of IDI, 0.1 mM propylthiouracil (PTU), or 12mM
aurothioglucose (AuG) was added to each test. Samples were then loaded onto a sodium
dodecyl sulphate/polyacrylamide-gel electrophoresis (SDS-PAGE) gel and the proteins
separated and visualised by autoradiography as described subsequently.
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2.034 Sodium dodecyl/sulphate polyacrylamide-gel electrophoresis (SDS-
PAGE)
SDS-PAGE was carried out at room temperature in gels consisting of a stacking gel (32 ml H20;
7.2 ml acrylamide (30% acrylamide, 0.8% bis-acrylamide); 20 ml 0.375M Tris/HCI pH6.8; 0.6 ml
10% SDS; 0.2 ml TEMED [N,N,N',N'-tetramethylethylenediamine]; 0.2 ml 10% ammonium
persulphate) and a 14 cm long 12% resolving gel (17 ml H20; 32 ml acrylamide; 30 1M tris/HCI
pH 8.85; 0.8 ml 10% SDS; 0.15 ml TEMED; 0.15 ml 10% ammonium persulphate).
Protein samples were prepared for electrophoresis by heating at 90°C for 10 minutes in "boiling
mix" at a final protein concentration of 1mg/ml. Electrophoresis was performed using a Protean II
electrophoresis system (Bio-Rad Laboratories Ltd, Watford, Herts, U.K) with a 0.3% Tris/1.44%
Glycine 0.1% SDS electrode buffer through the stacking gel at 200V, 35mA 50 watts and 300V,
50mA, 50 watts through the resolving gel. The gel was stained in 0.2% (w/v) Coomassie Brilliant
Blue R in a water/methanol/acetic acid (50:50:7, by volume) solution for 30 minutes and
destained in two changes of a water/methanol/acetic acid (88:5:7 by volume) solution overnight.
The stained gel was then sandwiched between two sheets of distilled water pre-soaked drying
film and dried under vacuum using a programmable gel drier. The molecular weights of the
standard proteins were plotted against the distance travelled, and a standard curve drawn, which
was used to determine the molecular weights of unknown proteins.
2.035 Autoradiography of SDS/PAGE gels
Autoradiography was performed on gels which had been used to run samples labelled with 125l or
75Se using Kodak X-OMAT XAR-5 x-ray film and consisted of placing the dried gels in close
contact with the film in an exposure cassette. Gels were laid down at -70°C for 15 hours to 4
days to produce a sharp image. Films were kindly processed by the staff of the Department of
Radiology, the Royal Infirmary of Edinburgh.
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2.036 Protein Determination
All protein determinations were carried out using the methods descibed by Bradford (1976),
adapted for automated use on a Cobas Fara centrifugal analyzer (Roche Diagnostics, Welwyn
Garden City, U.K). Bradford reagent was prepared by dissolving 100mg of Coomassie Brilliant
Blue G-250 in 50 ml 95% ethanol. To this solution, 100ml 85% (w/v) phosphoric acid was added
and stirred for 30 minutes before being diluted to 1000ml with distilled water and filtered through
grade 1 Whatman filter paper.
Bradford reagent (256gl) was added to each cuvette and incubated for 100 seconds at 37°C, with
an initial absorbance reading (595 nm) at 95 seconds. After the addition of 25pl of sample and
50gl distilled water, the cuvettes were incubated at 37°C for 180 seconds when a final
absorbance (595 nm) was taken.
These absorbance values were read against a standard curve constructed using diluted BSA (0
to 100 mg/L). Samples over 100 mg/L were diluted with distilled water until they fell within the
range of the standard curve.
2.037 Isolation and Culture of Thyrocytes
Feline thyrocytes were isolated from thyroid glands following thyroidectomy for the treatment of
the disease ("adenomatous hyperplasia", "thyroid adenomas" "feline nodular goitre", referred to
throughout the text as 'FNG'), or from cats immediately following euthanasia for diseases other
than hyperthyroidism ('normal' thyrocytes referred to throughout the text as 'FT'). Thyroid glands
from the Edinburgh area were refrigerated in 0.9% saline until collected (never more than 2 hours
after removal). Glands from more distant sites were placed in RPMI media containing penicillin
(100U/ml), streptomycin (100pg/ml), and L-glutamine (2 mmol/L) and sent by first class mail.
On receipt, glands were finely minced with scissors in Earle's balanced salt solution (EBSS) and
repeatedly washed until most of the red blood cells were removed. Thyroid tissue was digested
at 37°C for 2 hours in a 50ml enzyme cocktail of dispase (0.5% w/v), trypsin (0.25% w/v),
collagenase (0.1% w/v) and BSA (2% w/v) in EBSS. The digest mix was shaken every 10 to 15
minutes during this period. Following digestion, the cell suspension was filtered through a 100pm
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mesh gauze to remove undigested tissue. The resulting suspension was centrifuged at 125g for
5 minutes to pellet cells. The pellet was resuspended in RPMI media containing penicillin
(100U/ml), streptomycin (100jj.g/ml), L-glutamine (2mmol/L), and 5% normal calf serum, filtered
through a 30pm mesh gauze and centrifuged again to pellet cells. The pellet was then
resuspended in RPMI media, the cells counted in a haemocytometer and plated into wells or
flasks at a density of approximately 10x106 cells per 75 cm2 flask.
Cells were incubated at 37°C for 24 hours before being washed with EBSS to remove excess
RBCs and fresh medium was then added (Figure 2.01).
2.038 Maintenance of FRTL-5 Cell Line
These TSPI dependent, transformed rat thyroid follicular carcinoma cells were maintained in
Coon's modified Ham's F-12 medium supplemented with a six hormone mixture consisting of
bTSH (10mU/ml), bovine insulin (10pg/ml), hydrocortisone (10"8M), transferrin (5gg/ml),
somatostatin (10ng/ml), glycyl-L-histidyl-L-lysine acetate (GHL) (10ng/ml) and 5% newborn calf
serum. They were passaged weekly with trypsin/EDTA(1x). Before growth or cAMP assays were
carried out, the cells were deprived of TSH for 5 days to 'upregulate' the TSH receptor.
2.039 Maintenance of Chinese Hamster Ovary (CHO) Cells Tranfected With
Human TSH (hTSH) Receptor (JP09) and Untransfected (JP02) CHO Cells.
These cells were maintained in Ham's F-12 medium and 5% newborn calf serum. They were
passaged bi-weekly with 1x trypsin/EDTA(1x). They were tested and found to be mycoplasma
free and re-tested every 6 months. When used for experiments, these cells were also
supplemented with penicillin (100U/ml) and streptomycin (100pg/ml),
All cells (primary and cell lines) were cultured with the same batch of newborn calf serum to
avoid batch variation between experiments.
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2.040 IgG Preparation
Serum samples were treated with 6000MW PEG to a final concentration of 12.5% w/v to
precipate immunoglobulins. Samples were then centrifuged at 1200g for 30 minutes at 4°C and
the pellet redisolved in 20mM Na2P04, pH 7.0. The resuspended immunoglobulins were then
passed through a Staphlococcol Protein G column and the IgG subclass eluted in 0.1 M glycine-
HCI pH 2.7 according to the manufacturers recommendations.
Purity was checked by SDS-PAGE, demonstrating the presence of heavy and light chain bands
(Figure 2.02). They were then concentrated in Amicon 10 microconcentrators by centrifugation at
12 OOOg. The samples were then dialysed against the medium used (NaCi free HBSS for cAMP
assays, and medium for growth assays) and the protein concentrations in the final solution was
determined via the Bradford method as described above. All samples were diluted to a final
concentration of 10mg/mi and added to cells at a final concentration of 1mg/ml.
2.0413H-Thymidine Incorporation For Cell Growth - Filter Method
All cell types used were plated at low density of 0.1 to 0.2 x 106 per ml. The following day, test
substances were then added in fresh medium. For the last 6 hours of the experiment or
overnight, 5pCi/ml [3H]-TDr was added to each well. Following incorporation of [3PI]-TDr, the cells
were gently washed twice with EBSS. Nonidet [1ml 0.1% (v/v)] in phosphate buffered saline
(PBS) was then added to each well. Cells were incubated at 37°C for 30 minutes and the
suspension removed from each well and the contents added to glass fibre filters attached to a
vacuum manifold filtration unit. Wells were washed with a further 1ml 0.1% (v/v) Nonidet in PBS
and the contents added to the respective filter. Each filter was then washed twice with 5ml of
0.1% (v/v) Nonidet in PBS. Ethanol (2ml) was added to each filter to facilitate drying and the
filters dried in a fume cupboard. Once dry, the filters were placed in scintillation vials to which 3
ml scintillant was added. Scintillation vials were counted in a scintillation counter for 1 minute.
67
Materials and Methods Chapter 2
2.042 cAMP Radioimmunoassay
An 'in house' cAMP assay was developed using the following method.
i) Preparation of antibody reagents
0.1 M Sodium acetate anhydrous (1.231 g/150ml) was brought to a pH of 4.8-5.0 by the addition of
0.1 M acetic acid ([572pl] glacial acetic acid/100ml water). This was diluted 1:2 with distilled
water. Bovine serum albumin (BSA) (0.1%) was added immediately before use.
The primary antibody used was the kind gift of Dr Brent Williams of the Department of Medicine,
The University of Edinburgh, Western General Hospital. It was developed by the injection of the
acetylated form of cAMP into rabbits. Primary antibody dilution was determined for each new
batch of tracer by performing an antibody dilution curve to establish 50% binding and was
generally between 1:16 000 and 1:30 000.
The secondary antibody was made by mixing 20ml of donkey anti-rabbit serum with 1.5ml of
normal rabbit serum and gently rotating overnight at 4°C. The resultant mixture was centrifuged
at 230g for 15 minutes and the pellet resuspended in 10ml of 0.05M phosphate buffer and made
up to 50ml.
ii) Preparation of standards, samples, controls and tracer.
Controls (3.2nM and 1.6nM) were made by diluting 32pM stock cAMP in acetate buffer without
BSA and stored at -20°C for up to 2 months. The standard curve was prepared in acidified media
(10ml medium to 100pl 20% acetic acid) at the time of experiment and acetylated with the
samples.
Tracer was iodinated within the Department of Clinical Biochemistry by Mrs Susan Anema.
Tracer was diluted such that approximately 4000cpm was added to each tube.
Samples were immediately acidified with 5pl 20% acetic acid for every 500pl of medium and
frozen at -20°C. Acetylation with 15pl per 500pl sample of 2:1, triethylamine:acetic anhydride was
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carried out immediately before each assay, along with the standard curve. Acetylation was
carried out to improve the sensitivity of the assay.
iii) Assay
The radioimmunoassay was performed as follows: 50pl of acetylated sample or standard was
added into duplicate tubes with 10Opil of tracer. 100pl of primary antibody was then added to
each tube (except totals and non-specific binding [NSBs]), the tubes vortexed and the assay
incubated at 4°C overnight.
Following overnight incubation, 10Opil of secondary antibody was added to each tube (except
totals), the tubes vortexed, and placed on a shaker at room temperature for 1 hour. 3ml of wash
solution (containing a small amount of microcrystalline cellulose, 1.5ml of Brij and 1L of distilled
water) was added to each tube and the tubes immediately centrifuged at 1000G for 30 minutes.
The supernatant was decanted by tipping and counted in a gamma counter for 6 minutes.
Standard curve and interpolation of results was carried out by the "RIACALC" system (Wallace).
2.043 Radioimmunoassay of Thyrotropin Receptor Antibodies
Thyrotropin receptor antibodies were assayed using a commercially available RIA kit, (RSR Ltd,
Cardiff). The assay was performed according to the pack insert instructions. Briefly, 50pl of
sample was pipetted into 4mi tubes with 50pl of reconstituted TSH receptors. Tubes were
vortexed for 5 seconds and allowed to incubate for 15 minutes. 10Opil of 125I-labelled TSH was
added to each tube and the tubes vortexed for 5 seconds and incubated at room temperature for
2 hours. Precipitating solution (2ml at 4°C) was then added to each tube (except total tubes) and
the tubes vortexed and centrifuged at 1500g for 30 minutes at 4°C. The supernatant was
decanted by tipping, and the tubes counted in a gamma counter for 5 minutes. Modification of the
assay was necessary when purified IgG was used (Chapter 6). In this case, the eluted IgG was
diluted 1:2 with TRABs negative human serum to correct for non-specific binding and matrix
effects.
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2.044 Assay For Phosphoinositols
The assay was performed as follows:
i) Solutions prepared:
1M formic acid: ammonium formate (formic acid as salt)/0.1M formic acid (63.06g/L ammonium
formate in 0.1 M formic acid). Stable for up to 1 week at 4°C.
10mM EDTA (93mg/25ml): 1:1 (v/v) suspension of anion exchange resin in distilled H20.
500ml EBBS + 1g BSA + 0.5g glucose.
500ml EBBS + 1g BSA + 0.5g glucose + 10mM myo-inositol + 10mM LiCI.
ii) Experimental procedure
The inositol phospholipids are present in all mammalian cells. The procedure describes the
radiolabelling of these lipids in response to cell stimulation. Cells are incubated in medium with
[3H]-inositol which becomes incorporated into inositol lipids through basal turnover.
Cells were preincubated with 10pCi/ml [3H]-inositol for 48 hours in Ham's F-10 medium (low
inositol medium). The medium was then removed from each well and replaced with 0.5ml of
EBS/BSA (0.2%)/glucose (0.1%) and incubated for 15 minutes to wash away the extracellular
tritiated inositol. This medium was removed from each well and replaced with 0.45ml of EBS/BSA
(0.2%)/glucose (0.1%) with 10mM cold inositol for a further 15 minutes to allow the unlabelled
inositol to enter the cells and displace the tritiated inositol, and also for the lithium to inhibit the
inositol phosphate phosphatases. At the end of the 15 minute incubation period test substances
were added as required to triplicate wells in a 50gl volume. Cells were then incubated as required
(usually for two hours).
The experiment was terminated by the addition of 250pil of ice cold 15% perchloric acid. All of the
well contents were removed to a 1.5ml Eppendorf tube. The wells were rinsed with 0.5ml water
and transfered to the same Eppendorf tube. Samples were spun in a microfuge at 3300g for 3
minutes. The supernatant (containing phosphoinositols) was removed to a glass tube and
processed as described subsequently.
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iii) Supernatant processing : recovery of inositol /phosphoinositols
1. 1.5 ml of trichlorotrifluroethane and octylamine (1:1 v/v) were added to each sample and
mixed on a vortex mixer.
2. Samples were then centrifuged at 1 500g for 2 to3 minutes on a bench microcentrifuge to
separate into 3 phases.
3. 0.9 ml of aqueous upper phase was removed for processing as stated subsequently, taking
care not to remove the lower phase.
iv) Assay for inositol /phosphoinositols
1. 10Optl EDTA was added to each sample to chelate calcium.
2. 0.5ml resin/water mix was added to each column. 4ml distilled H20 was added to each to
rinse the column and prevent air locks.
3. Samples were loaded onto each column. Samples were then rinsed with 1 ml dH20 plus
2x4ml of dH20 and allowed to drain completely to remove unbound inositol.
4. Over a rack of scintillation vials, 2ml ammonium formate/formic acid buffer was added to
each column to elute radiolabeled inositol phosphates into the scintillation vials. The
procedure was repeated once.
5. 3ml scintillation fluid was added to each vial and the tubes counted in a scintillation counter.
iv) Calculation of results
The results were calculated by adding the disintigrations per minute (DPM) obtained from the two
column fractions. As only 0.9ml of the total cell extract (1.25ml) was used, a factor (of 1.4) was
used to correct for the dilution of the sample.
2.045 Radioimmunoassay of Thyroid Hormones
The TT4 (DPC; TT4) and TT3 (Amerlex; MT3) assays were optimised and validated for use with
cat serum, in advance of assaying the samples, by SCL Diagnostics as described in detail in
Chapter 9.02. Serum reverse T3 concentrations were determined by radioimmunoassay using a
primary antibody with polyethylene glycol separation system (Biostat Diagnostics).
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2.046 Cloning of the Feline TSH Receptor
i) DNA extraction and polymerase chain reaction (PCR)
Genomic DNA was obtained from thyroid and uterine tissue and peripheral blood leukocytes
using SDS lysis, proteinase K digestion and phenolchlorophorm extraction. Oligonucleotide
primers based on areas of homology between exon 10 of the human, bovine and canine TSHR
gene were designed to yeild a 537 base pair (bp) PCR product encompassing codons 480 to 640
of the feline TSH receptor. The sequence of these primers was FeTSHRIOF 5' CTG GTA GAC
CTC TAC ACT CAC TCT GAG 3" and FeTSHRIOR 5' GTT CAG AAT TGC TGA CAG AGC ATA
3". PCR was performed at an annealing temperature of 60°C.
ii) Single stranded conformational polymorphism analysis and DNA sequencing
The feline TSHR PCR product was cleaved with the restriction enzyme Ncol (NBL Gene
Sciences, Cramlington, UK) to yield digestion products of 302 and 235 bp. Single stranded
conformational polymorphisms (SSCPs) were resolved on precast 12.5% polyacrylamide minigel,
which had been precooled to either 10°C or 20°C and the gels (Phast system, Pharmacia LKB,
Uppsala) were run for 240 Vhrs. Samples were each run in duplicate at both temperatures on
different days. The DNA sequences of both strands of PCR products were determined by
semiautomated cycle sequencing (Applied Biosystems, 377 sequencer, Foster City, CA) as
described. The normal sequence of the feline TSHR from codon 480 to 640 was determined by
analysis of DNA from normal feline hysterectomy specimens and compared with that of the
thyroid DNA from five thyrotoxic cats and peripheral blood DNA from two thyrotoxic littermates
using Sequence Navigator software (Applied Biosystems).
2.047 Plasma Selenium Concentrations
The method of detecting selenium in serum samples is based on the formation of a piazselenol
between selenium and 2,3-diaminonaphthalene followed by extraction and flourometry.
Plasma samples were stored at -80°C until analysis was carried out. The assay has been
described elswhere (Olsen et a!., 1975). Briefly, 0.25ml plasma was digested overnight in 2ml
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concentrated nitric acid (BDH) in a 75ml "quickfit" glass boiling tube. The samples were then
heated slowly to boiling point and kept boiling until brown fumes disappeared (approximately 5
minutes). Concentrated perchloric acid (2ml) (BDH) was then added dropwise to the sample and
the samples then boiled until white fumes appeared. Boiling was continued for 30 minutes when
2ml 10% (v/v) hydrochloric acid (BDH) was added dropwise to the samples to drive off any
excess nitric acid and to convert selenium as selenate to selenite.
When cooled, 5ml hydroxyamine/EDTA solution (25g hydroxylamine and 9.24g EDTA per litre
distilled water) was added to each sample, followed by five drops of the colour indicator (cresol
red [0.05g cresol red in 250ml distilled water containing 1ml of 40% {v/v} ammonia]). Ammonia
solution (40% v/v in distilled water) (BDH) was added to each sample until the sample turned
green (approximately 3ml), then 10% (v/v) HCI was added to each sample to turn the colour of
the solution orange (approximately 2ml). This brought the pH of the sample to 1.5 to 2.5 which is
ideal for the formation of the diaminonaphthaline-selenium complex. The samples were then
diluted to 50ml with distilled water.
Diaminonaphthalene solution (5ml) was added to each sample and incubated for 30 minutes at
50°C in a covered water bath. The samples were then cooled to room temperature and 6ml
cyclohexane (Analar, BDH) was added to each sample. Each tube was covered with a glass
stopper and shaken vigorously for 20 seconds to extract the diaminonaphthalene/selenium
complex. The sample was left for 10 minutes to allow the diaminonapthalene layer to separate.
2.5ml of the top layer was removed and the fluorescence was measured. The samples were read
off a standard curve, prepared from selenous acid (BDH) supplied at 1mg/ml. Standards were:
Opg/ml, 25pg/ml, 50pg/ml and lOOpg/ml. A dried blood standard was used as a control (Analytical
Quality Control Services, Atomic Energy Authority, Austria).
2.048 Glutathione Peroxidase Activity Assay
Initially, a reaction mix was made from 5mg NADPH2, 46mg reduced glutathione, 3ml distilled
water, 24ml PBS, 1ml sodium azide (0.1125M), and 20U glutathione reductase. A 0.0022M
solution of H202 was also made prior to the beginning of this assay.
The following method was used to detect GPX activity in red blood cells (RBC-GPX) and plasma
(P-GPX). Whole blood samples were diluted 4 fold with PBS and mixed gently until no clots were
present. Plasma samples were diluted 1 in 10 with PBS. Red blood cells (in whole blood
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samples) were lysed by dilution (1:20) in distilled water. Plasma samples were not further diluted.
To measure the GPX activity in samples, 955pl of reaction mix, 10jal sample and 35pl H202 was
added to a cuvette. The rate of change of absorbance was followed at 340nM. A rate for a
reacgent blank (reaction mix plus H202) was subtracted from the rate in the samples.
Results were calculated as follows:
A unit of glutathione peroxidase is defined as that which oxidises 1pM of NADPH per minute. The
molar extinction coefficient of NADPH is 6220. The conversion factor for the assay was 16.077
and was calculated as follows:
x 1 1x106 1 000
x x x
6220 1000 1 10
molar dilution correction for pM amount of
extinction to 1L lysate used
coefficient
x dilution factor of original sample (20 for RBCs, 10 for serum).
Haemoglobin (Hb) concentrations were determined by the addition of 1pl of sample with 250pl
Drabkin's reagent and incubated for 15 minutes. The absorbance was read from an automated
plate reader (Dyrex Laboratories MRX, U.K.) with 18g/dl Hb as standard.
2.049 Statistical Analysis
The specific tests used to statistically analyse results are described in the Materials and Methods
section of each results chapter. Tests were chosen under the direction of staff from the
Department of Medical Statistics and Computing, The University of Edinburgh. All tests were
considered significant if they had a p value of < 0.05. All statistics were performed using Minitab
Release 10xtra for the Power Macintosh.
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Figure 2.01a: Feline thyrocytes in culture at 2 days (x 20 magnification).
Figure 2.01b: Feline thyrocytes in culture at 2 days (x40) magnification.
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Figure 2.02: SDS-PAGE of nine feline immunoglobulin G (IgG) preparations illustrating heavy
and light chain bands.
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3.00 THYROID HORMONE DEIODINATION IN THE DOMESTIC
CAT
3.01 INTRODUCTION
The thyroid gland provides the sole source of circulating T4 which is regarded as a prohormone
requiring 5' monodeiodination to produce the metabolically active hormone T3. In selenium
replete humans and rats, approximately 20 per cent of circulating T3 originates from the thyroid
gland, whilst 80 per cent of T3 in plasma appears to arise from 5'-mono-deiodination of T4 in a
number of tissues, especially the liver and kidney (Silva and Larsen, 1986; Kohrle, 1994; St
Germain, 1994). Deiodination of thyroid hormones plays a crucial role in the regulation of T3
supply to both tissue and blood.
Deiodination of thyroxine and other iodothyronines is catalysed by the family of iodothyronine
deiodinases (ID) and current evidence suggests that these enzymes provide an autoregulatory
role in many tissues to maintain intracellular T3 in response to altered thyroidal secretion of
thyroid hormones. Three selenoenzymes are involved in the deiodination of thyroid hormones,
namely iodothyronine deiodinase types I, II and III (IDI, IDII, IDIII). IDI is the major isoenzyme
found in liver and kidney and this enzyme appears to provide the major proportion of T3 found in
plasma (St Germain and Croteau, 1989). IDI is also expressed in high concentrations in the
thyroid of some species including humans, dogs and rodents but many animal species including
goats, cattle and sheep fail to express the enzyme, or at least express it at very low levels within
the gland (Beckett, Beech, Nicol et at., 1993). IDI can catalyse both 5' and 5 mono-deiodination
to produce T3 and rT3, respectively, from T4. In rats and humans, IDI appears to show a
substrate preference for rT3, although it can readily act on T4 (Visser, Kaptein, Terpstra et al.,
1988).
A number of methods have been employed to assay for IDI expression and activity. Expression
of the enzyme is usually assessed with an affinity labelling technique using 125l-bromoacetyl
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derivatives of rT3, T3 or T4 (Kohrle, Rasmussen, Ekenbarger et at., 1990; Schoenmakers,
Pigmans and Visser, 1992). Activity is measured by assessing the ability of IDI and IDII to
metabolise T4 or rT3 in the presence of an active thiol agent such as dithiothreitol (DTT). IDI and
IDII show very different sensitivities to inhibition by the addition of propylthiouracil (PTU) and
aurothioglucose (AuG) (St Germain, 1994). IDI activity with rT3 or T4 as substrate is readily
inhibited by both these agents, whilst IDII is relatively resistant to inhibition by PTU or AuG .
These inhibitors are thus often used to indicate which isoenzyme is expressed by tissues.
Previous studies have suggested that IDI has similar properties in all species investigated. The
main differences reported have been confined to small variations in molecular mass
(Schoenmakers, Pigmans and Visser, 1992), differences in turnover number of approximately
10-fold between species (Santini, Chopra, Hurd et at, 1992; Schoenmakers, Pigmans and Visser,
1992) and differences in sensitivity to inhibition by AuG (Santini, Chopra, Hurd et at, 1992).
However there have been reported clear species-differences concerning the degree of IDI
expression by the thyroid (Beckett, Beech, Nicol et at., 1993; Beech, Walker, Dorrance et at.,
1993).
The aims of this study were therefore to:
• examine the expression of IDI in the thyroid, liver and kidney of the domestic cat
• examine the sensitivity of IDI to PTU and AuG
• examine the kinetics of IDI to the substrates rT3 and T4
78
Thyroid Hormone Deiodination In The Domestic Cat Chapter 3
3.02 MATERIALS AND METHODS
a) ANIMAL TISSUES
Tissues (liver, kidney and thyroid) were obtained from cats not suffering from diseases of the
relevant organs immediately following euthanasia, placed in liquid nitrogen and stored at -80°C
until assays were carried out. Rat tissues were obtained and stored in a similar manner.
b) PREPARATION OF TISSUE HOMOGENATES AND MICROSOMAL
FRACTIONS
Portions of tissues were homogenised in 100mMKH2P04/1mMEDTA buffer pH 7.4 (IDI assay
buffer), at 20% w/v, and processed as described in Chapter 2.031
c) PROTEIN DETERMINATIONS
Protein concentrations were determined by the method described by Bradford (1976) using BSA
as standard as described in Chapter 2.036.
d) ASSAY OF DEIODINASE ACTIVITY USING 125l-rT3 AS SUBSTRATE
The assay procedure was based on that of Sawada et at. (1986). Prior to use, 200pl of 125l-rT3
(9250KBq/1,25ml; 27.8- 46.3MBq/pg) was purified as follows. Free ,25l was removed by passing
the tracer down a 2ml Sephadex G25 column in 100mmol/l potassium phosphate/1 mmol/l EDTA
(pH 7.4) (potassium phosphate buffer). The column was washed with 20ml of potassium
phosphate buffer to remove contaminating ,25l and the125l-rT3 was eluted with a 1% (w/v) solution
of BSA prepared in IDI assay buffer.
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Tissue homogenates (n=5) (post-1500g centrifugation) (200pl) in duplicate, were incubated with
10Opil of purified 12Sl-rT3 at a final activity of 0.0185MBq/ml in IDI assay buffer in the presence of
20mmol/l DTT. Unlabelled rT3 was added at a final concentration of 5pM. For kinetic
experiments, rT3 was added at concentrations spanning the range of 5 to 500pM. Samples were
incubated at 37°C for the times indicated in the results section and the reaction was stopped by
the addition of 0.4mls of normal human sera followed by 0.4ml 40% TCA. After centrifugation at
1500g for 10 minutes, 0.8ml supernatant was removed and counted together with tubes
containing the remaining supernatant and pellet. The percentage of 125l released was calculated
and used to determine the mass of rT3 that had been metabolised (as described in Chapter
2.031).
e) EFFECTS OF PTU AND AuG ON DEIODINASE ACTIVITY.
The inhibition of IDI in assays for activity was investigated by the addition of 1mM PTU or 12nM
AuG (final concentration). These conditions were chosen as these concentrations of PTU and
AuG are known to inhibit IDI activity in other species (Leonard and Rosenberg, 1978; Visser and
Overmeeren-Kaptein, 1981; Goswami and Rosenberg, 1986; St Germain and Croteau, 1989;
Berry, Kieffer, Harney etal., 1993)
f) ASSAY OF IDI ACTIVITY IN TISSUE HOMOGENATES USING T4 AS
SUBSTRATE
This was performed as described previously (Beckett, Beddows, Morrice et al., 1987) and in
Chapter 2.032. Briefly, a solution of T4 (56pM) was prepared in 0.25M sucrose/0.05M Tris/1mM
EDTA buffer pH 7.4 containing 3% BSA. Tissue homogenates (2ml) were then preincubated for
10 minutes at 37°C and T4 (200pl)(0.5 to 510nM final concentration) was added to start the
reaction. At designated time points, 200pl of sample was removed in duplicate into 400pl of
ethanol and centrifuged at 1500g for 5 minutes. The concentration of T3 was then determined by
immunoassay using a Vitros Eci immunoassay analyser (Ortho Clinical Diagnostics, Rochester,
U.S.A).
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g) AFFINITY LABELLING OF IDI IN MICROSOMAL LIVER FRACTION
N-Bromoacetyl-,25l-rT3 (BrAc 125l-rT3) was prepared as previously described (Beckett, Beddows,
Maurice et al., 1987) and in Chapter 2.033. Microsomal fractions isolated from tissues as
described (Chapter 2.031) were diluted to a final concentration of 1mg/ml protein in 50mM
TrisHCI, 3mM EDTA and 3mM DTT. Microsomes (50pl, 50pg protein) were then added to
0.02MBq of N-Bromoacetyl-[125l]rT3 affinity label, which had been evaporated to dryness under
dry nitrogen. The reaction was allowed to proceed for 15 minutes.
For experiments designed to study the effects of PTU and AuG on IDI affinity labelling, either
1mM PTU or 40nM AuG was added to each test prior to addition of the affinity label. The effects
of rT3 and PTU on affinity labelling were also studied with the addition of 6nM rT3 together with
1mM PTU.
After labelling, samples were diluted 2:1 with 'boiling mix' consisting of SDS (35mmol/L), glycerol
(1.4mmol/L), 2-mercaptoethanol (0.3mmol/L) and bromophenol blue (15mmol/L) and then heated
for 10 minutes at 90°C. Samples were subjected to SDS-PAGE using a 12% (w/v) gel, and the
125l-labelled proteins visualised using autoradiography.
h) DETERMINATION OF DEIODINATION KINETICS OF rT3 AND T4 FOR IDI
Km and Vmax values were determined according to the Michaelis-Menten equation by
construction of Lineweaver-Burk plots (Figure 3.01). Final concentrations of rT3 and T4 ranged
from 100nM to 50pM and 0.5nM to 510nM respectively.
i) SERUM rT3 CONCENTRATIONS
A commercial rT3 RIA kit (Biostat Diagnostics, Stockport, UK) was used to measure the rT3
concentrations in serum from 10 euthyroid cats and 10 euthyroid rats.
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j) STATISTICAL ANALYSIS
The Mann Whitney U test was used to test for significant difference between the rT3
concentrations in cats and rats.
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3.03 RESULTS
a) IODOTHYRONINE DEIODINASE ACTIVITY IN TISSUE HOMOGENATES
AND MICROSOMAL FRACTIONS USING rT3 AND T4 AS SUBSTRATES
i) 125l-rT3 as substrate
When 125l-rT3 (6nM) was used as substrate, feline liver and kidney homogenates showed
approximately 0.2% of the deiodinase activity found in rat liver (Table 3.01). Because of the low
deiodinase activity found in feline liver and kidney, it was necessary to use an incubation period
of between 4 and 24 hours whilst in contrast, using rat liver, an incubation period of only 5
minutes with a 1:10 dilution of homogenate was required, in feline liver and kidney homogenates,
deiodination was found to proceed at a linear rate (Figs. 3.02). No deiodinase activity could be
found in thyroid homogenates from three euthyroid and five thyrotoxic cats, even when the
incubation periods were as long as 48 hours (Table 3.01). Propylthiouracil (1mM) and AuG
(12nM) completely inhibited the deiodinase activity seen with 20mM DTT in both rat liver
homogenates and caused a reduction in activity to approximately 0.2% of the basal activity in cat
liver (Table 3.01).
ii) T4 as substrate
When T4 was used as substrate, the deiodinase activity in rat and feline liver were similar (Table
3.01). PTU and AuG markedly inhibited deiodination in cat and rat liver such that less than 10%
of the initial activity remained.
b) KINETIC STUDIES OF RAT AND FELINE IDI
The kinetic data for rat and feline liver homogenates for rT3 and T4 are shown in Table 3.02.
Lineweaver-Burk plots are illustrated for rat liver (n = 5) (Fig. 3.03) and cat liver (n = 5) (Fig.
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3.04). The Km for rat and cat liver using rT3 as substrate were markedly different, cat liver being
approximately five fold greater than that for rat liver. However, the Km values using rT3 in cat
liver homogenates could only be approximated as it was impossible to obtain rT3 in solution at
concentrations greater than 50pM. Thus data points with substrate concentrations well above the
Km of the enzyme could not be used.
With T4 as substrate, the Km and Vmax of the enzymes in rat and feline liver homogenates were
very similar. Lineweaver-Burk plots are illustrated for rat liver (n = 5) (Fig. 3.05) and cat liver (n =
5) (Fig. 3.06).
c) BROMOACETYL rT3 AFFINITY LABELLING
In rat liver microsomes (n = 4), affinity labelling with 125l-rT3-BrAcrT3 demonstrated an 125l -labelled
band with a Mr of 29.1 ±0.94 KDa. This labelled protein has previously been shown to be IDI in
this tissue and was used as a positive control on all gels. The labelling of this protein was
prevented in the presence of PTU and AuG (Figs. 3.07 to 3.14). Similarly, in feline liver and
kidney microsomes, a 125l-labeiled band was found with Mr 26.23±0.33 KDa and 27.16±0.12 KDa
(Figs. 3.07 & 3.09) respectively. As in rat liver, the labelling of this protein was prevented by the
addition of PTU (Fig. 3.07 for feline liver & Fig.3.09 for feline kidney) and AuG (Fig. 3.08 for feline
liver & Fig. 3.10 for feline kidney). The PTU and AuG inhibited affinity-labelled (27 KDa) protein in
cat liver and cat kidney, showed a similar labelling intensity to that of the 29kD labelled protein
found in rat liver. Although there were affinity-labelled proteins in feline thyroid and cerebral
cortex microsomes, none were inhibited by the addition of PTU (Fig. 3.11 for feline thyroid & Fig.
3.13 for feline cerebral cortex) or AuG (Fig. 3.12 for feline thyroid & Fig. 3.14 for feline cerebral
cortex).
d) SERUM rT3 CONCENTRATION IN EUTHYROID CATS
The median serum rT3 concentration in cats was 0.164 nmol/l (range 0.086 to 0.244 nmol/l; Q1:
0.099 nmol/l; Q3: 0.204 nmol/l). The median serum rT3 concentration in rats was 0.3305 nmol/l
range 0.2670 to 0.3710 nmol/l; Q1: 0.2868 nmol/l; Q3: 0.3593 nmol/l). The serum rT3
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Close up view of 14 to 30 KDa region of the above autoradiograph of SDS-
PAGE showing 125l-BArT3 affinity labelled proteins in rat and feline liver
microsomes.
Figure 3.07: Autoradiograph of SDS-PAGE showing 125l-BArT3 affinity labelled
proteins in rat and feline liver microsomes. Lanes: 1, rat liver microsomes; 2,
rat liver microsomes plus PTU; 3, rat liver microsomes plus PTU plus rT3; 4, 7,
10, cat liver microsomes; 5, 8, 11, cat liver microsomes plus PTU; 6, 8, 12, cat










Figure 3.08: Autoradiograph of of SDS-PAGE showing 125l-BArT3 affinity
labelled proteins in rat and feline liver microsomes. Lanes: 1, rat liver
microsomes; 2, rat liver microsomes plus AuG; 3, 5, 7, cat liver microsomes; 4,
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Close up view of 14 to 30 KDa region of the above autoradiograph of SDS-
PAGE showing 125l-BArT3 affinity labelled proteins in rat liver and feline kidney
microsomes.
Figure 3.09: Autoradiograph of SDS-PAGE showing 125l-BArT3 affinity labelled
proteins in rat and feline kidney microsomes. Lanes: 1, rat liver microsomes; 2,
rat liver microsomes plus PTU; 3, rat liver microsomes plus PTU plus rT3; 4, 7,
10, cat kidney microsomes; 5, 8, 11, cat kidney microsomes plus PTU; 6, 8, 12,
cat kidney microsomes plus PTU plus rT3. PTU, 1mM propylthiouracil; rT3,
6nM reverse T3.
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Figure 3.10: Autoradiograph of SDS-PAGE showing 125l-BArT3 affinity labelled
proteins in rat and feline kidney microsomes. Lanes: 1, rat liver microsomes; 2,
rat liver microsomes plus AuG; 3, 5, 7, cat kidney microsomes; 4, 6, 8, cat





















Close up view of 14 to 30 KDa region of the above autoradiograph of SDS-
PAGE showing 125l-BArT3 affinity labelled proteins in rat liver and feline thyroid
microsomes.
Figure 3.11: Autoradiograph of of SDS-PAGE showing 125l-BArT3 affinity
labelled proteins in rat and feline thyroid microsomes. Lanes: 1, rat liver
microsomes; 2, rat liver microsomes plus PTU; 3, rat liver microsomes plus
PTU plus rT3; 4, 7, 10, cat thyroid microsomes; 5, 8, 11, cat thyroid
microsomes plus PTU; 6, 8, 12, cat thyroid microsomes plus PTU plus rT3.






Figure 3.12: Autoradiograph of SDS-PAGE showing 125l-BArT3 affinity labelled
proteins in rat and feline thyroid microsomes. Lanes: 1, rat liver microsomes; 2,
rat liver microsomes plus AuG; 3, 5, 7, cat thyroid microsomes; 4, 6, 8, cat





















Close up view of 14 to 30 KDa region of the above autoradiograph of SDS-
PAGE showing 125l-BArT3 affinity labelled proteins in rat liver and feline brain
microsomes.
Figure 3.13: Autoradiograph of SDS-PAGE showing 125l-BArT3 affinity labelled
proteins in rat and feline brain microsomes. Lanes: 1, rat liver microsomes; 2,
rat liver microsomes plus PTU; 3, rat liver microsomes plus PTU plus rT3; 4, 7,
10, cat brain microsomes; 5, 8, 11, cat brain microsomes plus PTU; 6, 8, 12,







Figure 3.14: Autoradiograph of SDS-PAGE showing 125l-BArT3 affinity labelled
proteins in rat and feline brain microsomes. Lanes: 1, rat liver microsomes; 2,
rat liver microsomes plus AuG; 3, 5, 7, cat brain microsomes; 4, 6, 8, cat brain
microsomes plus AuG. AuG, 12mM aurothioglucose.
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3.04 DISCUSSION
The iodothyronine deiodinases play a crucial role in regulating thyroid hormone metabolism in
many tissues. The expression of the selenoenzyme IDI has been studied extensively in humans
and rats and such work has suggested that this enzyme provides the major source of plasma T3.
However, the observation that the preferred substrate for IDI in these species is rT3 and not T4
has led some to suggest that one of the major roles of IDI may be to metabolise rT3 (Visser,
Kaptein, Terpstra et ai, 1988). More limited studies of IDI have been reported in other species
but the use of affinity labelling with 125l- BrAc-rT3 has suggested that the hepatic expression of IDI
is highest in the rat and dog, with humans, mice, rabbits, cows, pigs, sheep, goats, chickens and
ducks having a similar level of expression (Schoenmakers, Pigmans and Visser, 1992). Activity
measurements of IDI with rT3 as substrate have shown that there are also clear species
differences in the turnover number of hepatic IDI. Rats, rabbits and goats have the highest
turnover number whilst dogs have the lowest, being approximately 10 times lower than that found
in the rat. No studies on feline IDI have been reported.
The results reported here show that although certain characteristics of hepatic and renal IDI are
similar in the cat and rat, the substrate specificity of the enzyme between these species is clearly
different. The kinetics and 125l-BrAc-rT3 affinity labelling of this enzyme have also been examined
in the present study.
Affinity labelling of hepatic microsomes using 125l-BrAc-rT3 demonstrated that the feline enzyme
was expressed at similar levels to that found in the rat, although the feline enzyme had an Mr
which was approximately 3 KDa smaller than the rat enzyme. Such modest differences in the Mr
of IDI have been reported previously between many species (Schoenmakers, Pigmans and
Visser, 1992). The sensitivity of the rat and feline enzyme to PTU and AuG was also similar in
that both these agents prevented affinity labelling of IDI by ,25l-BrAc-rT3. The feline kidney also
expressed levels of IDI similar to that found in feline liver as assessed by affinity labelling.
When the activity of IDI was compared in rat and feline liver homogenates using T4 as substrate,
we found that the relative activities of the enzyme were not significantly different between the
species (Table 3.01). More detailed kinetic analysis showed that the Km for T4 of the rat enzyme
was approximately only three times lower than the feline enzyme. However, the Vmax of the
enzyme in cat and rat liver was not significantly different, which was in agreement with the affinity
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labelling data that also suggested that similar masses of enzyme were present in each of the
tissues.
The use of rT3 as substrate showed marked differences in the ability of rat and feline IDI to
metabolise this substrate. The rate at which feline liver homogenates metabolised rT3 under the
standard assay conditions employed (6nM) was approximately 0.2 per cent of the reaction rate
found in rat homogenate. This low activity was inhibited by AuG and PTU. With rT3 as substrate
it was difficult to determine a precise and accurate estimate of Km in feline liver. This was
because the Km for this substrate appeared to be similar to the highest concentration of
substrate that could be obtained in solution. However, at a conservative estimate, the Km of the
feline enzyme was 7.5 fold higher than the enzyme in rat liver. This finding is similar to reports on
the characteristics of canine IDI. Laurberg and Boye (1982) have reported that dog IDI
metabolises rT3 much less effectively than rat IDI, and rT3 cannot inhibit in vitro deiodination of
T4 unless the concentration of rT3 is greater than that of T4. Additionally, Schoenmakers,
Pigmans and Visser (1992) demonstrated that rT3 was a less effective inhibitor of 125l-BrAc-
3,5,3'-triiodothyronine labelling in dogs than in humans and rats.
After successful cloning of human, canine and rat IDI cDNAs (Toyoda, Harney, Berry et a!.,
1994), it was established that there was significant sequence homology between the IDI cDNA of
humans (81%) and rats (76%) to the cDNA of dog IDI. The TGA selenocysteine codon
(considered to be the active site of IDI) was identically positioned in all three species (400 to
402), and the area surrounding the active site was well conserved (Toyoda, Harney, Berry et al.,
1994). The two histidine residues (153 and 169), previously regarded as essential for enzyme
function, were also conserved in dog IDI (Toyoda, Harney, Berry et al., 1994). The most obvious
differences were the absence of a highly-conserved (human and rat) 5 amino acid segment in
the amino-terminal portion in dog IDI and that canine IDI was 10-fold less sensitive to PTU, and
4-fold less sensitive to AuG inhibition, than human IDI (Toyoda, Harney, Berry et al., 1994). This
group concluded that the substitution of histidine for phenylalanine in the dog enzyme resulted in
important changes to the binding affinity for rT3. Whilst this may be true in dogs, the different
kinetics between feline and rat IDI do not appear to be the result of poor affinity for rT3 as our
results show that 125l-BrAc-rT3 labelling is similar between cats and rats.
These data suggest that in the cat, a major source of circulating T3 is likely to arise from hepatic
deiodination of T4. Indeed, the concentrations of serum T3 in the rat and the cat are similar
(Beckett, Beddows, Maurice et al., 1987; Rutgers, Heusdens and Visser, 1991). The data further
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suggest that hepatic metabolism of rT3 by IDI cannot proceed at a significant rate in the cat.
However, as the serum concentrations of rT3 were significantly lower in the cat (median,
0.164nmol/l; range, 0.086 to 0.244nmol/l) than the rat (median, 0.3305nmol/l; range 0.2670 to
0.371 Onmol/I), this suggests that either the major fraction of serum rT3 does not arise from the
liver in the cat, or that metabolism of rT3 must occur by alternative pathway(s). A clear candidate
for such a pathway is prior sulphation with subsequent deiodination of sulphated rT3 (Rutgers,
Heusdens and Visser, 1991).
In rats and humans, sulphation of thyroid hormones is considered to be an important regulator of
thyroid hormone metabolism. In these species, sulphation of some iodothyronines (T4 and T3,
but not rT3) accelerates deiodination by IDI compared to non-sulphated iodothyronines (Visser,
Mol and Otten, 1983; Rutgers, Heusdens and Visser, 1991). This has led to the suggestion that a
balance between the expression of the sulphotransferases, sulphatases and deiodinases
involved in thyroid hormone metabolism may be important regulators of thyroid hormone
expression during foetal development (Richard, Hume, Kaptein et at., 1998). In the present study,
the ability of feline IDI to metabolise rT3 sulphate or the ability of feline liver to synthesise rT3
sulphate was not investigated but clearly this would be of interest. Whilst sulphation prior to
deiodination does not appear to alter the deiodination rate of rT3 in rats and humans, it is
unknown whether sulphation may accelerate rT3 deiodination in the cat.
Using affinity labelling and activity assays, this study has shown that IDI is not expressed in the
thyroid of the cat. In this regard, cats are similar to goats, cattle, sheep, rabbits, pigs, llama and
deer. In contrast, thyroidal IDI is strongly expressed in humans, dogs, rats, mice and guinea pigs
(Beckett, Beech, Nicol et ai, 1993) and, in these species, expression of the enzyme appears to
be regulated through activation of the cyclic AMP cascade through changes in adenylate cyclase
activity. When it is expressed, thyroidal IDI appears to provide a significant source of circulating
T3 particularly when activation of the TSH receptor is initiated such as in hypothyroidism via TSH
or in Graves' disease through thyroid stimulating immunoglobulins. Clearly therefore, in the cat,
thyroidal deiodination cannot be involved in an adaptive response to hypothyroidism.
Spontaneous adult-onset hypothyroidism in the cat is known to be extremely rare (Rand, Levine,
Best et ai, 1993).
In conclusion, these data suggest that in the cat, plasma T3 originates largely from the
deiodination of T4 in the liver and kidney but clearance of rT3 must proceed by a metabolic route
that is not dependent on deiodination of the unsulphated molecule.
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4.00 CONTROL OF GROWTH OF THE NORMAL AND
ADENOMATOUS FELINE THYROCYTE
4.01 INTRODUCTION
The control of growth and function of thyrocytes involves the interaction of numerous hormones
with receptors including the TSH receptor. Receptor activation and subsequent stimulation of
growth and function is species-specific and will also vary within individual thyroid glands due to
the natural heterogeneity of thyrocytes. Despite thyrotoxicosis being the most common endocrine
disorder of cats and the similarities between feline and human toxic nodular goitre, little work has
been carried out regarding the control of growth in normal feline thyrocytes.
Peter et at. (1987) first reported on the autonomous nature of feline thyrocytes from cats with
hyperthyroidism in an in vivo model, transplanting thyroid nodules from hyperthyroid cats into
nude (nu/nu ICR) mice. They demonstrated that both growth, assessed by [3H]-TDr uptake, and
function, assessed by ,31iodine uptake, were independent of TSH. No stimulation of growth or
function was noticed following injection of mice with sera from hyperthyroid cats.
Only two reports on the characteristics of growth and function of autonomous feline thyrocytes in
vitro has been published (Gerber, Peter, Bosiger et at., 1991; Peter, Gerber, Studer et at., 1991).
Using isolated follicles (from cats affected with thyrotoxicosis) grown in a collagen matrix, Peter
et at. (1991) demonstrated that both growth (assessed by [3H]-TDr incorporation) and function
(assessed by 131iodine uptake) of adenomatous cells were independent of TSH. Furthermore,
these characteristics were spontaneously increased in adenomatous tissue compared to normal
tissue that surrounded these nodules, suggesting they were truly autonomous. In their report,
EGF was the most potent growth factor followed by calf serum, whilst TSH, IGF-1 and insulin had
no effect. Gerber et ai. (1991) studied the growth characteristics of thyrocytes in monolayer
isolated from cats with hyperthyroidism. They concluded that there were widely different growth
characteristics to TSH, EGF, retinoic acid and iodine between preparations. None of the feline
cells responded to TSH, but four out of five demonstrated growth stimulation with EGF and
retinoic acid. Three out of five grew in response to iodine.
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Brown et al. (1992), demonstrated that purified serum IgG from hyperthyroid cats stimulated
growth of FRTL-5 cells and displaced binding of TSH from its receptor using porcine and feline
thyrocyte membranes. It therefore appeared that there was a humoral factor which bound to the
TSH receptor that was possibly involved in the pathogenesis of feline hyperthyroidism. Brown's
group, however, did not use the optimal model system, i.e. feline thyrocytes, to test this
conclusion in the species of interest.
In vihu models can be used to infer characteristics of growth and function of lliyrocyles in vivu
and indeed such models have been widely employed to study growth of thyrocytes in a wide
range of species. The main disadvantage with using primary cells for determination of factors
involved with growth is the variability between preparations. Thyroid glands removed from cats
undergoing thyroidectomy are diseased and the ratio of diseased (adenomatous) to 'normal'
tissue will vary between each gland. It may, therefore, be preferable to use normal glands.
Transformed cell lines such as the FRTL-5 and cells expressing recombinant functional TSH
receptors (JP09/2), whilst being more consistent in responses to growth factors, do not behave
as normal thyroid cells. In vitro experiments suffer further because they do not mimic the in vitro
system where autocrine and paracrine factors can interact. Despite these disadvantages, cell
culture systems are widely used to study thyrocyte growth.
The aims of this study were:
• to test [3H]-TDr incorporation into DNA as a suitable method to detect growth in feline
thyrocytes and to investigate the growth response to known thyrotropic growth factors
(bTSH, EGF, IGF-1) in order to investigate some of the growth responses of feline thyrocytes
and.
• to examine the growth response of FRTL-5 cells and feline thyrocytes to purified IgG from
euthyroid and thyrotoxic cats to test the hypothesis that hyperthyroid cat serum contains
humoral factors which stimulate growth of thyrocytes.
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4.02 METHODS
a) ISOLATION AND MAINTENANCE OF FELINE THYROCYTES AND
EXPERIMENTAL DESIGN FOR GROWTH EXPERIMENTS
Feline thyrocytes were harvested as described in Chapter 2 from euthyroid cats euthanased for
reasons other than hyperthyroidism (FT), and from thyrotoxic cats undergoing surgical
thyroidectomy for the treatment of the disease (FNG). Cells were maintained in RPMI 1640,
supplemented with L-glutamine (2mmol) and penicillin/streptomycin (100U/ml and 100pg/ml
respectively), and passaged as required (usually weekly) with 1x trypsin-EDTA. Cells were plated
into 12 well plates for growth assays at a density of 1x104 cells/ml. For all experiments, cells were
below passage number two.
For experiments involving purified IgG, only normal feline thyrocytes were used. Feline IgG
(1mg/ml final concentration) dialysed against RPMI 1640 medium for 4 days was added to cells
in triplicate 12 well plates. NCS (5% final concentration), L-glutamine and penicillin/streptomycin
were added as above. The medium from each well was removed at day 3, and an aliquot of the
medium with purified IgG was replaced along with L-glutamine and penicillin/streptomycin. The
total cell incubation time for growth experiments was 7 days. This is similar to the method used
by Brown et at. (1990). At the end of day 6, 0.5pCi[3H]-TDr/ml of medium was added to each well
(0.5pCi[3H]-TDr/well) and the cells were left to incubate overnight to allow incorporation of the
tritiated thymidine.
b) MAINTENANCE OF FRTL-5 CELLS AND EXPERIMENTAL DESIGN FOR
GROWTH EXPERIMENTS
FRTL-5 cells were maintained as described in Chapter 2.038. Cells were deprived of bTSH for 5
days before experiments were undertaken and were below passage 10 for all experiments.
Purified IgG (1mg/ml final concentration) dialysed against Coon's F-12 medium for 48 hours was
added to cells in triplicate 12 well plates. "6H" mix and NCS (5% final concentration) were added
to each well to achieve a concentration of "6H" mix that was used for maintenance of this cell
line. Medium was replaced (along with purified lgG) after 3 days. The total cell incubation time for
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growth experiments was 7 days. At the end of day 6, 0.5pCi[3H]-TDr/ml of medium was added to
each well (0.5pCi[3H]-TDr/well) and the cells were left to incubate overnight. Growth was
assessed by incorporation of [3H]-TDr over 12 hours into DNA as described in Chapter 2.
c) STATISTICAL ANALYSIS
ANOVA was used to test for significant differences in growth response between doses of bTSH,
EGF in comparison to basal. The Mann-Whitney U test was used to test for significant
differences between groups (i.e. euthyroid and hyperthyroid cats).
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4.03 RESULTS
a) GROWTH RESPONSE OF NORMAL AND ADENOMATOUS FELINE
THYROCYTES TO bTSH, EGF AND IGF-1.
i) Growth response to bTSH
At doses from 0.001 n.U/ml to 100mU/ml, bTSH failed to produce a significant growth response in
one normal thyroid preparation (FT5) (Fig. 4.01) and two adenomatous preparations [FNG 26
(Fig. 4.02) & 29], At 1.0pU/ml bTSH, a statistically reduced growth response from basal occurred
in one FT preparation (FT5, Figure 4.01). At doses from 0.001 pU/ml to 500mll/ml bTSH, failed to
produce a significant growth response in all of eight adenomatous preparations (FNG 16 to 20
and 23 to 25) but a small but significant response was seen at a dose of 1000mU/ml. Growth
responses at this very high concentration of bTSH may be due to growth factor contaminants in
the pituitary-derived preparation of bTSH. Accumulated growth data using bTSH in each of the
eight adenoma preparations are represented in Figure 4.03 and show that overall, only a bTSH
concentration of 1000mU/ml gave a significant stimulation of approximately two fold.
ii) Growth response to EGF and IGF-1
EGF at doses from 1ng/ml to 200ng/ml produced a small but significant growth of a normal feline
thyrocyte preparation at 10 and 100ng/ml. IGF-1 at doses of 0.1 - 5ng/ml also produced a
significant growth response in one normal thyrocyte preparation (FT5) (Figure 4.04). In an
adenomatous thyrocyte preparation (FNG 26), EGF produced an approximately four fold
increase in growth at doses from 10 to 200ng/ml. IGF-1 at doses from 0.1 to 5ng/ml also
significantly stimulated growth in feline adenomatous thyrocytes (FNG 23, 24, 25, 26, 29), but to
a lesser extent than the normal thyrocyte preparation (Figure 4.05).
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b) GROWTH RESPONSE OF FRTL-5 TO bTSH AND PURIFIED IgG (1mG/ml)
FROM EUTHYROID AND HYPERTHYROID CATS.
i) Growth response to bTSH (0.001mU/ml to 100mU/ml).
Before experiments testing growth response of FRTL-5 cells in response to purified IgG were
undertaken, the growth response to bTSH was tested. This was necessary as it is well known
that FRTL-5 cells lose their TSH responsiveness over time and some strains respond to lower
doses of TSH than others. There was a significant and linear dose response to bTSH from
0.001 mU/ml - 100mU/ml (p < 0.05) (Fig. 4.06).
ii) Growth response to purified feline IgG (1mg/ml).
The growth response of FRTL-5 cells to purified IgG (1mg/ml) from euthyroid and hyperthyroid
cats was examined. There was a significant growth response to 100mU/l bTSH, and in seven out
of 10 (70%) euthyroid cats and six out of 11 (55%) hyperthyroid cats (p < 0.05)(Fig. 4.07) when
purified IgG was used. Euthyroid cat IgG samples as a group, produced a significantly higher
growth response than hyperthyroid cat IgG samples (p = 0.0258)(Fig. 4.08) but the differences
were small.
c) GROWTH RESPONSE OF NORMAL FELINE THYROCYTES TO PURIFIED
IgG (1mG/ml) FROM EUTHYROID AND HYPERTHYROID CATS.
The growth response of normal feline thyrocytes to purified IgG (1mg/ml) from euthyroid and
hyperthyroid cats was examined. bTSH was not used as a control in these cells as it had not
been possible to demonstrate a growth response to it previously. There was a significant growth
response to EGF (1ng/ml)(p = 0.000) compared to basal. There was no significant growth
response to purified IgG from euthyroid or hyperthyroid cats compared to basal (p = 0.2620 and
0.5508 respectively) (Fig. 4.09). However, the growth response in feline thyrocytes to
hyperthyroid cat IgG was slightly but significantly higher than that observed with euthyroid cat
IgG (p = 0.0333)(Fig. 4.10).
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4.04 DISCUSSION
There is general agreement that more than one factor and second messenger pathway are
responsible for expressing the full proliferation potential of thyrocytes (Tramontano and Villone,
1994). It is also accepted that without an initial rise in intracellular cAMP, thyrocytes cannot enter
S phase and therefore cell division cannot occur (Tramontano and Villone, 1994). Furthermore,
this increase in cAMP must be degraded before growth effects are seen. This fluctuation of
cAMP is thought to be the trigger for cell proliferation (Tramontano and Villone, 1994).
Additionally, "cross-talk" between second messenger systems is now regarded as an important
mechanism in the control of growth and function of cells, particularly thyrocytes (Burrow and
Eggo, 1994; Tramontano and Villone, 1994).
Methods used to detect growth, including the technique of [3H]-TDr incorporation used here have
been questioned. However, with this technique, it is usually false positive results that are
problematic.
There are a number of factors that can give rise to criticisms in the investigation of the presence
of growth stimulating immunoglobulins. In the present study, attempts were made to try to
eliminate these by using preferred methods of immunoglobulin preparation and growth assays.
Purification of IgG using ammonium sulphate precipitation reduces TSH receptor binding of IgG
compared to the use of diethylaminoethyl or protein A affinity chromatography (Brown, 1995).
Furthermore, protein A affinity purification results in a more pure preparation of IgG compared to
that obtained with DEAE ion exchange chromatography (Wardle, Weetman, Mitchell et ai, 1993).
The method of purification of IgG in the investigation of autoantibodies is sometimes critical in the
evaluation of a disease in vitro. Wardle, Weetman, Mitchell et at. (1993), investigating
adrenocorticotropic hormone receptor-blocking immunoglobulins in patients with Addison's
disease, demonstrated that IgG purified by DEAE cellulose appeared to show receptor blocking
antibodies in 41% of patients, whereas protein A affinity purification did so in only 2% of patients
leading to the conclusion that this receptor antibody was in fact a contaminant and not IgG.
Other difficulties in comparing results from growth stimulating experiments is the cell type used
and the conditions employed. FRTL-5 cells produce variable effects through widely divergent
growth characteristics between strains (Brown, 1995). A report of IgG-induced growth in FRTL-5
cells in patients with endemic and non-endemic goitre could only demonstrate this effect in the
presence of 50mll/ml bTSH (Wilders-Truschnig, Drexhage, Leb et at., 1990). Brown, Keating,
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Livingstone et al. (1992) could demonstrate a growth effect in cats with hyperthyroidism without
the addition of TSH. Ultrasensitive cytochemical assays used to detect growth (the Feulgen
reaction) do not require the addition of TSH to demonstrate growth effects (Brown, 1995) but
have not been confirmed to be accurate indicators of growth in vitro. No growth assays described
to date eliminate all error. In Brown's review on growth stimulating immunoglobulins (Brown,
1995), she concludes that one of the most important steps in determining growth effects in
goitrous diseases is to eliminate species differences.
The results presented here have been unable to demonstrate any significant biological effect of
bTSH on growth in normal or adenomatous feline thyrocytes at doses ranging from 0.001 mU/ml
to 500mU/ml. A growth response was detected in many thyrocyte preparations at concentrations
of bTSH of 1000mU/ml. However it is likely that other growth factors which contaminate this
pituitary extract of bTSH may be responsible for the growth response observed at this high
concentration. Although it is generally accepted that, both in vitro and in vivo, TSH acts as a
mitogen for thyrocytes of a number of species (dogs, rats and humans), it has not been
demonstrated to do so in others (pigs, cattle, sheep) (Dumont, Maenhaunt, Pirson et al., 1991).
In species where TSH acts as a mitogen, the growth effect is reproduced by agents that enhance
cAMP accumulation in cells (Vassart and Dumont, 1992). A lack of growth in response to TSH
may reflect the inherent growth characteristics of the species studied, species specificity between
TSH used and the species studied, or the cell culture environment (e.g. lack of specific growth
factors required to enhance the TSH effect). Previous cell culture environment may also have
permanent effects on the growth characteristics of cells. This is particularly true of exposure of
thyrocytes to iodine (Dumont, 1989), which can lead to inhibition of growth in vitro. Passage
number may also affect growth: FRTL-5 cells may lose their TSH responsiveness with increased
passage number, whilst human thyrocytes sometimes show increased TSH responsiveness, and
decreased EGF responsiveness, with increased passage number (Goretzki, West, Koob et al.,
1987). The fact that many investigators have demonstrated that TSH is a mitogen for thryocytes
in vitro , and that human patients with thyroid carcinoma have increased longevity if their
endogenous TSH is suppressed by supplementation with thyroid hormones, leads to the
conclusion that TSH is important for growth of thyrocytes (Dumont, 1989).
In this study, feline thyrocytes, whether normal or adenomatous, grew in response to 10 to
200ng/ml EGF. This growth response observed is not unusual. EGF acts through a tyrosine
kinase second messenger system and is a known growth factor of most mammalian cells
(Nilsson, 1995). It is mitogenic for human, canine, porcine, ovine and bovine thyrocytes.
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However, in some species such as dogs, EGF acts as a growth factor for thyrocytes only in the
presence of insulin (Gartner, Tsavella, Bechter et al., 1987). EGF growth stimulation is
accompanied by a reversible loss of differentiated expression (Gartner, Tsavella, Bechter et al.,
1987). The present observations that IGF-1 also stimulated growth in normal and adenomatous
feline thyrocytes at doses from 0.1 to 5ng/ml is also similar to that reported in other species. IGF-
1 stimulates growth in porcine, ovine and human thyrocytes and FRTL-5 cells (Dumont,
Maenhaut, Pison et al., 1991). As bTSH did not produce growth in feline thyrocytes, EGF was
used in these studies as a positive control in experiments where purified IgG was used as a
stimulus for growth.
These results help to classify some of the in vitro growth characteristics of feline thyrocytes and
demonstrate that [3H]-TDr incorporation can be used to detect growth in this cell model. Although
normal feline thyrocytes appeared to have increased [3H]-TDr incorporation in response to EGF
and IGF-1, it is difficult to compare absolute data between experiments. Generally, there
appeared to be no inherent difference between the growth responses of normal or adenomatous
thyrocytes to bTSH, EGF or IGF-1.
In this study, identical methods were used in an attempt to confirm the results described by
Brown et al. (1992) who reported that purified IgG from some hyperthyroid cats caused
significant growth compared to that from euthyroid cats in FRTL-5 cells, and that this effect was
similar to that of 10mU/l bTSH. Brown's group showed that 0.5 to 1mg/ml (final concentration)
IgG caused maximum growth of FRTL-5 cells. The present study also demonstrated growth
stimulation in this cell line using purified IgG (1mg/ml) but this occurred with IgG from both
euthyroid and hyperthyroid cats. Overall, there was a significantly greater growth response in IgG
preparations from euthyroid cats compared to hyperthyroid cats (p = 0.0258), although this
difference was small. This difference may be statistically significant but is not as great as the
growth effect reported in this cell line by Brown et al. (1992), and is unlikely to be of biological
significance. FRTL-5 cells are useful for detecting TGIs for a number of reasons. Their growth
characteristics are well-defined and the population of cells is heterogenous. They do not,
however, respond as primary cultures of thyrocytes do, as they have an absolute requirement for
TSH and a complex hormonal mix in the culture medium.
When normal feline thyrocytes were used in the present study in an attempt to examine the
growth effects of feline IgG, that derived from hyperthyroid cats significantly stimulated growth
compared to that derived from euthyroid cats (p = 0.0333). Like the results in FRTL-5 cells, this
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difference was statistically significant but is so small that it is unlikely to be of biological
significance. Furthermore, neither IgG from euthyroid nor hyperthyroid cats stimulated growth
when compared to basal (p = 0.2620 and 0.5508 respectively). Primary cell cultures are useful
for determining the presence of TGIs to eliminate cross-species differences. The cell population,
however, is not homogenous and the cells are not immortal. Hence, the isolated cells can only be
used for 1 to 2 weeks, and ideally within the first 1 to 2 passages for growth experiments
(Ambesi-lmpiombata and Villone, 1987). Each preparation from a different individual will
undoubtedly share different growth characteristics.
There are a number of reasons that may explain why purified IgG from feline serum causes
growth of FRTL-5 cells, whilst not stimulating growth of feline thyrocytes in vitro. The first is the
possibility of a contaminating factor in the IgG preparation which was able to stimulate the growth
of FRTL-5 cells but not feline thyrocytes. Crude IgG preparations (from PEG or ammonium
sulphate precipitation) can sometimes contain EGF which stimulates growth, although the further
purification with DEAE sepharose or Staphlococcal protein A should eliminate this contamination
(Gartner, Tsavella, Bechtner et al., 1987). Although the IgG preparations used in the present
study were shown to be pure by SDS-PAGE, they may have been contaminated with low
molecular weight growth factors that would not appear on the SDS-PAGE gel. However, it is
unlikely that EGF would be the responsible growth factor for FRTL-5 cells in either the present or
Brown's experiments, as these cells do not grow in response to EGF (Gartner, Tsavella,
Bechtner et al., 1987). Additionally, the feline thyrocytes in this study did not grow significantly
from basal in response to the feline IgG preparation. The fact that the growth effect observed in
FRTL-5 cells with purified IgG did not stimulate growth in feline thyrocytes suggests that the
growth effect observed may be due to an unidentified contaminant. Furthermore, the growth
demonstrated in FRTL-5 cells in response to IgG preparations from both euthyroid and
hyperthyroid cats further increases this suspicion. As the growth effect was not significantly
different from basal in feline thyrocytes, it is difficult to imagine that IgG has a role in the
pathogenesis of feline hyperthyroidism.
Brown et al. (1992) concluded that some hyperthyroid cats had an antibody that bound to the
TSH receptor and induced growth. They were, however, unable to demonstrate activation of the
cAMP pathway which is thought to be a prelude to growth in thyrocytes. It is possible that these
TGIs act to directly stimulate the PIP pathway to induce growth. Receptor antibodies are able to
act with discreet units of the TSH receptor and it is possible that TGIs could preferentially
activate the PI pathway. The exact mechanism(s) for selective triggering of pathways is
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unknown. However, as cAMP and its analogues are such common inducers of growth in
thyrocytes from many species, it is difficult to imagine that in feline thyrocytes, cAMP stimulation
would not be a prerequisite for growth in the pathogenesis of hyperthyroidism. TSH is known to
induce PI stimulation only in high concentrations. As the results in Chapter 5 indicate, the results
of this study were also unable to demonstrate increased cAMP accumulation in a number of cell
types (normal and adenomatous feline thyrocytes and CHO cells), whether sera or purified IgG
was used.
Another possible explanation for the difference between these results and those of Brown et al.
(1992) may be the population of cats studied. Goitrogenic antibodies may appear early in the
disease process (described in detail in Chapter 5) and may actually be produced within the
thyroid by intrathyroidal lymphocytes (Schatz, Ludwig, Wiss et al., 1987).
The existence of TGIs in human thyroid disease other than Graves' disease has caused much
debate. In 1978, Brown and others demonstrated that purified IgG from patients with Graves'
diseases, Hashimotos thyroiditis and toxic and non-toxic nodular goitre could inhibit binding of
radiolabeled TSH to its receptor. Although no assessment of the growth potential of these IgGs
was undertaken at this time, it began the debate as to the significance of TGIs in forms of
thyrotoxicosis not previously thought to be immune-mediated. Drexhage, Bottazzo, Doniach et al.
(1980) and later Smyth, McMullen, Grubeck-Loebenstein et al. (1986) reported that 60 to 70% of
patients with non-endemic sporadic goitre had serum TGIs.
In the present study, feline IgG was used to test for growth effects in feline thyrocytes and none
were found. In the present study, the differences found between the growth effect from basal in
FRTL-5 cells and feline thyrocytes may be due to the different medium used to supplement
FRTL-5 cells. FRTL-5 cells are supplemented with '5H' medium in these experiments and feline
IgG may require additional growth factors (such as insulin, somatostatin, transferrin) to stimulate
growth in feline thyrocytes. The most important point is that there was no biological difference
between purified IgG from euthyroid and hyperthyroid cats in either cell system. Had a
biologically significant growth effect occurred in either FRTL-5 cells or feline thyrocytes cell
counting would have been used to confirm it. The lack of a growth effect in feline thyrocytes in
response to purified IgG from hyperthyroid cats in these experiments, and the lack of adenyl
cyclase activation in Brown's experiments or the present experiments (Chapter 5), all strongly
suggest that a humoral stimulus is not involved in the pathogenesis of feline hyperthyroidism.
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5.00 SECOND MESSENGER PATHWAY ACTIVATION IN THE
FELINE THYROCYTE AND THYROID STIMULATING
IMMUNOGLOBULINS
5.01 INTRODUCTION
Two major signalling pathways, (adenyl cyclase and phospholipase C) produce the majority of
physiological and biochemical effects in the thyrocyte of many species. The TSHR is coupled to
both systems and the stimulation of one or more of the signalling pathways is both species and
effector dependent. In Graves' disease, a range of antibodies directed against the TSH receptor
are produced. Some are able to displace TSH binding from the TSHR in vitro (TBIls), some
stimulate cAMP accumulation in various cell types (primary cultures of thyrocytes, FRTL-5, CHO)
(TSIs), whilst others stimulate growth (TGIs).
The presence of thyrotropin receptor antibodies (TRABs) can be determined by a number of
methods. These include investigating the second messenger response of cells in culture,
measurement of iodide uptake in FRTL-5 cells or using a competition assay to determine the
displacement of binding of radiolabeled TSH from porcine thyrocyte membranes by TSHR
antibodies: the classic TRABs' assay. The sensitivity and specificity of each technique varies.
Graves' disease patients commonly have antibodies in serum that cause cAMP accumulation
and stimulate iodine uptake. TBIls are often also present (Kasagi, Hatabu, Tokuda et al., 1988).
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The degree by which sera stimulate such assay systems is dependent on the patient's TRABs
titre and other factors such as type of sample (unpurified sera, crude immunoglobulin
preparations, or purified IgG), the cell system (e.g. FRTL-5, JP09) and the culture medium used
(Hank's buffered saline [HBSS], NaCI-free HBSS). The methods of purification of IgG also vary
widely and can influence the degree of stimulation in biological systems. Variations in methods
for the purification of immunoglobulins have been previously discussed in Chapter 1.03.
A number of cell types have been used to demonstrate thyroid stimulating activity. Primary cell
isolates as reporter cells were first used to investigate second messenger pathway activation
with TRABs. Kasagi, Konishi, lida et al. (1982), reported on cAMP production in human thyroid
adenoma cells following exposure to serum from hyperthyroid and euthyroid (treated) Graves'
disease patients. PEG precipitated immunoglobulin fractions in NaCI-free conditions were used in
their assay. Rapoport, Filetti, Takai et al. (1982) also measured cAMP responses in human
thyroid cells but Graves' immunoglobulins were prepared by ammonium sulphate precipitation in
NaCI-free conditions.
More recently, the development of cell lines has allowed further investigations into the effects of
TSIs. The ease of obtaining and maintaining cell lines has made them a popular cell system.
Such cell lines include the transformed rat thyrocyte cell line (FRTL-5) and the Chinese hamster
ovary cell line transfected with human TSHR (JP09).
Using crude PEG-precipitated immunoglobulin fractions in salt-free conditions, the cAMP
production, TSH binding inhibitory characteristics and stimulation of radioiodine uptake in FRTL-5
cells in response to hyperthyroid and euthyroid Graves' disease patients have been previously
reported (Kasagi, Konishi, lida et al, 1988; Hidaka, Kasagi, Takeuchi et al, 1994).
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JP09 cells have also been widely used to assess the presence of cAMP-stimulating
immunoglobulins (Michelangeli, Munro, Poon et al., 1994). The main advantages of these cells
are that they have simpler growth requirements in comparison to FRTL-5 cells, do not require
withdrawal of TSH prior to the assay and respond to unpurified sera from TRABs positive
patients compared to FRTL-5 cells (Michelangeli, Munro, Poon et a!., 1994). For these reasons,
JP09 cells may be a preferable bioassay system compared to FRTL-5 cells for detecting cAMP
dependent thyroid stimulators.
The sensitivity of cell lines to cAMP stimulation in response to TRABs antibodies depends greatly
on the isotonicity of the medium used. It appears that NaCI-free medium improves sensitivity of
TRABs detection in FRTL-5 cells (Kasagi, Konishi, Arai et al., 1986; Kasagi, Konishi, lida et al.,
1987; Hikada, Kasagi, Takeuchi et al., 1994), porcine thyrocytes (Kasagi, Hidaka, Hatabu et al.,
1989), human thyroid adenoma cells (Kasagi, Konishi, lida et al., 1982) and human thyroid cells
(Rapoport, Filetti, Takai et al., 1982). The mechanisms for this are reported to include increased
ligand binding, increased membrane permeability and post-receptor mechanisms that prevent
TSHR damage and promotion of intracellular cAMP production (Kasagi, Hidaka, Hatuba et al.,
1989).
Cell conditions also affect cAMP response. FRTL-5 cells that are seeded into wells in 5H medium
initially plate down, but do not grow, and show poor cAMP responses compared to those initially
seeded into wells with 6H medium and deprived of TSH over a 5 day period (Vitti, Rotella,
Vaiente et al., 1983). Cell density is also important, the ideal number of cells for second
messenger experiments being 5 x 104 to 5 x 105 cells per well in 24 well plates (Vitti, Rotella,
Vaiente et al., 1983).
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Whilst immortalised cell lines such as FRTL-5 and JP09 cells may provide a useful model to
study the presence of TSIs in the cat, they may be unsatisfactory because of possible species
differences in the specificity and sensitivity of the TSHR to feline TSIs. The use of primary
cultures of feline thyrocytes may provide a more reliable and sensitive means of studying the
presence of TSIs in the serum of thyrotoxic cats. Studying second messenger systems in the
feline thyrocyte in addition to CHO cells not only allows us to determine the sensitivity of cAMP
and PIP pathways to TSH in the feline thyrocyte, but may also allow an in vitro system for
diagnosis or subclassification of feline thyrotoxicosis if TSIs are important in the pathogenesis of
this condition.
The aims of this study were therefore to :
• determine if bTSH produces a consistent cAMP response in adenomatous feline thyrocytes
(FNG) and normal feline thyrocytes (FT) as would be expected from studies in other species
• study the phosphoinositol cascade in feline thyrocytes in response to bTSH and ATP
• to assess the cAMP response of FNG, FT, transfected (JP09) and untransfected (JP02)
CHO cells, to unpurified pooled sera, unpurified non-pooled sera and purified IgG from
biochemically euthyroid and hyperthyroid cats, using bTSH and TRABs positive human
serum as positive controls and serum from biochemically euthyroid human blood donors as
negative controls.
• to assay for TBIls in sera and purified IgG preparations from hyperthyroid cats.
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5.02 MATERIALS AND METHODS
a) STIMULATION OF cAMP BY bTSH, SERUM, AND PURIFIED IgG IN
FELINE THYROCYTES AND CHO CELLS (JP09 & JP02).
Feline thyrocytes were isolated as described in Chapter 2.037. All cell types (feline thyrocytes
and JP09) were gently trypsinised from flasks with 1x trypsin/EDTA at 37°C and plated out at a
density of 5x105 cells per ml into 24 well plates. For feline thyrocytes (FNG & FT), a passage
number of up to two was used. JP09 and JP02 cells were all below passage number 10. It is
known that FRTL-5 cells lose their sensitivity to TSH with increasing passage number and this
may also be true in other thyrocytes (such as FNG & FT) or cells expressing TSH receptors
(JP09). After 24 hours, the cells were washed twice with 0.5ml of EBSS. For experiments
involving serum, 450pl of respective medium (RPMI for feline thyrocytes, Hams F-12 for CHO
cells) was then added to each well in the presence of 800pm IBMX (potent phosphodiesterase
inhibitor to prevent breakdown of cAMP), and the cells incubated for 15 minutes prior to the
addition of test serum to their final concentration (1 to 5% v/v). Initially, pooled serum was used to
determine if there was a particular time point that showed significant cAMP accumulation. For
experiments involving purified IgG (1mg/ml), NaCI-free HBSS was used instead of medium. An
IgG concentration of 1mg/ml was chosen as this concentration has previously been shown to be
optimal for cAMP (Vitti, Rotella, Valente eta!., 1983) and growth assays (Vitti, Elisei, Tonachera
et at., 1993) in human studies and feline studies (Brown, Keating, Livingstone et al., 1992). For a
positive control, bTSH (500mll/l final concentration) was used to assess cAMP stimulation
unless otherwise stated.
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At the end of incubation, the medium was removed, placed in glass tubes and immediately
acidified by the addition of 5gl of 20%v/v acetic acid per 500pl of medium. Samples were then
kept at 4°C until the experiment was completed. Samples were acetylated with the same batch of
acetylation mix (triethylamine: acetic anhydride, 2:1) prior to assay for cAMP using an in-house
RIA as described in Chapter 2.042.
After incubation, the intact cells were gently washed three times with EBSS and 500pl of 1M
NaOH was added to each well. The cells were left to solubilise overnight at 5°C and protein
concentrations determined as described in Chapter 2.036. The cAMP concentration in the culture
medium was then corrected for protein concentration.
b) PHOSPHOINOSITOL CASCADE ACTIVATION IN FELINE THYROCYTES
IN RESPONSE TO bTSH AND ATP.
Feline thyrocytes (FT) were gently trypsinised from flasks with 1x trypsin/EDTA and plated out at
a density of 5x105cells per ml into 24 well plates. After 24 hours, the medium was removed and
replaced with 500|il of F-10 medium (low inositol) containing 5% NCS to allow the incorporation
of tritiated inositol. After 48 hours, 0.37MBq/ml of tritiated inositol was added to each well. The
rest of the assay was performed as described in Chapter 2.044 with ATP (10~4 final
concentration) and TSH (10mU/l final concentration) additions made in 50pl medium.
c) THYROTROPIN RECEPTOR ANTIBODY (TRABS) ASSAY
A commercial assay (TRABs Assay, RSR Ltd, Cardiff) was used to establish the presence of
TRABs in the serum and in purified immunoglobulin preparations from hyperthyroid and euthyroid
cats. The method used is described in Chapter 2.043. The TRABs titre was used to determine
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the percentage displacement of TSH compared to non-specific binding (NSB) by the following
equation as per the method used by Brown, Keating, Livingstone et al., 1992:
% bound in test - NSB
1 - x 100
% bound in 0 standard - NSB
When purified IgG was substituted for serum samples from the same cats in this assay, the TBII
ranged from 93.5 to 100% in both euthyroid and hyperthyroid cats (data not shown). This was an
artefact of the assay due to marked change of the matrix from serum to low salt HBSS (in which
the immunoglobulins were solubilised). It was therefore necessary to dilute the assay standards
and the IgG samples 1:2 with TRABs negative human serum to prevent this displacement of TSH
binding.
d) STATISTICAL ANALYSIS
The ANOVA test was used to determine statistical difference between time points and the Mann
Whitney U test was used to test for differences between groups.
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5.03 RESULTS
a) cAMP ACCUMULATION IN MEDIUM WITH FELINE THYROCYTES IN
RESPONSE TO bTSH
Both normal (n=1) and adenomatous cells (n=3) showed an approximately linear response to
500mU/l bTSH over 720 minutes (12 hours), thereafter the rate of cAMP accumulation increased
over the next 12 hours. The cAMP concentrations were significantly elevated from basal (p<0.05)
at all time points from 30 minutes to 1440 minutes (24 hours) (p< 0.05) An example of the cAMP
response in a normal thyrocyte preparation and adenomatous thyrocyte preparation is illustrated
in Figs. 5.01 and 5.02 respectively.
b) PHOSPHOINOSITOL CASCADE ACTIVATION IN NORMAL FELINE
THYROCYTES IN RESPONSE TO bTSH AND ADENOSINE TRIPHOSPHATE
(ATP)
The phosphoinositol cascade in normal feline thyrocytes was examined in response to 10mU/ml
bTSH and ATP (10'4). Activation of the PI pathway in response to TSH and ATP was observed in
feline thyrocytes at 120 minutes. ATP induced a more consistent and greater response than TSH
(Fig. 5.03).
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c) cAMP ACCUMULATION IN FELINE THYROCYTES IN RESPONSE TO
POOLED SERUM FROM EUTHYROID AND HYPERTHYROID CATS AT
CONCENTRATIONS FROM 1 to 5% v/v FINAL CONCENTRATION.
i) Nodular goitre thyrocyte preparations
Two thyrocyte preparations from cats with thyrotoxicosis were tested for cAMP accumulation in
response to pooled sera from thyrotoxic and euthyroid cats at concentrations of 1%, 2%, or 5%
v/v final concentration in the medium.
Feline nodular goitre preparation 15 (FNG15)
At 30 minutes incubation, pooled euthyroid cat serum at 2% and 5% significantly stimulated
cAMP accumulation compared to basal (no additions) (p=0.004 and 0.0100 respectively). Pooled
hyperthyroid serum at 2% and 5% also stimulated cAMP accumulation at 30 minutes (p= 0.0040
and 0.0470 respectively) and at 240 minutes (p= 0.0000 and 0.0100 respectively). At 1440
minutes incubation, only 2% pooled thyrotoxic cat serum showed a significantly increased cAMP
response compared to basal (p=0.0210). All increases in cAMP accumulations from serum were
eight to 10 fold less than 500mU/l bTSH (Fig. 5.04) (bTSH results previously displayed in Fig.
5.02).
Pooled hyperthyroid cat serum produced an enhanced cAMP response in this preparation at 240
minutes at concentrations of 2 and 5% (v/v) (p = 0.0180 and 0.0340 respectively), and at 2%
(v/v) at 1440 minutes (p = 0.0460). No other time point demonstrated that pooled euthyroid or
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hyperthyroid feline serum caused significant stimulation of cAMP over basal in this cell
preparation.
Feline nodular goitre preparation (FNG 16)
Only 500mll/ml bTSH proved to significantly increase cAMP concentrations in FNG16 above
basal, although bTSH produced an approximately four-fold lower response over 1440 minutes
than in FNG15 (Figure 5.02). Neither euthyroid nor hyperthyroid cat serum caused any significant
increase in cAMP accumulation from basal over 1440 minutes (Fig. 5.05). Only thyrotoxic cat
serum at 1% (v/v) significantly increased cAMP accumulation in this preparation at 720 minutes
(p = 0.0460). At no other time points or concentrations tested were there any significant
differences between euthyroid and hyperthyroid cats in this preparation.
ii) Euthyroid cat thyrocyte preparation
Normal feline thyrocyte preparation (FT4)
Pooled euthyroid cat serum (2%) at 480 minutes increased cAMP accumulation significantly
above basal (p = 0.0090) (Fig. 5.06). Pooled hyperthyroid serum (1%, 2% and 5%) at 480
minutes also significantly increased cAMP accumulation above basal (p = 0.0450, 0.0420 and
0.0190 respectively). No other time point demonstrated that pooled euthyroid or hyperthyroid
feline serum produced a significant stimulation of cAMP over basal in this cell preparation.
Thus, significant elevations in cAMP accumulation produced by normal feline thyrocytes occurred
with both euthyroid and thyrotoxic pooled cat sera. Hyperthyroid cat serum failed to induce an
enhanced cAMP accumulation when compared to euthyroid cats in this normal cat thyrocyte
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preparation at any time point or serum concentration tested (Figure 5.06). In fact, at one time
point (30 minutes), euthyroid cat serum at 1% (v/v) increased cAMP accumulation more
significantly than thyrotoxic cat serum (p = 0.0250).
d) cAMP ACCUMULATION IN FELINE THYROCYTES IN RESPONSE TO
INDIVIDUAL SERUM SAMPLES FROM EUTHYROID AND HYPERTHYROID
CATS, TRABS POSITIVE HUMAN GRAVES' DISEASE PATIENTS AND
EUTHYROID BLOOD DONORS AT 5% v/v FINAL CONCENTRATION
cAMP response was measured in feline nodular goitre cells (FNG 43) for a 2 hour incubation
period with either 5% v/v unpurified feline serum from euthyroid or thyrotoxic cats, serum from
TRABs positive Graves' disease patients or negative human blood donors as positive and
negative controls respectively. Serum samples were added in NaCI-free HBSS, to enhance the
cAMP response.
Serum from six of 10 (60%) euthyroid cats, and five of 10 (50%) hyperthyroid cats showed a
significant cAMP response compared to basal. Serum from five of five (100%) TRABs positive
and zero of five (0%) TRABs negative euthyroid human blood donors showed a significant cAMP
response compared to basal. When data were grouped, there was a significant stimulation from
basal with 500mU/ml bTSH (p = 0.0040), euthyroid feline serum (p = 0.0142), thyrotoxic feline
serum (p = 0.0142), TRABs positive human sera (p = 0.0282) and TRABs negative euthyroid
human sera (p = 0.0369) (Fig 5.07).
There was no significant difference between the cAMP response using euthyroid and
hyperthyroid cat serum (p = 0.4963)(Figure 5.08), however there was a significant difference
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between sera from TRABs positive Graves' patients and TRABs negative euthyroid sera (p =
0.0081).
e) cAMP RESPONSE OF JP09 AND JP02 CELLS TO POOLED SERA FROM
EUTHYROID AND HYPERTHYROID CATS AT 5% v/v FINAL
CONCENTRATION
JP09 cells failed to show any significant response to pooled (5% v/v final concentration)
euthyroid (p = 0.5690, 0.5650, 0.1800, 0.5230, 0.754 and 0.4000 for times 30, 120, 240, 480, 720
and 1440 minutes respectively), or thyrotoxic feline serum (p = 0.3530, 0.0880, 0.2220, 0.6810,
0.5070 and 0.1500 for times 30, 120, 240, 480, 720 and 1440 minutes respectively). 500mU/ml
bTSH showed a significant stimulation in these cells at 30, 120, 240, 480, 720 and 1440 minutes
(p = 0.0200, 0.0120, 0.0125, 0.0010, 0.0010 and 0.0029 respectively) (Fig 5.09). bTSH cAMP
stimulation is shown separately in Fig. 5.10.
In contrast, JP02 (control cells, no TSH receptor) cells did not show any significant cAMP
response to bTSH, euthyroid or hyperthyroid cat sera at any time point. (Fig. 5.11).
f) cAMP RESPONSE IN JP09 CELLS TO SERA FROM INDIVIDUAL
EUTHYROID AND HYPERTHYROID CATS, TRABs POSITIVE HUMAN
GRAVES' DISEASE PATIENTS AND TRABs NEGATIVE EUTHYROID HUMAN
BLOOD DONORS AT 5% v/v FINAL CONCENTRATION.
JP09 cells showed a significant increase in cAMP accumulation following a 2 hour incubation
with 500mll/ml bTSH (p = 0.028), and with sera from six out of 10 euthyroid cats (p = 0.0100,
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0.0090, 0.0080, 0.0150, 0.0080, and 0.0030). No thyrotoxic cats showed any significant increase
in cAMP accumulation although this was probably due to the poorer precision of the assays
when sera from hyperthyroid cats were used compared to euthyroid cats. A TRABs positive
Graves' patient showed a significant increase in cAMP accumulation (p = 0.0270), whereas the
euthyroid blood donor sample showed no significant cAMP accumulation from basal (Fig 5.12).
Overall, there was no significant difference in cAMP response between euthyroid and thyrotoxic
cats (p = 0.1124) (Fig 5.13).
g) cAMP RESPONSE IN JP09 CELLS TO PURIFIED IgG (1mg/ml) FROM
INDIVIDUAL EUTHYROID AND HYPERTHYROID CATS, TRABS POSITIVE
HUMAN GRAVES' DISEASE PATIENTS AND TRABs NEGATIVE EUTHYROID
BLOOD DONORS.
JP09 cells showed a significant increase in cAMP accumulation following a 2 hour incubation
with 500mU/ml bTSH (p = 0.0030), eight of 10 euthyroid (range of p = 0.0020 to 0.0320) and four
of 10 thyrotoxic cats (range of p = 0.0170 to 0.0280), compared to basal. The TRABs IgG
preparation also showed significant increase in cAMP accumulation (p=0.0020) whilst the
euthyroid blood donor IgG sample did not (Fig 5.14). Overall, euthyroid cat sera showed
significant cAMP stimulation in these cells (p=0.0142) compared to basal, whilst that from
hyperthyroid cats did not (p=0.0759). Overall, there was no significant difference between
euthyroid and hyperthyroid cats (p= 0.0757) (Fig. 5.15).
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h) THYROTROPIN RECEPTOR ANTIBODIES (TRABs) IN EUTHYROID AND
HYPERTHYROID CATS.
A commercial assay TRABs assay was used to determine the percentage displacement of TSH
from its receptor compared to the zero standard (TBII) as described in the methods section of
this chapter. The serum and lgG preparations (1mg/ml IgG) from 10 euthyroid and 10
hyperthyroid cats were used in this study.
Significant displacement of binding of TSH from the thyrotropin receptor was detected in the sera
of 10 euthyroid and 10 hyperthyroid cats. However,,the two TRABs positive samples gave a
greater displacement. Euthyroid TRABs negative human serum gave no displacement (Fig.
5.16). However, there was no statistically significant difference between the TBIls in euthyroid or
hyperthyroid cats (p = 0.6776). There was no significant difference between the TBIls of
euthyroid or hyperthyroid cat IgG preparations from these 10 euthyroid and 10 hyperthyroid cats
(p = 0.2413) (Fig. 5.17).
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5.04 DISCUSSION
Feline thyrocytes demonstrate cAMP and phosphoinositol responses to bTSH. In the present
study, the cAMP response in feline thyrocytes to bTSH was approximately 25 to 500 fold less
than the response in JP09 cells. This reflects either the increased number of TSH receptors
expressed in JP09 cells (Harfst, Ross, Nussey et al., 1994), or differences in the sensitivity of
the TSH receptors to bTSH between species. The stimulation of the phosphoinositol cascade in
feline thyrocytes was similar to that observed in JP09 cells. Feline thyrocytes isolated in the
manner described showed a cAMP response to TSH and to sera from TRABs positive patients
demonstrating that they are a suitable bioassay system for the investigation of TSIs in feline
hyperthyroidism. The development of such a bioassay system is important to help reduce the
problems of sensitivity and specificity that cross-species studies may produce.
While each of the cell types investigated responded to bTSH and human serum containing
TRABs, this study was unable to detect the presence of any significant TSI, or TBII-like activity in
the sera of hyperthyroid cats. This was the case when using a number of cell types and systems
to assay for such antibodies. Thus it was not possible to detect the presence of any
immunoglobulins or humoral agents in serum that could be responsible for the pathogenesis of
feline nodular goitre.
A number of assay systems for cAMP production gave positive results for both euthyroid and
hyperthyroid cat serum and IgG preparations, illustrating the lack of specificity of such systems
for investigating specific interactions with the TSH receptor. Cells have a number of receptors
that may lead to changes in cAMP production. The expression of these receptors and their
activation (including that of the TSH receptor) may vary depending on the environment of the
cell. The lack of any significant differences between euthyroid and hyperthyroid cats in cAMP
accumulation in the culture medium from serum (whether pooled or from individual cats) in
primary cat cell preparations (FNG and FT), FRTL-5 and JP09 cells is a consistent finding in
these experiments. Additionally, purified immunoglobulins from hyperthyroid cats also showed no
significant cAMP accumulation compared to euthyroid cats. This is in agreement with the study of
Brown, Keating, Livingstone et al. (1992), who also found no significant cAMP stimulation with
purified IgG from hyperthyroid cats using FRTL-5 cells despite demonstrating a positive growth
effect in such cells. It is possible that growth in FRTL-5 cells may be due to the activation of
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alternative pathways to cAMP. Alternatively, it may be related to artefacts caused by a problem
of species-specificity (i.e. using a rat thyrocyte cell line to demonstrate feline TSI activity) .
In addition to being unable to demonstrate cAMP stimulating activity in hyperthyroid cat serum
above that seen in euthyroid cat serum, it was not possible in these experiments to demonstrate
a difference in the TBII in sera or purified IgG preparations of hyperthyroid cats when compared
to euthyroid cats. This is in contrast to the study by Brown, Keating, Livingstone et al. (1992),
who, with a similar assay system, reported that with purified lgG preparations, three of nine
(33%) hyperthyroid cats exhibited characteristics that suggested the presence of TBI Is. The
mean TBII of hyperthyroid cats (6.5%) was also significantly greater than the mean TBII of
euthyroid cats (1.1 %)(p < 0.01). Brown's group also demonstrated that when purified IgG was
used and porcine thyrocyte membranes were substituted for cat thyrocyte membranes, eight out
of 10 (80 per cent) hyperthyroid cats were positive (TBII of greater than 50%). The mean TBII
index of hyperthyroid cats (82.5%) was significantly greater than euthyroid cats (0.3%)(p <
0.001). The large difference between the mean TBII of hyperthyroid cats when porcine thyrocyte
membranes where used in place of feline thyrocyte membranes, may be explained by the fact
that the same IgG preparations were not used in each experiment. Furthermore, different buffers
were also used between these assays (Tris buffer for porcine membranes, and low-NaCI Tris
buffer for feline membranes) which was an additional confounding factor in these experiments.
Brown, Jackson, Pohl et al. (1978), have previously demonstrated that low-NaCI Tris buffer
increases the sensitivity of this assay system, which could easily explain the difference in TBII
index between her group's two experiments. In the present study, although six of 10 euthyroid
cats had TBIls of greater than 0%, none were greater than 50%.
In our hands, purified immunoglobulins at the same concentrations as Brown, Keating,
Livingstone et al. (1992) (1mg/ml) in low-NaCI buffer, could not be used undiluted in this assay as
they caused significant non-specific displacement of TSH binding regardless of whether they
were from euthyroid or hyperthyroid cats. Samples, therefore, had to be diluted with TRABs
negative serum to achieve meaningful results. There are two possible sequelae to this, one being
that Brown, Keating, Livingstone et al. (1992) were reporting TBII activity that was in fact non¬
specific displacement and by chance happened to find an effect in thyrotoxic cats more
commonly than euthyroid cats, or, alternatively, it is possible that the dilution with serum used in
the present experiments resulted in the dilution of TBII activity in our assay system, or more
likely, changes in matrix effects altering the binding of receptor antibodies.
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While the presence of thyroid stimulating immunoglobulins is well-defined as the major factor in
the pathophysiology of Graves' disease in humans, there is still controversy over the existence
and significance of thyroid stimulating immunoglobulins in non-immunogenic forms of
thyrotoxicosis in humans. The variability of assay systems to detect immunoglobulins which
interact with the TSH receptor has led to lead to the majority of debate. It is a common finding
that various forms of thyrotoxicosis other than Graves' disease have variable presence of TSIs,
TBIls and TGIs, and are not necessarily related to clinical parameters of thyrotoxicosis such as
age of patient, duration of disease or severity of thyroid disease (Goretzki, West, Koob et at.,
1987; Brown, 1995). Euthyroid humans with non-thyroidal illness may also demonstrate positive
TRABs titres although it is unclear if these are caused by the presence of similar IgGs which bind
to the TSH receptor, or other substances (Zakarija and McKenzie, 1987; Beckett and Toft,
personal communication, 1998).
The problems with such in vitro tests is that factors other than IgG may be present in the serum
matrix that can lead to responses in crude bioassay systems which are, in effect, assay artefact.
It is thus essential that comparative responses are studied between affected and unaffected
individuals. A number of studies reporting the presence of TSIs and TBIls in thyroid disease
other than Graves' disease do not compare these groups with healthy control subjects (Goretzki,
West, Koob et al., 1987). Using such a comparison, the present studies have been unable to
demonstrate any such differences between euthyroid and thyrotoxic cats.
Although histological changes in the thyroid glands of cats with thyrotoxicosis and in humans with
acute toxic nodular goitre (ATN) (Grubeck-Lobenstein, Derfler, Kassal et al., 1985) compatible
with Graves' disease have been reported, little convincing evidence as to the presence of TSIs in
the pathogenesis of feline hyperthyroidism has been published. Peterson, Livingstone and
Brown, (1987), could find no evidence of TSIs in 23 hyperthyroid cats using FRTL-5 cells and
cAMP as reporters. Thyroid microsomal and nuclear autoantibodies have been demonstrated in
10 of 29 (34 per cent) of thyrotoxic cats (Kennedy and Thoday, 1988) compared to none of the
control cats. However, these autoantibodies appeared non-functional (and, perhaps, therefore
non-specific) as Kennedy, Thoday and Mooney (1989), could find no evidence of TSI activity in
29 hyperthyroid cats using iodine uptake in FRTL-5 cells as a marker. In contrast, sera from
Graves' disease patients in the same assay system significantly increased iodine uptake.
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There are a number of reasons to suggest that it would be unusual to detect positive TSIs and
TBIls in the serum of hyperthyroid cats. The first is that nodular thyroid tissue from cats with
hyperthyroidism transplanted into nude mice continues to grow, remains hyperfunctional and
their growth is not stimulated by injecting sera from thyrotoxic cats into these mice (Peter,
Gerber, Studer et al., 1987). This study provided convincing evidence that even if TSIs are
involved in the pathogenesis of feline hyperthyroidism, they are not necessary for the
continuation of the disease. Indeed, without the presence of other markers of autoimmunity such
as heredity and histological evidence of autoimmunity such as lymphocytic infiltration, the
presence of TSIs, TBIls or TGIs, the significance of these putative immunoglobulins in the
pathogenesis of the disease is questionable.
It is possible that the lack of evidence for TSIs or TBIls in this study may reflect the UK cat
population that has been studied. It would appear that in the USA, the cats being presented for
diagnosis and treatment of thyrotoxicosis have a less severe clinical presentation than those cats
in which the disease was first reported (Broussard, Peterson and Fox, 1995) It is possible,
therefore, that cats with thyrotoxicosis in the USA (where Brown's feline samples were obtained)
are being diagnosed at an earlier stage of the disease and thus may have the humoral agent still
present. In humans it is believed that TBIls and TGIs appear early in the pathogenesis of some
forms of goitre and then disappear. Our data cannot exclude such a possibility occurring in cats.
A large prospective study in cats following their thyroid hormone status, thyroid disease
progression and TGI/TSI/TBII potential over time may help to determine this, but due to ethical
considerations, would be difficult to pursue. Furthermore, iodine intake of the cats in Brown's
study may have been radically different to the cats in our study. Iodine deficiency is known to
induce thyroid growth and human patients with endemic goitre have been found to have TGIs in
one study (van der Gaag, Drexhage, Wiersinga et al., 1985) but not another (Vitti, Chiovato,
Tonacchere et al., 1994). Iodine deficiency is known to directly enhance thyroid sensitivity to
growth stimuli even in normal individuals, although this is relatively uncommon. This effect is
enhanced further in certain cases of thyroid disease such as Hashimoto's thyroiditis, treated
euthyroid Graves' disease patients, subclinical hypothyroidism, transient post-partum thyroiditis,
hemithyroidectomy for benign nodules and euthyroid patients following previous amiodarone
induced destructive thyrotoxicosis (Roti and Vagenakis, 1996).
The differences between our study and that of Brown, Keating, Livingstone et al., (1992) may
also be explained by laboratory methods. As previously discussed, many human studies using
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similar methods have published conflicting reports on the existence of TSIs. Whatever the
consequence, the fact that both human (Smeds, Peter, Gerber et al., 1988) and feline (Peter,
Gerber, Studer et al., 1987) adenomas are truly autonomous and do not require the presence of
a humoral factor for growth or stimulation of function, would confirm that these nodules are
TSI/TBII independent. Indeed, it is now well known that the primary pathological event in the
generation of adenomas in human nodular goitre is somatic mutations in the TSH receptor or its
associated G protein (see Chapters 1.0 and 6.0).
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6.00 MUTATIONAL ANALYSIS OF THE FELINE THYROTROPIN
RECEPTOR
6.01 INTRODUCTION
Somatic mutations of the TSHR and its associated G-proteins are now recognised as the major
cause of toxic nodular goitre (functional adenomas) in humans. Germline TSHR gene mutations
also result in the autosomal dominant syndrome of hereditary toxic thyroid hyperplasia, which is
characterised by biochemical and clinical evidence of thyrotoxicosis from birth. In both of these
syndromes, the TSHR mutations occur within exon 10 of the gene (codons 450 to 680), which
encodes the seven transmembrane regions, and the extracellular and intracellular loop of the
receptor.
The pathogenesis of feline hyperthyroidism is unclear but is speculated to be mutifactorial.
Previous investigations into the pathogenesis of feline thyrotoxicosis are discussed in Chapter
1.03 and 1.04.
The aim of this study was to
• examine the gene for the feline TSHR in the region of codon 480 to 640 to determine if gain of
function somatic mutations are a common cause of toxic nodular goitre in cats.
6.02 MATERIALS AND METHODS
a) PATIENT DATA
The clinical data of 11 cats with sporadic thyrotoxicosis and two littermates (who had the same
owner) who were also thyrotoxic, are represented in Table 6.01. No history of thyroid disease in
the mother, 2 other siblings, or 3 half-siblings of the related cats could be ascertained from their
owners. Thyroid tissues from cats I to M was not evaluated histologically but macroscopically
they appeared enlarged, hyperaemic, and contained multiple nodular areas.
161
Mutational Analysis Of The Feline Thyrotropin Receptor Chapter 6
b) METHODS
Genomic DNA was obtained from the thyroid tissue from glands removed for the treatment of the
disease, peripheral blood leucocytes and two normal cat ovariohysterectomy samples. Single
stranded conformational polymorphisms (SSCPs) were constructed and the DNA sequences of
SSCPs of the PCR products were determined by semiautomated cycle sequencing. The normal
sequence of the feline TSHR was determined from ovariohysterectomy samples using
"Sequence Navigator" software. Methodological details are described in detail in Chapter 2.046.
The molecular biology was performed by Dr Simon Pearce of the Endocrine Unit, Department of
Medicine, University of Newcastle upon Tyne, U.K.
6.03 RESULTS
a) NORMAL FELINE TSHR SEQUENCE
The previously uncharacterised normal feline TSHR DNA sequence between codons 480 to 640
was determined (Figure 6.01). The amino acid sequence over this transmembrane region was
found to be highly homologous to that of the cloned mammalian TSHRs with 95%, 92% and 90%
amino acid identity between the derived feline TSHR sequence and canine, human and bovine
TSHRs respectively (Figure 6.02).
b) MUTATIONAL ANALYSIS
The DNA screening method of SSCP analysis was performed on thyroid DNA from the 11 cats
with sporadic thyrotoxicosis, on leucocyte DNA from the two thyrotoxic littermates, and two
samples from healthy cats as controls. No abnormal SSCPs were detected in DNA samples from
any of the 13 thyrotoxic animals. To confirm the findings of the SSCP analysis, direct DNA
sequence analysis of codons 480 to 640 of the feline TSHR was performed on thyroid DNA from
seven of the thyrotoxic cats (cats A, B, C, F, I J and L). This analysis confirmed the normal cat
TSHR sequence and failed to show any DNA sequence abnormality.
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6.04 DISCUSSION
Mutations of the TSHR can result in loss or gain of function. Somatic 'gain of function' mutations
are the major cause of benign toxic thyroid adenomas and of some cases of multinodular goitre
in humans (Duprez, Parma, Van Sande et at., 1998). For this reason, we decided to investigate
the TSHR of feline thyroid adenomas to determine if somatic mutations of the TSHR are involved
in the pathogenesis of feline thyrotoxicosis
Hyperfunctioning thyroid adenomas are responsible for 5 to 30 per cent of cases of human
thyrotoxicosis (Ledent, Parma, Dumont et a!., 1994). The majority of somatic mutations occur in
the tenth exon of the TSHR which encodes for the domain of the active G protein (Gs). The
mutation is confined to the adenomatous tissue demonstrating the monoclonal nature of solitary
adenomas (Ledent, Parma, Dumont et ah, 1994). In human toxic nodular goitre, gain of function
mutations are scattered over most of the carboxyl half of the TSHR in the first and second
extratracellular loops, the third, sixth and seventh transmembrane segments and the third
intracellular loop, and more recently described, deletions in the third intracellular loop (Wonerow,
Schoneberg, Schultz et al., 1998). These mutations have been shown to be functional by
transfection into COS cells and demonstrating increased basal cAMP accumulation over wild
type. In the only series where exon 10 of the TSHR was entirely sequenced, 81 per cent of toxic
adenomas harboured an activating mutation (Parma, Van Sande, Swillens et ah, 1995), making
somatic mutations of the TSHR the most common cause of toxic nodular goitre in humans.
Mutations of the stimulating G-protein (GsOC) probably account for the remainder of cases (Ledent,
Parma, Dumont et ah, 1994). There are known 'hot spots' for somatic functional TSHR mutations
in humans. These include Ser281, Ile486, Ile586, Phe631, and Asp 633 (Parma, Duprez, Van
Sande et ah, 1997). Whilst there is emerging agreement on the prevalence of TSHR and Gsa
mutations in human patients with toxic nodular goitre, there are still some 12 per cent of cases
that do not have demonstrable mutations, leaving room for other pathophysiological mechanisms
or gene targets (Duprez, Parma, Van Sande et ah, 1998).
Our DNA sequencing and SSCP studies have not demonstrated TSHR gene abnormalities
between codons 480 and 640 in thyroid DNA from 11 cases of sporadic feline thyrotoxicosis and
in leukocyte DNA from 2 littermates with familial feline thyrotoxicosis. In human toxic follicular
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thyroid adenomas and hereditary toxic thyroid hyperplasia, 13 of the 17 reported TSHR gene
mutations have occurred between codons 480 and 640. If mutations of the feline TSHR are able
to cause a gain of function, such mutations are likely to occur in the same area, because of the
92% amino acid retention of identity between the human and feline TSHRs that we have
demonstrated in this region. However, our study did not examine the whole of the feline TSHR
coding sequence for such mutations, and we cannot exclude the possibility that the molecular
dynamics of feline TSHR activation are significantly different from those of the human TSHR,
such that gain of function mutations of the feline TSHR occur in regions of the gene we have not
examined.
Single strand conformational polymorphism (SSCP) analysis is the most widely used method to
demonstrate somatic mutations. It is simple and versatile and works on the principle that single-
stranded DNA molecules adopt specific secondary structures under denaturing conditions
(Tonacchera, Cetani, Van Sande et at., 1996). This method is useful as a screening test, but can
lead to false negative results if not used with another method, such as DNA sequencing
(Tonacchera, Cetani, Van Sande et a!., 1996). We have used both of these techniques and have
found no mutations in the DNA from the TSHR in feline adenomas.
The molecular genetic approach that we have taken in this study may be more widely applicable
to the investigation of feline thyrotoxicosis, as a variety of genetic abnormalities have been
demonstrated in differerent forms of human thyrotoxicosis, such as point mutations of the
stimulatory G-protein a-subunit in toxic follicular adenomas or monoclonality of nodules within
multinodular goitres. Our analysis suggests that feline thyrotoxicosis is not commonly caused by
TSHR gene mutations and does not therefore provide an animal model for the study of somatic
or hereditary human toxic follicular adenomas. Further investigation into feline thyrotoxicosis may
yield insights into the pathogenesis of human thyrotoxicosis and provide a much needed
spontaneous model for at least one form of the human disorder.
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7.00 THYROIDAL SELENOENZYME EXPRESSION AND
SELENIUM STATUS IN THE DOMESTIC CAT
7.01 INTRODUCTION
The thyroid gland contains more selenium per gram weight than any other tissue suggesting an
important role for this trace element in the normal homeostasis of the gland. Selenium acts
through the expression of selenoproteins and in the thyroid gland these include glutathione
peroxidase (GPX) which catalyses the production of H202 and protects the thyrocyte from
oxidative damage and thioredoxin reductase (TR), which also has oxidant protective properties
and has been shown to be involved in the regulation of growth of normal and tumourous cells.
Deiodination is also catalysed in the thyroid gland by the iodothyronine deiodinases but this
family of selenoenzymes are not expressed in the thyroid tissue of all species.
Selenium status has been reported to influence thyroid hormone status and metabolism in rats
and humans. Conversely, thyrotoxicosis (resulting from Graves' disease and autonomous
nodules) results in lowering of serum selenium concentrations and whole blood GPX activity
(Beckett, Peterson, Choudhury et at., 1991).
The expression of human thyroidal TR has been shown to be increased by PMA and the calcium
ionophore A23187 (Beckett, Howie, Nicol efal., 1998; Howie, Arthur, Nicol et a!., 1998). TR also
appears to have an important role in cell proliferation. TR has been shown to act as an
intracellular growth factor for both normal and tumour cells in culture (Berggren, Gallegos,
Gasdaska et al., 1996; Gallegos, Gasdaska, Taylor, 1996) by activating transcription factors that
lead to cell division (Powis, Gasdaska, Gasdaska et al., 1997). To date, no TR binding sites have
been found on the surface of cancer cells. TR also acts in an autocrine manner by enhancing the
cellular response to other growth factors (Berggren, Gallegos, Gasdaska et al., 1996; Gasdaska,
Kirkpatrick, Monfort et al., 1996; Powis, Gasdaska, Gasdaska et al., 1997).
Selenium status can also modify TR expression/activity. TR activity is inhibited by high
concentrations of selenite (Bjornstedt, Kumar and Holgrem, 1995) and, in vivo, TR activity in rat
liver, lung and kidney undergoes transitory increased expression when these animals are fed a
high selenium diet (Berggren, Mangin, Gasdaska et al., 1999).
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Selenium- and iodine-status are closely linked to thyroidal pathology. Combined selenium and
iodine deficiency appears to be responsible for the formation of myxoedematous cretinism. The
proposed mechanism for this is that iodine deficiency results in stimulation of the thyroid by TSH
which results in increased production of H202. In addition, there is a large increase in TSH
secretion in the neonatal period which further enhances the production of H202. Selenium
deficiency results in cGPX deficiency and a subsequent increase in accumulation of H202. The
end result is thyroid necrosis and fibrosis (Sunde, 1994; Contempre', Dumont, Denef et al., 1995;
Delange, 1996).
In addition to iodine causing suppression of thyroid hormone synthesis (by the Wolff-Chaikoff
effect), iodine has effects on thyrocyte growth and immunity. Iodine deficiency leads to increased
thyrocyte growth in vivo (endemic goitre). In humans with Hashimoto's thyroiditis, the
administration of excess dietary iodide may result in hypothyroidism (due to permanent Wolff-
Chaikoff inhibition) in greater than 60 per cent of patients (Roti and Vagenakis, 1996). Iodine
intake also regulates the pathological type of thyroid disease that occurs in humans. In iodine
deficient areas, the percentage of cases of autonomously functioning thyroid nodules is
increased compared to that of iodine replete areas (Hay and Morris, 1996). Studies in animals
suggest that iodine has an important role in the development of autoimmune thyroid disease.
Iodine administration has been shown to induce lymphocytic thyroiditis in hamsters, beagles,
mice, certain strains of rats and chickens (Roti and Vagenakis, 1996).
There is, therefore, a strong possibility that dietary factors such as selenium and iodine may play
a role in the development of feline toxic nodular goitre.
To date, there have been no reports of the selenium status of the domestic cat. The seemingly
marked variation in incidence of feline hyperthyroidism may reflect important differences in
environmental and/or dietary factors in cats. As selenium status can dramatically influence
thyroid status and expression of certain selenoenzymes such as the deiodinases and TR, we
have investigated selenium status in cats as a possible risk factor associated with the
development of toxic nodular goitre.
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The aims of this study were to:
• examine the expression of selenoenzymes in feline thyrocytes and compare the expression of
these enzymes in normal and adenomatous tissue and the response of these selenoenzymes
to stimulators of the Ca"/PIP signalling pathway.
• determine the selenium status of cats from areas with allegedly marked differences in the
incidence of feline thyrotoxicosis, and to therefore determine if there was any correlation
between the apparent incidence of thyrotoxicosis in cats and selenium status in these
regions.
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7.02 MATERIALS AND METHODS
a) SELENOENZYME EXPRESSION IN THE FELINE THYROCYTE
Feline thyrocytes were harvested and maintained as described in Chapter 2.037. Cells were
grown to 80 to 90 per cent confluence, the medium changed and 0.02MBq 75selenium selenite
/10ml medium was added to each flask along with the agonist. For each cell preparation, six
flasks were used as follows: (1) control 1 (no additions); (2) control 2 (1 per cent v/v DMSO [as
DMSO was used for solubilisation of A23187 and PMA]), (3) bTSH (10U/I); (4) calcium ionophore
A23187 10'6; (5) PMA 10"6; (6) A23187 10"6 plus PMA 10"6. Cells were grown for 48 hours in the
75Se-selenite as previous work in other cell types had shown after this time a steady state had
been reached for labelling. Cells were washed four times with EBSS and harvested into
approximately 10ml EBSS. The cell suspension was centrifuged for 10minutes at 2000g. The
supernatant was discarded and the cell suspension sonicated in 200pl of EBSS. The protein
concentration was determined by the Bradford assay (Chapter 2.036) and the sample diluted to
1mg/ml. The sample was then added to 'boiling mix' and heated at 90°C for 10 minutes and
subject to SDS-PAGE (Chapter 2.034). The selenoproteins were visualised by autoradiography
(Chapter 2.035).
b) SELENIUM STATUS IN CATS FROM AREAS WITH VARYING
INCIDENCES OF HYPERTHYROIDISM
i) Collection and transportation of samples
Cats (total n = 50) were recruited from areas with apparent varying incidences of feline
hyperthyroidism. These included two areas of high incidence (Edinburgh, U.K. [n = 16]) and
Sydney, Australia [n = 14]) and two areas where the disease appears to be less commonly
reported (Greve, Denmark [n = 10] and Perth, Western Australia [n = 10]).
Blood was obtained from euthyroid cats being investigated for reasons such as pre-anaesthetic
checks and viral tests and also from hyperthyroid cats being bled for diagnostic purposes.
Heparinised whole blood (2ml) was immediately frozen at -40°C. A further 2ml of heparinised
blood was immediately centrifuged and the plasma and red blood cells were also stored
separately at -40°C.
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Samples were kept at -40°C until transportation in bulk to Edinburgh was carried out by air freight
on dry ice (TNT, Ltd.).
ii) Plasma selenium concentration
Plasma selenium concentration was carried out by the method described in Chapter 2.047.
Hi) Plasma and whole blood glutathione peroxidase activity
Plasma and whole blood glutathione peroxidase activity were determined as described in
Chapter 2.048. Whole blood glutathione peroxidase activity was corrected for haemoglobin
concentration as described in Chapter 2.048.
iv) Statistical analysis
The Kruskall-Wallis test was used to test for statistically significant differences between groups
overall. The Mann Whitney U test was used to test for significant differences between two
individual areas, with p < 0.05 being considered significant.
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7.03 RESULTS
a) SELENOPROTEIN EXPRESSION
i) Selenoproteins expressed by feline thyrocytes
Figure 7.01 shows an autoradiograph of an SDS-PAGE demonstrating selenoprotein expression
in four FT cell preparations (FT 13, 14, 17 and 20) and four FNG cell preparations (FNG 63, 90,
92 and 95). Both normal and adenomatous feline thyrocytes appeared to express a maximum of
10 major selenoprotein bands but numerous minor bands were also apparent. The
selenoproteins expressed in feline thyrocytes that have been previously characterised by our
laboratory and others are TR with an Mr of approximately 58KDa, cGPX with an Mr of
approximately 24KDa, phospholipid GPX (phGPX) with an Mr of 21 KDa and fatty acid binding
protein with an Mr of 14KDa. The identification of TR in human thyrocytes and its regulation by
the Ca+7PIP signalling pathway in this laboratory has been recently published (Howie, Arthur,
Nicol et at., 1998).
The expression of certain selenoenzymes was variable between FT and FNG cells. One
adenomatous preparation showed a markedly different selenoenzyme profile to any other feline
thyrocyte preparation (FNG63). This preparation showed an overexpression of TR, and a loss
the 14KDa band observed in all other preparations. TR expression in two adenomatous
preparations (FNG90 and FNG92) was similar to that of four normal glands (FT17, FT14, FT13
and FT20). TR expression was high in two adenoma preparations (FNG63 and FNG95). Normal
thyrocyte preparations showed some variation in selenoprotein expression such as differences in
expression of the 21 KDa band and TR (Figure 7.01). Both normal and adenomatous feline
thyrocytes expressed two bands that migrated closely in the 58KDa region and may
subsequently prove to be different isoforms of TR.
ii) Type 1 deiodinase (IDI) in feline thyrocytes
Figures 7.01, 7.02 and 7.03 demonstrate the selenoprotein expression from a number of normal
and adenomatous feline thyrocyte preparations with the cell lines FRTL-5 and HepG2 cells as
controls. Both of the two control cell line types show the expression of a 29KDa selenoenzyme
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previously characterised as IDI (Chapter 3). There is no evidence of a similar IDI band in any of
the feline thyrocyte preparations, even after the addition of bTSH (10U/I) (Figure 7.04).
iii) Thioredoxin reductase (TR) expression in feline thyrocytes
In both FT and FNG cells, bTSFI resulted in no change in the expression of TR (Fig. 7.04). The
calcium ionophore A23187, resulted in variable changes in TR expression from no change in
expression (FNG90 and FT13) to increased expression in the majority of both normal (FT14, 15,
17 and 20) and adenomatous cell preparations (FNG63, 92 and 95). TR clearly appeared to be
overexpressed in two FNG preparations (FNG63 and FNG95).
The phorbol ester, phorbol-12-myristate-13-acetate (PMA) produced a more convincing up-
regulation of TR in both normal and adenomatous feline thyrocytes. The addition of A23187 and
PMA in combination resulted in a further enhancement of this expression in some FT and FNG
preparations studied (Figs. 7.02 and 7.03). This pattern of regulation by A23187 and PMA has
also been previously demonstrated in sheep (Fig. 7.05) and human thyrocytes in this laboratory
(Beckett, Howie, Nicol etal., 1998).
b) SELENIUM STATUS IN CATS FROM AREAS WITH VARYING
INCIDENCES OF HYPERTHYROIDISM.
i) Clinical data for the 50 cats studied
The clinical data and thyroid status for the 50 cats is presented in Table 7.01.
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Breed Sex Euthyroid / hyperthyroid
Greve, Denmark
1 6 Persian MN Euthyroid
2 11 Persian MN Euthyroid
3 8 Persian MN Euthyroid
4 6 British Shorthair MN Euthyroid
5 14 Oriental FN Euthyroid
6 6 DSH MN Euthyroid
7 7 DSH FN Euthyroid
8 8 DSH FN Euthyroid
9 6 DSH MN Euthyroid
10 8 DSH MN Euthyroid
Perth, Western Australia
11 5 Siamese MN Euthyroid
12 3 Persian ME Euthyroid
13 1 Persian FE Euthyroid
14 1 Persian ME Euthyroid
15 1 Persian FE Euthyroid
16 9 Persian FE Euthyroid
17 10 Persian FE Euthyroid
18 3 Burmese MN Euthyroid
19 10 Burmese MN Euthyroid
20 3 Persian ME Euthyroid
Sydney, Eastern Australia
21 12 DSH MN Hyperthyroid
22 18 DSH FN Hyperthyroid
23 9 DSH MN Euthyroid
24 6 DSH FN Euthyroid
25 12 DSH FN Euthyroid
26 14 DSH MN Hyperthyroid
27 18 DSH MN Euthyroid
28 6 DSH MN Euthyroid
29 5 DSH MN Euthyroid
30 8 DSH MN Euthyroid
31 2 DSH FN Euthyroid
32 12 DSH FN Euthyroid
33 4 Siamese MN Euthyroid
34 6 DSH FN Euthyroid
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Table 7.01 (continued): Clinical data for the 50 cats investigated from areas with varying
incidences of hyperthyroidism.
Edinburgh, U.K.
35 12 DSH MN Hyperthyroid
36 10 DSH FN Euthyroid
37 12 Siamese MN Euthyroid
38 10 DSH MN Euthyroid
39 8 DSH FN Euthyroid
40 8 DSH MN Euthyroid
41 14 DLH MN Euthyroid
42 7 DSH MN Euthyroid
43 10 DSH FN Euthyroid
44 9 DSH FN Euthyroid
45 12 DSH FN Euthyroid
46 11 DSH MN Euthyroid
47 7 DSH MN Euthyroid
48 16 DSH FN Hyperthyroid
49 14 DSH MN Hyperthyroid
50 12 DSH MN Hyperthyroid
DLH, Domestic longhair; DSH, Domestic shorthair; FE, Entire female; FN,
Ovariohysterectomised female; ME, Entire male; MN, Castrated male. NB: The numbers
identifying the cats in this table do not represent the cases studied in the selenoprotein
expression section.
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ii) PLASMA SELENIUM CONCENTRATIONS.
Data for plasma selenium concentrations from all cats are presented in Table 7.02 and
graphically in Figure 7.06. There was no significant difference between the groups overall (p =
0.1650). Further, there was no significant difference between any two individual groups (e.g.:
Greve and Perth) (p > 0.05 in every case).
iii) WHOLE BLOOD GLUTATHIONE PEROXIDASE ACTIVITY.
Data for whole blood GPX activity are presented in Table 7.03 and graphically in Figure 7.07.
There was no significant difference between the groups overall (p = 0.0800). However,
Edinburgh cats had significantly lower whole blood glutathione peroxidase activity than Greve
cats (p = 0.0481) but there was no significant difference between any other two individual groups
(p > 0.05).
iv) PLASMA GLUTATHIONE PEROXIDASE ACTIVITY.
Data for plasma GPX activity are presented in Table 7.04 and graphically in Figure 7.08. There
was no significant difference between the groups overall (p = 0.0510). However, Edinburgh cats
had significantly lower plasma GPX activity than Greve cats (p = 0.0112), but there was no
significant difference between any other two individual groups (p > 0.05).
v) CORRELATION BETWEEN PLASMA SELENIUM CONCENTRATIONS AND
WHOLE BLOOD AND PLASMA GLUTATHIONE PEROXIDASE ACTIVITY.
The was no correlation between plasma selenium concentration and whole blood glutathione
peroxidase activity in the 50 cats (p = 0.7380) (Figure 7.09). There was no correlation between
plasma selenium concentration and plasma glutathione peroxidase activity in the 50 cats (p =
0.0820) (Figure 7.10).
vi) PLASMA SELENIUM STATUS AND HYPERTHYROIDISM
Of the 50 cats studied, seven were thyrotoxic (three from Sydney and four from Edinburgh). The
range of plasma selenium concentrations of these seven cats was 0.3100 to 0.5980ppm/ml
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(mean 0.4397 ± 0.1014). There was no significant difference in plasma selenium concentration (p
= 0.4389), whole blood glutathione peroxidase activity (p = 0.4337) or plasma glutathione
peroxidase activity (p = 0.9251) between the euthyroid and hyperthyroid cats. There was no
significant difference in plasma selenium concentration (p = 1.0000), whole blood glutathione
peroxidase activity (p = 0.2772) or plasma glutathione peroxidase activity (p = 0.3496) between
the euthyroid and hyperthyroid cats from Edinburgh. There was no significant difference in
plasma selenium concentration (p = 0.4069), whole blood glutathione peroxidase activity (p =
0.8026) or plasma glutathione peroxidase activity (p = 0.7642) between the euthyroid and
hyperthyroid cats from Sydney.
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Table 7.02: Plasma selenium status (ppm/ml) in cats from areas with varying incidences of
hyperthyroidism.
Area Median Min Max Q1 Q3
Greve 0.5120 0.3320 0.6220 0.4352 0.5847
Perth 0.4100 0.3120 0.5720 0.3460 0.5180
Sydney 0.5190 0.3850 0.6610 0.4115 0.5545
Edinburgh 0.4230 0.3100 0.6870 0.3760 0.5050
All cats 0.4550 0.3120 0.6870 0.4050 0.5425
Table 7.03: Whole blood glutathione peroxidase activity (pM NADPH oxidised per gm
haemoglobin) in cats from areas with varying incidences of hyperthyroidism.
Area Median Min Max Q1 Q3
Greve 404.9 230.7 587.0 312.0 493.1
Perth 409.0 236.0 492.5 347.1 404.4
Sydney 356.5 153.1 522.8 291.0 425.0
Edinburgh 320.9 200.9 427.0 286.7 377.0
All cats 354.3 153.1 587.0 304.1 449.0
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Table 7.04: Plasma glutathione peroxidase activity (pM NADPH oxidised per gm haemoglobin) in
cats from areas with varying incidences of hyperthyroidism.
Area Median Min Max Q1 Q3
Greve 8.6 6.20 11.40 7.25 10.60
Perth 6.9 5.30 16.32 6.30 9.65
Sydney 7.6 4.50 11.70 6.33 9.38
Edinburgh 6.0 4.70 13.30 5.30 6.80
All cats 7.30 4.50 16.32 6.10 9.20
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Figure 7.01: Autoradiograph of SDS-PAGE of four normal and four adenomatous feline
thyrocyte (75Se) selenoprotein profiles with FRTL-5 and HepG2 cells as controls grown
under basal conditions. FNG, feline adenomatous cells; FT, normal feline thyrocytes; GPX,





















































































































Figure 7.02: Autoradiograph of SDS-PAGE of two normal and two
adenomatous feline thyrocyte (75Se) selenoprotein profiles with FRTL-5 and
HepG2 cells as controls. CAI, calcium ionophore 10"6 (A23187); FNG, feline
adenomatous cells; FT, normal feline thyrocytes; GPX, intracellular glutathione
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Figure 7.03: Autoradiograph of SDS-PAGE of three normal and two
adenomatous feline thyrocyte (75Se) selenoprotein profiles with FRTL-5 and
HepG2 cells as controls. CAI, calcium ionophore 10"6 (A23187); FNG, feline
adenomatous cells; FT, normal feline thyrocytes; GPX, intracellular glutathione
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Figure 7.04: Autoradiograph of SDS-PAGE of one normal feline thyrocyte
preparation (FT10) and one adenomatous feline thyrocyte preparation
(FNG65) (75Se) selenoprotein profiles. bTSH, bovine thyrotropin stimulating
hormone (10U/I); CAI, calcium ionophore 10"6 (A23187); FNG, feline
adenomatous cells; FT, normal feline thyrocytes; GPX, intracellular glutathione








































Figure 7.05: Autoradiograph of SDS-PAGE of sheep
thyrocytes (75Se) selenoprotein profiles. bTSH, bovine
thyrotropin stimulating hormone; CAI, calcium ionophore 10~6






E E Q. C o c
<U








Figure7.06:Plasmaseleniumconc ntrations(pp / l)i a sfrarew hv ryingncid ncesofhype thyr idism.B t theboxrepresentsfiquartile(Q1),pfthi dquartile( 3 .W i kersdefit geofha.




















0.34567 Plasmaseleniumconce tration(ppm/ l)











co7X Q_ C5 CO E co co
y=2.77182+10. 650X R-Squared=0.163 p=0.0820 Regression »«■95%Confidenceinterval mm"95%Predictioninterval
_lT| 0.456 Plasmaseleniumconcentration(ppm/ l)
0.3
0.7
Figure7.10:Regressionanalysisofpl maseleniumconce trationvl slutath nep roxidasea tivi y.
Thyroidal Seienoenzyme Expression And Selenium Status In The Domestic Cat Chapter 7
7.04 DISCUSSION
The human thyroid gland contains higher concentrations of selenium than any other human
organ per gram of tissue (Aaseth, Frey, Glaattre et al., 1990). When there is adequate iodine
supply, the rate limiting step in thyroid hormone synthesis is the amount of H 02 present at the
apical membrane of the thyrocyte. Degradation of H in the follicular lumen is regulated by E-
GPX and intracellular GPXs detoxify H202 to produce H20 and thus protects the thyrocyte from its
harmful oxidant effects. It has been suggested that E-GPX is an important regulator of thyroid
hormone synthesis in the human thyrocyte (Howie, Walker, Akesson et at., 1995). In humans,
stimulation of the PIP pathway increases H202 synthesis and decreases secretion of E-GPX into
the follicular lumen thus leading to increased H20? concentrations into this space. In addition,
thyroid hormone deiodination is also influenced by selenium status. Hepatic and renal deiodinase
type I are down-regulated in selenium deficiency, whilst thyroidal IDI (if expressed) is up-
regulated. These observations suggest a hierarchy of selenium supply to specific tissues and
between selenoenzymes within a tissue. As the present work has demonstrated in Chapter 3, the
cat is unique as an obligate carnivore in that it lacks the expression of thyroidal IDI. The marked
geographical distribution of feline hyperthyroidism makes the investigation of dietary factors such
as selenium status in cats of particular interest. In addition, selenoenzymes such as TR have
been shown to regulate growth of a number of cell types and may have important roles in the
development of toxic nodular goitre in the cat. The thioredoxin redox system plays an important
role in regulating cell growth and death (Gasdaska, Berggren, Berry et al., 1999).
Feline thyrocytes (FT and FNG) appear to express at least 10 major selenoproteins. The
selenoproteins of particular interest are cGPX (24KDa) and TR (58KDa). The lack of expression
of IDI (29KDa) confirms data presented in Chapter 3, i.e. that cats are unique among
carnivores/omnivores previously studied (Beckett, Beech, Nicol et al., 1993). The selenoprotein
profiles of normal thyrocyte preparations varied between each other as did the selenoprotein
profiles from the adenomatous thyrocyte preparations. TR appeared to be more commonly
overexpressed in adenomatous cells compared to normal feline thyrocytes. TR has been
demonstrated to be a 58KDa protein and is expressed in many cell lines and tissues. Our
laboratory has confirmed TR expression in human thyrocytes (Howie, Arthur, Nicol et al., 1998)
and HepG2 cells by selenoprotein labelling and Western blotting with HepG2 cells being used as
a control.
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A number of TR enzymes have been sequenced (Gasdaska, Gasdaska, Cochran et at., 1995;
Gladyshev, Jeang and Stadtman, 1996; Tamura and Stadtman, 1996; Zhong, Arner, Ljung et ah,
1998). Recently, the possibility that TR occurs in multiple forms has been raised. In the present
study, feline thyrocytes expressed two bands that migrate closely in the 58KDa region, further
characterisation (including cloning and function expression in other cell types) may prove these
to be two different isoforms of TR.
The regulation of TR expression by PMA and calcium ionophore (A23187) was also variable
among preparations. PMA is an activator of protein kinase C in vivo and in vitro and potentiates
forskolin induced cAMP formation (Alberts, Bray, Lewis et at., 1989). The calcium ionophore
(A23187) is used to increase intracellular Ca++ concentrations and uncouple oxidative
phosphorylation (Alberts, Bray Lewis et at., 1989). In our laboratory, both human and sheep
thyrocytes show an increased expression of TR with PMA alone (Beckett, Howie, Nicol et al.,
1998). A23187 also increased TR expression in human thyrocytes, but not in sheep thyrocytes
(Figure 7.0). The combined addition of PMA and A23187 in FRTL-5 cells resulted in increased
TR expression, but PMA or A23187 alone did not (Beckett, Howie, Nicol et al., 1998). TSH
produced no noticeable change in TR expression in any cell type. These observations are similar
to those in the present study of feline thyrocytes. TR showed no change in expression when
A23187 was used alone (as in sheep thyrocytes), a variable increase in expression when PMA
was used alone and a more consistent increase in expression when PMA/A23187 were used in
combination. There were two adenomatous feline thyrocyte preparations with high basal
expression of TR (FNG63 and FNG95). It is not surprising that the expression of TR and other
selenoproteins is variable amongst adenoma preparations as there is a heterogenous mixture of
cells. What is perhaps more surprising is the variable expression of selenoenzymes in 'normal'
feline thyrocyte preparations. The reasons for this are unknown, but may include different
selenium status, breed, sex and age related differences and variable states of thyroid hormone
production (i.e.: active glands versus more quiescent glands).
TR has been shown to be associated with the regulation of growth in certain cell lines (Gallegos,
Gasdaska, Taylor et al., 1996). TR is secreted by cells and may, therefore, act as an autocrine
growth factor (Berggren, Gallegos, Gasdaska et al., 1996). A number of human primary cancers
(such as those from lung, colon, cervix and liver) have also been shown to over-express
thioredoxin and transfection with thioredoxin can increase tumour growth and inhibit apoptosis
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(Gasdaska, Berggren, Berry et ai., 1999). It may be that in some adenomas TR acts as a growth
stimulus. It would be interesting to determine the growth characteristics of feline thyroid
adenomas, and correlate this with TR expression to determine if there is an association between
TR and growth in this feline disease. The patterns of seienoenzyme expression in feline
thyrocytes and the possible role of TR in the regulation of growth of feline thyrocytes and
subsequent development of adenomas warrants further investigation.
Because of the marked influence that selenium status has on thyroid hormone synthesis and
metabolism, and that certain selenoenzymes (e.g. TR) have effects on the growth of cells, we
compared the selenium status in cats from four different regions. Anecdotal evidence suggests
that feline thyrotoxicosis is a less common disease of cats in Greve, Denmark and Perth,
Western Australia. For this reason, we chose to examine the selenium status of cats from two
areas with apparently high incidence of hyperthyroidism (Edinburgh, U.K. and Sydney, Eastern
Australia) and two areas with seemingly low incidences of hyperthyroidism (Greve, Denmark and
Perth, Western Australia).
The present study demonstrates there was no significant difference in plasma selenium
concentrations between the four areas overall. Markers of selenium activity (whole blood, or
plasma glutathione peroxidase) were also not significantly different between the four groups.
Although the population of Greve cats studied had statistically significantly higher plasma and
whole blood glutathione peroxidase than the Edinburgh samples, the difference is likely to be of
little clinical significance.
The most surprising finding was that cats had approximately 10 times the concentrations of
plasma selenium and whole blood GPX activity of selenium replete rats and humans (Koller and
Exon, 1986; Arthur, Nicol, Hutchinson et ai, 1990; Foster and Sumar, 1997). Whilst no studies
have been reported on selenium requirements of cats, National Research Council (NRC)
requirements for cats are used to calculate selenium concentrations of cat foods by at least one
major pet food company (Waltham, personal communication 1999). Selenium content of cat
foods from Waltham are stated as being in the range of 10 to 40 pg/400Kcal ME. The stated
calorific requirement of cats (70 to 90 kcal/kg/day) should, therefore, lead to an average daily
intake of approximately 7 to 36pg of selenium per cat, per day. This selenium intake
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(approximately 1.75 to 9pg/kg/day) is far higher than that recommended for the average human
(55 and 70pg/day in adult women and men respectively, approximately 1 pig/kg) (Neve, 1998) and
greater than that which is thought to be consumed daily by humans in the U.K. (20 to 300pg/day;
approximating to 0.3 to 4.5pg/kg/day)(Foster and Sumar, 1995). The fact that cats have
approximately 10 times the serum selenium concentration of humans may be the result of
increased dietary intake, the ability of cats to absorb selenium and store it more efficiently than
other animals, or that they are less able to excrete it. The present study appears to show that the
calculation of selenium requirements for cats may be overestimated.
Our studies showed no difference between selenium status in euthyroid and hyperthyroid cats.
This is in contrast to published human studies which demonstrate that the selenium status in
Graves' disease and multinodular goitre patients are lower than that found in euthyroid age-
matched controls (Beckett, Peterson, Choudhury et al., 1991; Bellisola, Cinque, Galassini et ai,
1998). It may be that the cats we investigated had such high selenium intakes that their selenium
states could not be affected by the thyroid status. Alternatively it may be the population we
selected to study. Our hyperthyroid and euthyroid cats were not age-matched and this may have
affected the results.
No papers and only two abstracts have been published reporting the bioavailability of selenium in
dog and cat foods. These abstracts suggest that in a bioavailability assay, selenium appears to
be poorly bioavailable in dog and cat food (Wedekind, Coweli and Combs, 1997; Wedekind,
Bever and Combs, 1997). From our data, this assumption, at least for cats, appears unlikely.
The fact that our data shows that there is no correlation between plasma selenium
concentrations nor either whole blood or plasma glutathione activities, strongly suggests that
most cats are selenium replete. Correlation between plasma selenium concentrations and
glutathione peroxidase activity is apparent only when plasma or selenium concentrations are low.
At high intakes of selenium, GPX activity in whole blood plateaux but plasma selenium
concentrations continue to rise (Foster and Sumar, 1995).
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Whilst the incidence of feline hyperthyroidism is reported to have increased since it was first
recognised it is difficult to establish what separate roles of increased awareness, diagnostic
ability, longevity and numbers of cats, or the possibility of increased exposure to goitrogens,
have played in this increased incidence. It does appear, however, that the increase in incidence
goes beyond what might be reasonably expected from the increased awareness of the disease.
An important question still remains to be answered: is selenium involved in the pathogenesis of
feline thyrotoxicosis? It may appear that as the plasma selenium concentrations from areas with
variable incidences are not significantly different from each other, that this trace element has little
involvement in the pathogenesis of this disease. There may however be other important factors
which do not allow the development of feline hyperthyroidism in Greve or Perth. Risk factors that
have been demonstrated in one epidemiological survey included the use of flea-sprays,
pesticides/herbicides, living indoors and eating mainly tinned food (Scarlett, Moise and Rayl.,
1988). Another important factor may be the possible variability in the longevity of cats between
the regions. More extensive studies on the longevity of cats and the actual incidence of feline
hyperthyroidism from these areas, may help to explain the marked geographical boundaries of
feline hyperthyroidism and elucidate risk factors.
In addition, the combined roles of selenium and iodine in thyroid physiology and growth of
thyrocytes may be an important area of investigation in the pathogenesis of feline
hyperthyroidism. Certainly, these two trace elements interact in the development of thyroid
disease in humans, for example, combined selenium and iodine deficiency in areas of endemic
goitre appears to alter the ratio in favour of myxoedematous cretinism (Delange, 1996). Iodine
intake has marked effects on thyroid hormone production, thyrocyte growth, thyroid immunity
(Roti and Vagenakis, 1996) and, in addition, regulates the pathological type of thyroid disease
that occurs in humans. In iodine deficient areas, the percentage of cases of autonomously
functioning thyroid nodules is increased compared to that of iodine replete areas (Hay and
Morris, 1996).
The iodine content of cat food has been shown to be very variable. Mumma, Rashid, Shane et at.
(1986) showed that it could contain up to 10 times the recommended daily intake, possibly due to
the inclusion of thyroid glands from slaughtered animals. In another study, Johnson, Ford,
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Tartellin et al. (1992) reported that two brands of commercial cat food contained excess amounts
of iodine whilst nine contained less than the recommended intake. They speculated that a wide
variation in iodine intake may be responsible for thyroid dysfunction in the cat. One major pet
food company regulates iodine content in cat foods to provide adult cats with approximately 0.1
to 4.5mg of iodine per cat per day (personal communication 1999, Waltham). It is certainly
possible that high a selenium intake may modify selenoprotein growth factors such as TR and
this, coupled with variable iodine intake which is also known to affect the growth of thyrocytes
and local thyroid immunity, may lead to the formation of toxic nodular goitre. Long term studies
investigating the selenium and iodine status of cats would be of very significant interest.
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8.00 THE USE OF PROPRANOLOL AND POTASSIUM IODATE IN
THE PRESURGICAL MANAGEMENT OF HYPERTHYROID CATS
8.01 INTRODUCTION
The induction of euthyroidism by prior short-term medical therapy dramatically reduces peri-
surgical mortality in hyperthyroid cats (Birchard, Peterson & Jacobson, 1984). The most
commonly used drug to treat cats prior to surgical thyroidectomy in the UK is the thioglyoxaline
carbimazole. However, adverse effects (vomiting, anorexia and depression) requiring withdrawal
of the drug, occur in approximately 8 per cent of treated cats (Mooney, Thoday & Doxey, 1992)
and these cats usually go to surgery still thyrotoxic.
It has previously been shown in humans with hyperthyroidism caused by Graves' disease, that a
combination of propranolol and potassium iodide (as a source of stable iodine) induced
euthyroidism before surgical thyroidectomy (Feek, Sawers, Irvine et al., 1980). A pharmaceutical
preparation of potassium iodide is no longer available in the UK and potassium iodate is now
being used in its place.
The aim of this prospective study was to determine whether a combination of propranolol and
potassium iodate might be an effective method of preparing cats for surgical thyroidectomy.
8.02 MATERIALS AND METHODS
a) CLINICAL MATERIAL
The clinical material comprised a series of 23 hyperthyroid cats presented to the Small Animal
Clinic of The University of Edinburgh's Royal (Dick) School of Veterinary Clinical Studies. A
tentative diagnosis of hyperthyroidism was made on the basis of compatible historical and
physical features and confirmed by the presence of elevated serum TT4 concentrations in all
cases.
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Before admission to the study, blood was collected by jugular venepuncture for haematological
examinations and determination of a 13 parameter biochemical profile. Urine was collected by
cystocentesis. Animals with identified concurrent non-thyroidal diseases were excluded from the
study. After the informed consent of their owners, animals were assigned alternately to one of
two groups (A and B) and hospitalised for the duration of the study.
b) STUDY PROTOCOLS
Group A cases received propranolol (Inderal, Zeneca) alone at 2.5mg/cat every eight hours from
days 1 to 10 inclusive. The heart rate was determined each morning. If an animal's heart rate
exceeded 200 beats/minute on day 4, the propranolol dosage was increased to 5mg/cat every
eight hours and if it still exceeded this rate on day 7, to 7.5 mg/cat every 8 hours for the
remainder of the 10 days. Subsequently, the same dose of propranolol and, initially, 42.5mg
potassium iodate (equivalent to 25mg free iodine, Potassium lodate tablets 85mg, Cambridge
Self-Care Diagnostics) were administered every eight hours from days 11 to 20 until the time of
surgery. The potassium iodate tablets were placed in gelatin capsules. Surgery was carried out
on day 21. Potassium iodate was stopped immediately before thyroidectomy while propranolol
was continued post-operatively for a further 3 days.
Group B cases were treated in the same way with the exception that they received potassium
iodate alone from days 1 to 10 inclusive followed by potassium iodate and propranolol in
combination from days 11 to 20 inclusive, with propranolol alone being continued post¬
operatively for a further three days.
Potassium iodato at tho above dose appeared to cause an unacceptable degree of adverse
effects (intermitent anorexia, vomiting and mild depression) in some cats. Consequently, the
dosage was reduced to 21.25mg (equivalent to 12.5mg free iodine) and no further adverse
effects were observed.
Cats were bled daily from day 1 to day 20 inclusive by jugular venepuncture. Two ml of whole
blood was collected in a plain tube. Serum was harvested and stored at -40°C for subsequent
assay of TT4, TT3 and rT3, which was carried out in respective batch modes. Complete blood
counts woro carriod out at 5 day intervals on each cat to ensure that repeated blood campling did
not result in values outside the respective reference ranges. Serum potassium concentrations
were determined in three cats which became anorexic on days 15 (one in group A and one in
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group B, on 42.5 and 21.25mg potassium iodate respectively) and on day 17 in one cat in group
A on 42.5mg potassium iodate.
c) LABORATORY STUDIES
Complete blood counts, serum biochemical tests and urine analyses were carried out by
standard techniques.
Serum TT4 concentrations were determined using a double antibody RIA technique (DPC; TT4).
Serum TT3 concentrations were determined using a single antibody RIA technique (Amerlex;
MT3). Serum rT3 concentrations were determined using a single antibody RIA with PEG
separation (Biostat Diagnostics; reverse T3).
The serum TT4 and TT3 assays were validated for use with cat serum by SCL Biosciences,
Cambridge, U.K. The validation data is presented in Tables 8.01 and 8.02. The accuracy of the
assays was assessed by determining the recovery of known added amounts of T4 or T3 which
had been added to feline serum. For TT4 and TT3, the mean recovery of low and high
concentrations in 12 experiments per analyte was 104.9 per cent and 97.9 per cent respectively.
The specificity of the assays was demonstrated by dilutional parallelism. The precision of the
assays and an acceptable degree of drift were assessed by the inclusion of low, medium and
high pools of human serum (TT4 concentrations of 46, 103 and 201nmol/l respectively; TT3
concentrations of 0.82, 2.05 and 3.7nmol respectively) and one feline pool (TT4 concentration of
81.48nmol/l; TT3 concentration of 1.39nmol/l) in each assay. The mean within-assay coefficients
of variation for TT4 and TT3 were 4 per cent and 8 per cent respectively and the mean between-
assay coefficients of variation for TT4 and TT3 were 6.6 per cent and 6.0 per cent respectively.
The working ranges of the assays were 4.0 to 300.0 nmol/l for TT4 (reference range 19.0 to 65.0
nmol/l) and 0.20 to 12.00 for TT3 (reference range 0.90 to 3.10 nmol/l).
The RIA for rT3 was not specifically optimised and validated for feline serum but each cat acted
as its own control during the study. The cross reactivity of T4 and T3 in the Biodata
radioimmuoassay kit for rT3 is approximately 0.029 and 0.0086 per cent respectively.
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d) STATISTICAL ANALYSES
The Friedman test was used to examine overall differences in thyroid hormone concentrations
between days 1 to 20 within the treatment groups. The Wilcoxon Signed Rank test was used to
test for differences in heart rates and thyroid hormone concentrations between days 1,11 and 20
within groups. The Mann-Whitney U test was used to examine differences in heart rates and
thyroid hormone concentrations between days 1,11 and 20 between groups. With all tests, a p
value of < 0.05 was considered significant.
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Table 8.01: Recovery data for total L-thyroxine (T4) and total L-triiodothyronine (TT3) assays
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Table 8.02: Dilutional parallelism data for the total L-thyroxine (TT4) and total L-triiodothyronine
(TT3) assays.
Dilution Expected Actual Percent deviation
TT4 (nmol/l)
1:1 191 191 0
1:2 96 92 -4.2
1:4 48 46 -4.2
1:8 24 21 -12.5
1:16 11.9 10 -16.0
1:32 5.9 5.3 -10.2
TT3 (nmol/l)
1:1 7.85 7.85 0
1:2 3.93 3.71 -5.6
1:4 1.96 1.76 -10.2
1:8 0.98 0.79 -19.4
1:16 0.49 0.40 -18.4
1:32 0.24 0.19 -20.8
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8.03 RESULTS
Twenty-three cats were admitted to the trial. One cat had to be withdrawn from group A on day 8
due to the development of congestive cardiac failure and was successfully treated with
carbimazole followed by surgical thyroidectomy. One cat in Group A died suddenly on day 8 of
treatment due to an hepatic infarct.
Twenty-one cats completed the trial with 11 in Group A and 10 in Group B (Table 8.03), although
one cat in each group died on induction of anaesthesia. There were 16 Domestic Shorthaired
and five Domestic Longhaired animals with 15 being ovariohysterectomised females and six
castrated males (three castrated males being present in each of the groups). The median age
was 13 years (range 7 to 16 years). There was no significant difference in the age of the cats
between groups A (median 13 years; range 7 to 16 years) and B (median 12.5 years, range 9 to
15 years) (p = 0.8603).
a) GROUP A CATS
In this group, four cats were treated with 42.5mg three times daily and seven were treated with
21.25mg of potassium iodate three times daily. The only cat in the study which required 7.5mg
propranolol three times daily was in this group.
i) Clinical Response
The drugs were reasonably well-tolerated by most cats. No adverse effects were noted when the
cats were taking the propranolol alone. However, intermittent anorexia and mild depression were
seen in six of the 11 cats in this group once potassium iodate was introduced. Of the six cats that
developed inappetance, three were on 42.5 mg three times daily and three were on 21.25 mg of
potassium iodate three times daily. Six cats vomited at some point during the trial, two of which
which had vomiting as part of their previous history, with four cats vomiting whilst on propranolol
alone.
Figure 8.01 shows the heart rates of the cats in group A over the study period and the data are
summarised in Table 8.04.
Heart rates were well-controlled by the propranolol alone and fell significantly from days 1 to 11
(p = 0.0040), over the entire treatment period (days 1 to 20) (p = 0.0040) but not from days 11 to
20 (p - 0.2490).
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ii) Thyroid Hormone Concentrations
Figure 8.02 shows the serum TT4 concentrations of the cats in group A over the study period
and the data are summarised in Table 8.05.
Of the 11 cats in this group, all had elevated TT4 concentrations on day 1 of the study. Of these,
four (36 per cent) had normal TT4 concentrations on day 20 of the study. The serum TT4
concentrations on day 20 were significantly lower than those on day 1 (p = 0.0370) and there
was a significant difference between the days over the treatment period (p = 0.0000). There was
no significant difference in TT4 concentrations between the first and last days of propranolol
treatment alone (day 1 compared to day 11) (p = 0.3070) but the TT4 concentrations fell
significantly between the first and last days of combined propranolol and potassium iodate
treatment (day 11 compared to day 20) (p = 0.0370).
Figure 8.03 shows the serum TT3 concentrations of the cats in group A over the study period
and the data are summarised in Table 8.05.
Of the 11 cats, nine (82 per cent) had elevated total T3 concentrations at the time of diagnosis
and eight of these (89 per cent) had reference range TT3 concentrations at the time of surgery.
The serum TT3 concentrations on day 20 were significantly lower than those on day 1 (p =
0.0040), and there was a significant difference between the days over the treatment period (p =
0.000). There was a significant fall in the serum TT3 concentrations between day 1 and day 11 (p
= 0.0370) and between days 11 and 20 (p = 0.0040).
Figure 8.04 shows the serum rT3 concentrations of the cats in group A over the study period and
the data are summarised in Table 8.05.
The serum rT3 concentrations on day 20 were significantly lower than on day 1 (p = 0.0040). The
rT3 concentrations did not change significantly from days 1 to 11 (p = 0.1850) but fell significantly
from days 11 to 20 (p = 0.0090).
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b) GROUP B CATS
In this group, four cats were treated with 42.5 mg potassium iodate three times daily and sixwere
treated with 21.25 mg of potassium iodate three times daily.
i) Clinical Response
This regimen seemed less well-tolerated by the cats generally. Anorexia and depression were
noted in four cats (three on 42.5 mg potassium iodate three times daily and one on 21.25 mg
potassium iodate three times daily). Jaundice developed in two cats being given 42.5 mg
potassium iodate towards the end of the treatment period (days 16 and 18 respectively). Both
completed the study. One underwent surgical thyroidectomy and liver biopsy via exploratory
laparotomy. Histopathological examination revealed hepatic lipidosis. The cat survived for 7 days
but subsequently died due to complications of its liver disease. A further cat in this group also
died on induction of anaesthesia. Post-mortem examination revealed no abnormalities in this cat
other than bilateral thyroid adenomatous hyperplasia. Eight out of 10 cats vomited during the
trial, five of which were presented for vomiting as part of their previous history.
Figure 8.05 shows the heart rates of the cats in group B over the study period and the data are
summarised in Table 8.04.
Heart rates were best controlled when propranolol therapy had begun but fell significantly from
days 1 to 20 (p = 0.0060), from days 1 to 11 (p = 0.0060) and from days 11 to 20 (p = 0.0210).
ii) Thyroid Hormone Concentrations
Figure 8.06 shows the serum TT4 concentrations of the 10 cats in group B over the study period
and the data are summarised in Table 8.05.
Of the 10 cats in this group, all had elevated serum TT4 concentrations on day 1 of the study. Of
these, one (10 per cent) had a normal serum TT4 concentration on day 20 of the study, although
a further three cats were transiently euthyroid (during days 4 to 15 inclusive [two cats] and days
16 and 17 [one]). The serum TT4 concentrations on day 20 were not significantly lower than
those on day 1 (p = 0.2340), although there was a significant difference between the days over
the treatment period (p = 0.0020). This may have been due to the outlier on day 20. When this
cat's data were removed, the serum TT4 concentrations on day 20 were significantly lower than
those on day 1 (p = 0.0350). TT4 concentrations fell significantly between the first and last days
of potassium iodate treatment alone (day 1 compared to day 11) (p = 0.041), but not between the
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first and last days of combined propranolol and potassium iodate treatment (day 11 compared to
day 20) (p = 0.2800). The removal of the outlier in this case did not affect this result (p = 0.4470).
Figure 8.07 shows the serum TT3 concentrations of the cats in group B over the study period
and the data are summarised in Table 8.05.
Of the 10 cats in group B, four (40 per cent) had elevated TT3 concentrations on day 1 of the
study. Of these four cats, three (75 per cent) had normal TT3 concentrations at the time of
surgery. The serum TT3 concentrations on day 20 were not significantly lower than those on day
1 (p = 0.1240), although there was a significant difference between days over the treatment
period (p = 0.002). There was no significant fall in serum TT3 concentrations from days 1 to 11 (p
= 0.1390) or from days 11 to 20 (p = 0.7220). The removal of the outlying data did not affect the
statistical outcome.
Figure 8.08 shows the serum rT3 concentrations of the cats in group B over the study period and
the data are summarised in Table 8.05.
The serum rT3 concentrations were not significantly different between days 1 and 20 (p =
0.6360), between days 1 and 11 (p = 0.4760) or 11 and 20 (p = 0.2860). The removal of the
outlying data did not affect the statistical outcome.
c) COMPLETE BLOOD COUNTS
No significant abnormalities attributable to repeated blood sampling were seen in any parameter
in any cat in the study.
d) SERUM POTASSIUM CONCENTRATIONS
The three anorexic cats which had serum potassium concentrations determined all showed
values within the reference range (4.00 to 5.00 nmol/l).
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e) COMPARISON OF GROUP A AND GROUP B CATS
i) Heart Rates
The data comparing the heart rates of the cats in Groups A and B are summarised in Table 8.02.
There was no significant difference in heart rates between group A and B cats at days 1,11 or 20
(p = 0.9439, 0.1809 and 0.3981 respectively).
ii) Thyroid Hormone Concentrations
The data comparing the serum TT4, TT3 and rT3 concentrations of the cats in Groups A and B
are summarised in Table 8.03.
For serum TT4 concentrations, there was no significant difference between group A and B cats
at days 1, 11 or 20 (p = 0.3418, 0.6472 and 0.3069 respectively). Scatter plots showing data
points for serum TT4 concentrations of individual cats in Groups A and B on day 1 and day 20
are shown in Figure 8.09.
For serum TT3 concentrations, there was no significant differences between group A and B cats
at days 1, 11 or 20 (p = 0.5035, 0.1300 and 0.3823 respectively). Scatter plots showing data
points for serum TT3 concentrations of individual cats in Groups A and B on day 1 and day 20
are shown in Figure 8.10.
For serum rT3 concentrations, there was no significant difference between group A and B cats at
days 1, 11 or 20 (p = 1.000, 0.3847, and 0.4033 respectively). Scatter plots showing data points
for serum rT3 concentrations of individual cats in Groups A and B on day 1 and day 20 are
shown in Figure 8.11.
f) LIVER PATHOLOGY
Histological examination of the liver was carried out on three cats, identified by the numbers in
Table 1. All were taking 42.5mg of potassium iodate three times daily. Cat 3 was in Group A and
was the sole cat taking 7.5 mg propranolol three times daily from day 7 of the study. This cat died
on anaesthetic induction. Liver pathology showed hepatocellular necrosis, with minimal periportal
lymphocyte and neutrophil infiltration, indicative of mild cholangitis. The liver changes were not
considered severe enough to have contributed to the cat's death.
207
The Use Of Propranolol And Potassium lodate In The Presurgical Management Of Hyperthyroid
Cats Chapter 8
Two (cats 14 and 15) were in Group B and were taking 5mg propranolol three times daily when
they developed jaundice. Cat 14 was improving at the end of the trial when it had an ultrasound-
guided needle liver biospy. Liver histology from this cat showed mild fatty degeneration together
with acute cholangitis. Cat 15 had a liver biopsy at the time of thyroidectomy. The biopsy results
showed focal fatty nodules and areas of fatty degeneration of cytoplasm indicative of hepatic
lipidosis. However, at post-mortem examination, histological examination showed more chronic
degenerative changes without significant associated fatty abnormalities.
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1 13 DSH MN Vaccination 42.50 No No
2 14 DLH FN Vomiting 42.50 No No
3 15 DSH MN Weight loss 42.50 No No
4 14 DSH FN Weight loss 42.50 Yes Yes
5 16 DSH FN Vaccination 21.25 No No
6 9 DLH FN Weight loss 21.25 Yes No
7 7 DSH FN Weight loss 21.25 No No
8 8 DSH FN Polyphagia 21.25 No No
9 8 DSH FN Heart murmur 21.25 Yes Yes
10 12 DSH MN Weight loss 21.25 Yes Yes





















12 15 DLH MN Vomiting 42.50 No No
13 13 DSH FN PU/PD 42.50 No No
14 10 DSH FN Weight loss 42.50 No No
15 14 DSH MN Weight loss 42.50 Yes No
16 14 DSH FN Polyphagia 21.25 No No
17 10 DLH FN Weight loss 21.25 Yes Yes
18 9 DSH FN Weight loss 21.25 Yes No
19 15 DLH MN Vaccination 21.25 No No
20 12 DSH FN Matted fur 21.25 No No
21 12 DSH FN Anorexia 21.25 Yes No
DLH, Domestic Long Hair; DSH, Domestic Short Hair; FN, Ovariohysterectomised female; MN,
Castrated male; PD, Polydipsia; PU, Polyuria; TID, Three times daily, TT4, Total serum thyroxine
concentration
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Table 8.04: Comparison Of Heart Rates Of Cats In Groups A and B Before, During And At The
End Of Treatment Periods With Propranolol And Potassium lodate
Heart Rate (beats per minute)
Cat Group Day Range Median Quartiles
180-280 240 220 260
11 140-220 180 178 200
20 140-200 180 160 180
B 1 180-270 250 195 260
11 140-240 200 170 220
20 140-210 180 175 200
Group A cats had propranolol from days 1 to 20 and potassium iodate from days 11 to 20
inclusive. Group B cats had potassium iodate from days 1 to 20 and propranolol from days 11 to
20 inclusive
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Table 8.05: Comparison Of Serum Thyroid Hormone Concentrations Of Cats In Groups A And B
Before, During And At the End Of The Treatment Periods With Propranolol And Potassium
lodate.
Thyroid Hormone Concentration (nmol/l)
Thyroid Hormone Cat Group Day Range Median Quartiles
1 88.8 - 275.6 165.6 104.4 214.6
A 11 62.5 - 275.8 155.7 95.4 173.2
20 45.3 - 264.1 97.5 46.2 120.1
Thyroxine
1 88.6 - 313.2 219.7 105.7 285.3
B 11 39.2 - 279.5 120.1 26.3 220.4
20 39.5 - 453.5 120.1 84.0 212.9
1 3.16 - 5.26 4.06 3.48 4.37
A 11 2.47 - 4.74 2.84 2.68 3.49
20 1.18-2.60 1.76 1.36 2.38
Triiodothyronine
1 1.95 - 10.63 2.94 2.19 4.61
B 11 0.54 - 5.87 1.91 0.83 3.05
20 1.00-7.85 1.95 1.63 2.31
1 0.75 - 9.30 3.70 1.22 4.95
A 11 0.62 - 5.55 3.05 1.21 4.36
20 0.50 - 3.30 1.69 0.72 2.10
reverse Triiodothyronine
1 0.87 - 9.50 2.64 1.21 8.43
B 11 0.54 - 4.90 1.72 0.86 3.88
20 0.31 - 7.45 2.60 1.07 3.13
Group A cats had propranolol from days 1 to 20 and potassium iodate from days 11 to 20
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8.04 DISCUSSION
Feline hyperthyroidism is the most commonly diagnosed endocrine disease of cats (Thoday and
Mooney, 1992a). Despite a number of treatment options, the most reliable in the medium to long-
term for the practitioner is surgical thyroidectomy. As hyperthyroid cats are poor anaesthetic risks
(Peterson and Becker, 1983) it is recommended that euthyroidism is induced prior to surgery
(Birchard, Peterson and Jacobson, 1984). The drugs of choice are the thioglyoxalines
carbimazole (NeoMercazole, Roche) available in Europe and methimazole (Tapazole, Eli Lilly)
available in the U.S.A.
Mild clinical adverse reactions (anorexia, vomiting and lethargy) requiring drug withdrawal occur
in approximately 8 per cent and 15 per cent of cats treated with carbimazole and methimazole
respectively (Peterson, Kintzer and Hurvitz, 1988; Mooney, Thoday and Doxey, 1992). Serious
adverse effects, such as thrombocytopenia and agranulocytosis, have been reported in up to 3
per cent of cats treated with methimazole (Peterson, Kintzer and Hurvitz, 1988) but not in cats
treated with carbimazole.
It is clear, therefore, that an alternative method of preparation for surgery is required for a
relatively small percentage, but, because of the high incidence of the disease, a very significant
number, of hyperthyroid cats.
In this study, two groups were chosen to examine initially the independent action of propranolol
and potassium iodate and then to investigate their combined effect. As thyroid hormone
concentrations may fluctuate markedly in hyperthyroid cats not receiving any form of therapy
(Peterson, Graves and Cavanagh, 1987) and, in some cats, TT3 concentrations may fall rapidly
when treated with potassium iodate and propranolol (Thoday, 1986), blood sampling was carried
out daily. No adverse effects on haematological parameters from this protocol were noted.
The cases included in the trial comprised a combination of Domestic Short and Longhaired cats,
with a median age in the two groups of 12.5 and 13 years. This part of the signalment is highly
comparable to previously reported series of hyperthyroid cats (Peterson, Kintzer, Cavanagh et
ah, 1983; Thoday and Mooney, 1992a). There were 2.5 times the number of
ovariohysterectomised females than castrated males. However, this is likely to have arisen by
chance as there is no reported sex predisposition for feline hyperthyroidism, either in our clinic
(Thoday and Mooney, 1992a) or elsewhere (Hoenig, Goldschmidt, Ferguson et a!., 1982;
Peterson, Kintzer, Cavanagh et al., 1983). As the study was designed to evaluate the effect of
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the drugs on serum thyroid hormone concentrations and as concurrent diseases may affect
these, animals with any identified non-thyroidal diseases were excluded from the study.
In the human Graves' disease study (Feek, Sawers, Irvine et at., 1980), patients were treated
with 60mg potassium iodide (yielding 33mg free iodine) three times daily. A proportionately
higher dose of free iodine (25mg three times daily) was initially administered to the cats in this
study to ensure that any potential effect would be induced. Although this dose was subsequently
reduced to 12.5mg three times daily, this is unlikely to have had any effect on the outcome of the
study as 3.3mg free iodine three times daily has previously been shown to have significant
inhibitory effects on thyroid hormone production in cats (Thoday, 1986). The dose of propranolol
used (2.5 to 7.5 mg per cat three times daily) has been shown to be effective in blocking the
increased sympathetic effects of hyperthyroidism in most affected cats. Efficacy was determined
by reduction of heart rate to below 200 beats per minute. This has been reported to be an
appropriate clinical method of determining adequate (3-adrenergic blockade in cats (Jacobs,
Whitten, Sama et al., 1997).
At the beginning of the trial, all cats had elevated TT4 concentrations, while a number in both
groups had reference range TT3 concentrations. The latter has been well-recorded in
hyperthyroid cats and may result from within- or between-day variations in mildly affected
animals or the effects of non-thyroidal illness (Peterson, Graves and Cavanagh, 1987; Peterson
and Gamble, 1988). As cats with non-thyroidal illness were, as far as could be determined,
excluded from the study, the reference range TT3 values in some cats at the beginning of this
study probably resulted from intra- or inter-daily variations which is the far commoner cause in
feline thyrotoxicosis (Thoday and Mooney, 1992a). No cat that had a TT4 concentration at
diagnosis of more than 190nmol/l attained a reference range value during the trial. Although
three cats in Group A and two cats in Group B with serum TT4 concentrations less than
190nmol/l also failed to develop reference range values, it appears that cats with biochemically
more severe hyperthyroidism are less likely to benefit from this regimen than those with lower
TT4 concentrations.
Some animals in both groups developed variable anorexia or depression. No adverse effects
were noted in Group A cats when on the propranolol alone and the number affected was greater,
and the degree of the adverse effects were worse, on the higher dosage of potassium iodate and
in Group B where the drug was given for the full length of the trial. This strongly suggests that
these adverse effects were associated with the potassium iodate and were dose and time
related. Concentrated aqueous solutions of potassium iodide may cause salivation, inappetance
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or anorexia, proportedly as a result of its unpleasant, brassy taste and administration in gelatin
capsules has been recommended to prevent this (Thoday and Mooney, 1992b). Despite this
method of administration, variable anorexia or depression still occurred in some cats suggesting
that the effect may be systemic rather than local.
Although a number of cats vomited occasionally during treatment, this occurred with almost
equal frequency when comparing those on propranolol or potassium iodate alone. Vomiting
occurs in approximately 30 per cent of untreated hyperthyroid cats (Thoday and Mooney, 1992b)
and may result from a direct action of thyroid hormones on the chemoreceptor trigger zone
(Rosenthal, Jones and Lewis, 1976), gastric stasis (Parkin, Nisbet and Bishop, 1982) or rapid
overeating (Peterson, Kintzer, Cavanagh et at., 1983), particularly in multicat households
(Bernstein, 1984). It is therefore difficult to attribute the vomiting to the potassium iodate therapy.
The cause of the liver disease in the three affected cats was not determined. As well as the
adverse effects described above, administration of iodine to cats has been reported to cause
muscle spasms, hypothermia, cardiovascular collapse and death (Wilkinson, 1990). We have
been unable to trace reports of any direct hepatotoxic effects of iodine in either cats or humans.
The clinical, and particularly the histopathological changes, were very different between the three
affected cats also making a direct toxic effect less likely. One possible explanation is that the
well-recognised liver abnormalities of hyperthyroid cats (Mooney, Thoday and Doxey, 1992) may
have been exacerbated by anorexia resulting from iodine administration, leading to hepatic
lipidosis and hepatopathy. Hepatic lipidosis has been reported in a hyperthyroid cat (Center,
1994). Another is the development of thyrotoxic storm as described in humans. This is usually of
unknown cause but may be associated with increased iodine intake. Thyrotoxic storm results in
systolic hypertension and variable gastrointestinal abnormalities including splenomegaly,
hepatomegaly, abnormalities in liver function tests and jaundice, leading to high mortality
(Wartofsky, 1996). Survival is improved by the administration of propranolol although some
workers have reported that standard doses may not prevent storm (Eriksson, Rubenfeld, Garber,
et at., 1977). Thyrotoxic storm has not been reported in cats. To our knowledge, propranolol has
not been reported as a cause of liver abnormalities in either humans or cats.
Group A cats showed no significant fall in serum TT4 concentrations whilst on propranolol alone.
However, there was a significant fall after potassium iodate was introduced. By contrast, serum
TT3 concentrations fell significantly over the first 10 day period of treatment in this group and fell
significantly further once potassium iodate therapy was begun. The fail in serum TT3
concentrations after beginning propranolol was presumably due to decreased peripheral
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conversion of T4 to T3, as in humans so managed (Cooper, Daniels, Ladenson et at., 1982).
Effects of propranolol on the peripheral conversion of T4 to T3 in cats does not appear to have
been previously reported in cats. However, from data presented in this thesis in Chapter 3,
peripheral deiodination of T4 to T3 occurs at similar rates to that in the rat. The fall in both the
TT4 and TT3 concentrations after the addition of potassium iodate therapy is likely to have been
due to the Wolff-Chaikoff effect. Four (36 per cent) cats in this group had TT4 concentrations
within the reference range at the time of surgery. A further cat developed reference range serum
TT4 concentrations on day 15, but showed a secondary rise on day 16. Eighty two per cent of
cats in this group had reference range serum TT3 concentrations at the time of surgery
compared with only 37.5 per cent prior to drug administration.
The reduction in rT3 that occurred in this group during the study is likely to have been a
consequence of the fall in serum TT4 which is converted to rT3 in many tissues, combined with
reduced de novo synthesis.
Group B cats failed to show a significant reduction in serum TT4 concentrations between days 1
and day 20, although overall, there was a significant difference between the days over the
treatment peiiud. This was due to the uulliei which became more thyrotoxic during the treatment
period, as there was a significant fall in TT4 concentrations during the trial period when this data
was excluded. Only one cat had a reference range serum TT4 concentration at the time of
surgery. Although there was a significant difference in serum TT3 concentrations in Group B cats
over the entire treatment period, there was no significant fall during either the first or the second
10 days of the therapeutic regimen. The median serum TT3 concentration on day 20 was lower
than at the beginning of the trial. This suggests that the reduced serum TT3 concentrations could
not be further lowered by inhibition of TT4 to TT3 conversion as propranolol therapy alone
significantly reduced TT3 concentrations in group A. However, 75 per cent of the cats with
elevated serum TT3 concentrations in group B on day 1 of the study had reference range TT3
concentrations at the time of surgery and there was no secondary rise in serum TT3
concentrations in the remainder. Interestingly, serum rT3 concentrations were not significantly
reduced at any time in this group which had potassium iodate administered for the whole study
period, compared with a significant reduction in the cats in group A which only had the potassium
iodate for 10 days. The reasons for this are unknown.
The clinical features of thyrotoxicosis improved in all cats in both groups in this study, even in the
sole cat in which serum thyroid hormone concentrations increased markedly during therapy.
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Feek, Sawers, Irvine et al. (1980) showed that a combination of propranolol and potassium iodide
(as a source of stable iodine) induced clinical and biochemical euthyroidism in all and nine of 10,
human Graves' disease patients respectively, prior to thyroidectomy. In successfully treated
patients, both the serum TT3 and TT4 concentrations fell to within their reference ranges within
means of 5 and 8 days respectively. There was also a significant fall before surgery, and a
transient rise after surgery, of rT3. A secondary rise or 'escape' of thyroid hormones was seen in
only two (20 per cent) of patients. The authors suggested that there may be a previously
unrecognised synergism between the drugs and that the combination may be the optimal
preoperative preparation for patients with Graves' disease.
Although there was no significant difference between the groups, the reduction in heart rates in
the group A and B cats in the first halves of the trial respectively is likely to have resulted from
different mechanisms. In group A cats, it is likely to have been the result of both (3-adrenoceptor
blockade and a reduction in serum TT3 concentrations due to the propranolol. In group B cats,
heart rates are likely to have been controlled by the rapid reduction of serum thyroid hormone
concentrations caused by iodine released from potassium iodate.
These drug combinations induced reference range TT4 concentrations in only five of the 21 cats
(23.8 per cent) in this study (four in group A [36.4 per cent] and one in group B [10 per cent]).
However, the fall to reference range TT3 concentrations was more marked (89 compared with 75
per cent of those with initially elevated serum concentrations in groups A and B respectively). In
the cats which did not achieve values within the respective reference ranges, TT4 and TT3
concentrations were markedly reduced in all but one cat which became more thyrotoxic when
given potassium iodate. It has long been recognised that in some humans, the use of stable
iodine may exacerbate thyrotoxicosis, both alone (Thompson, Thompson, Brailey et al., 1930)
and, rarely, in combination with propranolol (Unger, Couturier, Durez et al., 1981). Whilst this cat
had uneventful surgery and outcome, it would be unwise to proceed with potassium iodate
treatment if the signs of thyrotoxicosis were clearly worsening.
Another alternative regimen for the medical management of hyperthyroidism in cats, using
calcium ipodate, was recently published (Murray and Peterson, 1997). The results are difficult to
compare with the present study but 33 per cent of their cats failed to respond and the serum TT4
concentration remained high in all cats, although the serum TT3 concentration fell into the
reference range in 66 per cent of the cases. The lack of a fall in TT4 concentrations in a large
number of cats is not surprising as ipodate acts on peripheral deiodination of T4 to T3, and not to
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reduce de novo synthesis of T4. No adverse effects attributable to ipodate therapy were reported
in that study.
As previous studies had been carried out on the two drugs individually in humans, it was
proposed that the combination of propranolol and potassium iodide may be synergistic in
lowering serum thyroid hormone concentrations of patients with Graves' disease (Feek et al.,
1980). The separate effects of the two drugs have not been determined in cats and no such
conclusions can be made from this study.
Cats in group A appeared to tolerate this regimen better and more cats in this group had
reference range TT4 and TT3 concentrations at the time of surgery. Furthermore, Group A cats
had a significant reduction in TT3 concentrations over the treatment period whilst Group B cats
did not, suggesting the regimen for Group A may be the preferred treatment for clinical cases
which cannot tolerate carbimazole. As three cats developed liver pathology, biochemical
monitoring of indices of hepatic damage should be undertaken regularly, particularly during the
potassium iodate administration phase of the treatment regimen.
In summary, the use of propranolol and potassium iodate may offer an alternative to presurgical
treatment with carbimazole in cats that cannot tolerate this drug. The regimen used in group A
(propranolol for all 20 days and potassium iodate for the last 10 days) was both the most
effective in lowering serum thyroid hormone concentrations and associated with the least
adverse effects. As the maximal reduction in both TT4 and TT3 concentrations occurred in the
majority of cats in either group, within the first 3 to 5 days of potassium iodate therapy, further
studies to determine whether 5 days of potassium iodate therapy would be adequate for
stabilisation prior to thyroidectomy may be useful. Further, reduced doses of potassium iodate
may be as effective in reducing TT4 and TT3 concentrations and may also prove to have less
deleterious effects on feline patients. As the study performed by Birchard, Peterson and
Jacobsen (1984) reporting a 75 per cent mortality in surgical feline patients not pretreated
medically is now almost 15 years old, the risk of thyroidectomy may be lower than that which this
group reported due to the advent of improved monitoring and modern anaesthetics.
The regimen investigated in the present study is unlikely to be of use in the long term medical
control of thyrotoxicosis in cats as it would be expected that cats would eventually 'escape' from




Hyperthyroidism caused by toxic nodular goitre, is the commonest endocrine disease of the
domestic cat. Despite this, little is known about feline thyroid physiology, pathophysiology, nor
the pathogenesis of the disease.
This thesis has examined several aspects regarding the pathogenesis and management of
hyperthyroidism and thyroid hormone deiodination in the domestic cat. The main objectives of
this thesis were to examine a number of possibilities regarding the pathogenesis of feline
hyperthyroidism. These included determining the possible existence and significance of thyroid
growth stimulating immunoglobulins and TSHR mutations in the pathogenesis of feline nodular
goitre. Selenoenzyme expression in the feline thyrocyte and selenium status in cats was also
studied to determine their possible role in the pathogenesis of this important endocrine disease.
In addition to this, thyroid hormone deiodination in the domestic cat was investigated since this
reaction is catalysed by selenoenzymes. Finally, a new method for pre-surgical stabilisation was
examined as a possible alternative treatment in cats which cannot tolerate carbimazole.
The work in this thesis has allowed the following conclusions to be reached.
1. While feline liver and kidney express IDI at similar concentrations, and the feline enzyme is
able to metabolise T4 at a similar rate to that of rats, feline IDI is unusual in that it has little
ability to metabolise reverse triiodothyronine which is the preferred substrate for this enzyme
in rats and humans. Additionally, unlike all other carnivores and omnivores studied thus far,
cats were not found to express thyroidal IDI. The sequence of the feline enzyme would be of
particular interest.
2. Brown's group (1992) reported the existence of thyroid growth stimulating immunoglobulins
in cats with thyrotoxicosis. We have been unable to confirm her findings in the most
appropriate cell model (feline thyrocytes). Using feline thyrocytes, Chinese hamster ovary
cells expressing human TSHR (JP09) and the rat thyrocyte cell line FRTL-5, no populations
of immunoglobulins were detectable in the sera of hyperthyroid cats which stimulated cAMP
production, displaced TSH binding from its receptor or induced growth when compared to
euthyroid cats. Similar results were found using unpurified sera. These results indicate that




3. As many selenoenzymes are involved in regulating thyroid hormone production (GPX),
metabolism (ID) and cell growth (TR), we investigated the selenoenzyme profile of both
normal and adenomatous feline thyrocytes and the selenium status in cats from four different
regions. TR was found to be overexpressed in a number of adenomatous thyrocyte
preparations. This may reflect the increased growth characteristics of these cells, or, in
addition, the enzyme may help to protect the adenomatous thyrocyte from oxidative damage
by H202 during thyroid hormone production. Alternatively, it may be that increased TR
expression may in turn promote the disease. Simultaneous experiments characterising
selenoenzyme and growth characteristics may help to determine the significance of
enhanced TR expression.
4. The plasma selenium status of cats from areas with high (Edinburgh, U.K. and Sydney,
Eastern Australia) and low (Greve, Denmark and Perth, Western Australia) incidences,
respectively, of hyperthyroidism were not significantly different from each other. Cats,
however, have plasma selenium concentrations and red blood cell glutathione peroxidase
activities which are approximately 10 times that of selenium replete rats and humans. High
selenium status of cats may increase their risk of thyrotoxicosis but other factors may not
allow the expression of this disease in certain areas (e.g. Perth and Greve). It would,
therefore, be interesting to examine other known risk factors of feline hyperthyroidism (indoor
lifestyle, eating canned food and the use of flea-sprays, herbicides and pesticides) and to
determine longevity of cats in these four regions. The possible link between iodine and
selenium intake in domestic cats may also provide further evidence for dietary triggers of this
disease.
5. Our work could find no evidence of activating mutations in the TSH receptor of affected cats.
In 11 hyperthyroid cats, the DNA for the TSHR region between codons 480 and 640 (the
most common site for somatic mutations in human toxic nodular goitre) were not found to
contain any such mutations.
6. The mainstay of presurgical treatment for hyperthyroidism is the use of carbimazole, a drug
which is poorly tolerated by approximately 8 per cent of affected cats. A combination of
propranolol and potassium iodate was found to normalise heart rates, serum T3, and to a
lesser extent T4 concentrations in a significant number of cats and may be used as an
alternative presurgical treatment in those cats which cannot tolerate carbimazole.
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Concluding Remarks
In conclusion, this thesis has provided evidence that:
1. Growth stimulating immunoglobulins do not appear to be an important part of the
pathogenesis of feline hyperthyroidism.
2. Unlike human toxic nodular goitre, somatic TSHR mutations appear to be an uncommon
cause of feline hyperthyroidism.
3. Feline thyroid hormone metabolism is different to that in other species. Cats appear to lack
the ability to metabolise rT3 by deiodination and (unlike other carnivores/omnivores
investigated) lack expression of thyroidal IDI. However, the majority of plasma T3 is likely to
be generated by the peripheral deiodination of T4 as in other species.
4. The expression of selenoenzymes in some adenomas appears to be different to that of
normal feline thyrocytes and may be an important part of the growth and functional
characteristics of thyroid adenomas.
5. Cats appear to have extremely high blood selenium status in many areas of the world. The
implications for feline health may be dramatic and require further investigation.
6. The use of beta-blocking drugs such as propranolol with the combination of stable iodine
may provide an important pre-surgical alternative to carbimazole.
Further studies that would be of interest would be to clone feline IDI to determine the important
sequence differences between cats and other species and to examine peripheral deiodination of
rT3 in this species in more detail. Whilst this thesis was in preparation, a collaborative study
between our group and a group in France was carried out to investigate the peripheral
metabolism of 14C-T4 in vivo in cats (compared to rabbits) to confirm our in vitro data that shows
feline IDI can deiodinate T4. It would be of interest to examine G-protein expression and
investigate the possibility for G-protein mutations which may be responsible for this disease and
possibly extend the cloning of the feline TSHR to determine if somatic mutations in other parts of
the receptor may be responsible for feline thyrotoxicosis. Multicentre epidemiological studies
from areas with varying incidences of thyrotoxicosis would be of interest to examine the possible
risk factors already determined to see if there is a difference between these areas. The iodine
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>301 THYROID HORMONE DEIODINATION IN THE THYROID AND LIVER OF THE DOMESTIC
CAT.
Foster DJ, Thoday KL *Beckett GJ. University Departments of Veterinary Clinical Studies and
*Clinical Biochemistry, Royal Infirmary, Edinburgh EH3 9YW.
The iodothyronine deiodinases are selenoenzymes that play an important role in the peripheral conversion of
thyroxine (T4) to triiodothyronine (T3), reverse triiodothyronine (rT3) and diiodothyronines. In most species
around 80% of circulating T3 originates from the 5' mono-deiodination of T4 in the liver and kidney by type
I iodothyronine deiodinase (IDI). In many omnivorous species, such as rodents and humans, thyroidal DDI
may also provide an important source of circulating T3 since the liver and thyroid of these species express
high activities of IDI. Little or no thyroidal IDI is expressed by herbivores (e.g. deer, llama, goat, sheep,
cattle) but high expression of IDI is found in the liver of these species. Type II iodothyronine deiodinase
(IDII) also carries out 5' monodeiodination of T4 to produce T3 but this enzyme usually contributes little to
circulating T3. IDII is not expressed by liver but is found mainly in brown adipose tissue and brain.
Hyperthyroidism is a common disease in the cat but little is known about the process of thyroid hormone
deiodination in this species. We have assessed thyroid hormone deiodination in the liver and thyroid of the
cat using l25I-rT3 as a substrate. We found we were unable to detect any deiodinase activity in the thyroid of
two euthyroid cats and three thyrotoxic cats. The deiodinase activity in liver homogenates prepared from
three cats was only approximately 10% of that found in rat liver. In cat liver, deiodinase activity could not
inhibited the addition of aurothioglucose (ljiM - lOmM) or propylthiouracil (ltiM - 10 mM), suggesting this
enzyme was not IDI but rather IDE. These results suggest that in the cat, hepatic and thyroidal deiodination
plays only a minor role in generating the circulating pool of T3. In the cat circulating T3 may be derived from
predominantly de novo thyroidal synthesis or by deiodinadon in other tissues.
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ABSTRACT
A prospective study was carried out using a
combination of propranolol and potassium
iodate to assess whether there were beneficial
effects in preparing hyperthyroid cats for
surgical thyroidectomy. Group A (n = 11)
received propranolol' from days 1 to 10
followed by propranolol and potassium iodate
from days 11 to 20 whereas group B (n = 10)
received the reverse regimen. Blood samples
were taken daily for subsequent determination
of serum total L-thyroxine (TT4), L-
triiodothyronine (TT3) and reverse T3 (rT3)
concentrations. The signs of hyperthyroidism
improved in all cats over the treatment period.
At surgery, in group A, 36 per cent of the cats
had reference range serum TT4 concentrations
while 89 per cent with initially elevated TT3
concentrations had reference range
concentrations. In group B, 10 per cent of the
cats had a reference range TT4 concentration
while 75 per cent with initially elevated TT3
concentrations had reference range
concentrations. The drug regimen used in
group A was better tolerated and more
effective and offers an alternative prior to
thyroidectomy in cats that cannot tolerate
carbimazole.
INTRODUCTION
The induction of euthyroidism by prior short-
term medical therapy dramatically reduces
peri-surgical mortality in hyperthyroid cats
(Birchard and others, 1984). The most
commonly used drug to treat cats prior to
surgical thyroidectomy in the UK is the
thioglyoxaline carbimazole. However, adverse
effects (vomiting, anorexia and depression)
requiring withdrawal of the drug, occur in
approximately 8 per cent of treated cats
(Mooney and others, 1992) and these cats
usually go to surgery still thyrotoxic.
It has previously been shown in humans with
hyperthyroidism caused by Graves' disease,
that a combination of propranolol and
potassium iodide (as a source of stable iodine)
induced euthyroidism before surgical
thyroidectomy (Feek and others, 1980). A
pharmaceutical preparation of potassium
iodide is no longer available in the UK and
potassium iodate is now being used in its
place.
The aim of this prospective study was to
determine whether a combination of
propranolol and potassium iodate might be an




The clinical material comprised a series of 23
hyperthyroid cats presented to the Small
Animal Clinic of The University of Edinburgh's
Royal (Dick) School of Veterinary Clinical
Studies. A tentative diagnosis of
hyperthyroidism was made on the basis of
compatible historical and physical features and
confirmed by the presence of elevated serum
total L-thyroxine (TT4) concentrations in all
cases.
Before admission to the study, blood was
collected by jugular venepuncture for
haematological examinations and
determination of a 13 parameter biochemical
profile. Urine was collected by cystocentesis.
Animals with identified concurrent non-thyroidal
diseases were excluded from the study. After
the informed consent of their owners, animals
were were assigned alternately to one of two
groups (A and B) and hospitalised for the
duration of the study.
Study Protocols
Group A cases received propranolol (Inderal,
Zeneca) alone at 2.5mg/cat every eight hours
from days 1 to 10 inclusive. The heart rate was
determined each morning. If an animal's heart
rate exceeded 200 beats/minute on day 4, the
propranolol dosage was increased to 5mg/cat
every eight hours and if it still exceeded this
rate on day 7, to 7.5 mg/cat every eight hours
for the remainder of the 10 days.
Subsequently, the same dose of propranolol
and, initially, 42.5mg potassium iodate
(equivalent to 25mg free iodine, Potassium
lodate tablets 85mg, Cambridge Self-Care
Diagnostics) were administered every eight
hours from days 11 to 20 until the time of
surgery. The potassium iodate tablets were
placed in gelatin capsules. Surgery was carried
out on day 21. Potassium iodate was stopped
immediately before thyroidectomy while
1
propranolol was continued post-operatively for
a further three days.
Group B cases were treated in the same way
with the exception that they received
potassium iodate alone from days 1 to 10
inclusive followed by potassium iodate and
propranolol in combination from days 11 to 20
inclusive, with propranolol alone being
continued post-operatively for a further three
days.
Potassium iodate at the above dose appeared
to cause an unacceptable degree of adverse
effects (intermitent anorexia and vomiting, and
mild depression) in some cats. Consequently,
the dosage was reduced to 21.25mg
(equivalent to 12.5mg free iodine) and no
further adverse effects were observed.
Cats were bled daily from day 1 to day 20
inclusive by jugular venepuncture. Two ml
whole blood were collected in a plain tube.
Serum was harvested and stored at -40°C for
subsequent assay of TT4, total L-
triiodothyronine (TT3) and 3,3', 5'
triiodothyronine (reverse triiodothyronine, rT3),
which was carried out in respective batch
modes. Complete blood counts were carried
out at five day intervals on each cat to ensure
that repeated blood sampling did not result in
values outside the respective reference
ranges. Serum potassium concentrations were
determined in three cats which became
anorexic on days 15 (one in group A and one
in group B, on 42.5 and 21.25mg potassium
iodate respectively) and on day 17 in one cat in
group A on 42.5mg potassium iodate.
Laboratory Studies
Complete blood counts, serum biochemical
tests and urine analyses were carried out by
standard techniques.
Serum TT4 concentrations were determined
using a double antibody radioimmunoassay
(RIA) technique (DPC TT4). Serum TT3
concentrations were determined using a
double antibody RIA technique (Amerlex MT3).
Serum rT3 concentrations were determined
using a polyethylene glycol separation
radioimmunoassay technique (Biostat
Diagnostics).
The serum TT4 and TT3 assays were
specifically validated for use with cat serum.
The accuracy of the assays was assessed by
determining the recovery of known amounts of
T4 or T3 which had been added to the diluent
used in the standard production. For TT4 and
TT3, the mean recovery of low and high
concentrations in six experiments per analyte
was 104.9 per cent and 97.9 per cent
respectively. The specificity of the assays was
demonstrated by dilutional parallelism. The
precision of the assays and an acceptable
degree of drift were assessed by the inclusion
of low, medium and high pools in each assay.
The mean within-assay coefficients of variation
for TT4 and TT3 were 4 per cent and 8 per
cent respectively and the mean between-assay
coefficients of variation for TT4 and TT3 were
6.6 per cent and 6.0 per cent respectively. The
working ranges of the assays were 4.0 to 300.0
nmol/l for TT4 (reference range 19.0 to 65.0
nmol/l) and 0.20 to 12.00 for TT3 (reference
range 0.90 to 3.10 nmol/l).
The RIA for rT3 was not specifically optimised
and validated for feline serum but each cat
acted as its own control during the study.
Statistical Analyses
The Friedman test was used to examine
overall differences in thyroid hormone
concentrations between days 1 to 20 within the
treatment groups. The Wilcoxon Signed Rank
test was used to test for differences in heart
rates and thyroid hormone concentrations
between days 1,11 and 20 within groups. The
Mann-Whitney U test was used to examine
differences in heart rates and thyroid
hormone concentrations between days 1, 11
and 20 between groups. With all tests, a p
value of < 0.05 was considered significant.
RESULTS
Twenty-three cats were admitted to the trial.
One cat had to be withdrawn from group A on
day 8 due to the development of congestive
cardiac failure and was successfully treated
with carbimazole followed by surgical
thyroidectomy. One cat in Group A died
suddenly on day 8 of treatment due to an
hepatic infarct.
Twenty-one cats completed the trial with 11 in
Group A and 10 in Group B (Table 1), although
one cat in each group died on induction of
anaesthesia. There were 16 Domestic
Shorthaired and five Domestic Longhaired
animals with 15 being ovariohysterectomised
females and six castrated males (three
castrated males being present in each of the
groups). The median age was 13 years (range
7 to 16 years). There was no significant
difference in the age of the cats between
groups A (median 13 years; range 7 to 16
years) and B (median 12.5 years, range 9 to 15
years) (p = 0.8603).
Group A Cats
In this group, four cats were treated with
42.5mg three times daily and seven were
treated with 21.25mg of potassium iodate three
2
times daily. The only cat in the study which
required 7.5mg propranolol three times daily
was in this group.
Clinical Response
The drugs were well-tolerated by most cats. No
adverse effects were noted when the cats were
taking the propranolol alone. However,
intermittent anorexia and mild depression were
seen in six of the 11 cats in this group once
potassium iodate was introduced. Of the six
cats that developed inappetance, three were
on 42.5 mg three times daily and three were on
21.25 mg of potassium iodate three times daily.
Six cats vomited at some point during the trial,
two of which which had vomiting as part of their
previous history with four cats vomiting whilst
on propranolol alone.
Table 2 shows the data for the heart rates of
the 11 cats in group A.
Heart rates were well-controlled by the
propranolol alone and fell significantly from
days 1 to 11 (p = 0.0040), over the entire
treatment period (days 1 to 20) (p = 0.0040)
but not from days 11 to 20 (p = 0.2490).
Thyroid Hormone Concentrations
Fig. 1 shows the serum TT4 concentrations of
the cats in group A over the study period and
the data are summarised in Table 3.
Of the 11 cats in this group, all had elevated
TT4 concentrations on day 1 of the study. Of
these, four (36 per cent) had normal TT4
concentrations on day 20 of the study. The
serum TT4 concentrations on day 20 were
significantly lower than those on day 1 (p =
0.0370), and there was a significant difference
between the days over the treatment period (p
= 0.0000). There was no significant difference
in TT4 concentrations between the first and
last days of propranolol treatment alone (day 1
compared to day 11) (p = 0.3070). but the TT4
concentrations fell significantly between the
first and last days of combined propranolol and
potassium iodate treatment (day 11 compared
to day 20) (p = 0.0370).
Fig. 2 shows the serum TT3 concentrations of
the cats in group A over the study period and
the data are summarised in Table 3.
Of the 11 cats, nine (82 per cent) had elevated
total T3 concentrations at the time of diagnosis
and eight of these (89 per cent) had reference
range TT3 concentrations at the time of
surgery. The serum TT3 concentrations on day
20 were significantly lower than those on day 1
(p = 0.0040), and there was a significant
difference between the days over the treatment
period (p = 0.000). There was a significant fall
in the serum TT3 concentrations between day
I and day 11 (p = 0.0370) and between days
II and 20 (p = 0.0040).
The data for serum rT3 concentrations of the
11 cats in group A are summarised in Table 3.
The serum rT3 concentrations on day 20 were
significantly lower than on day 1 (p = 0.0040).
The rT3 concentrations did not change
significantly from days 1 to 11 (p = 0.1850), but
fell significantly from days 11 to 20 (p =
0.0090).
Group B Cats
In this group, 4 cats were treated with 42.5 mg
three times daily and 6 were treated with 21.25
mg of potassium iodate three times daily.
Clinical Response
This regimen seemed less well-tolerated by the
cats generally. Anorexia and depression were
noted in four cats (three on 42.5 mg potassium
iodate three times daily and one on 21.25 mg
potassium iodate three times daily). Jaundice
developed in two cats being given 42.5 mg
potassium iodate towards the end of the
treatment period (days 16 and 18 respectively).
Both completed the study. One underwent
surgical thyroidectomy and liver biopsy via
exploratory laparotomy. Histopathological
examination revealed hepatic lipidosis. The cat
survived for 7 days but subsequently died due
to complications of its liver disease. A further
cat in this group also died on induction of
anaesthesia. Post-mortem examination
revealed no abnormalities in this cat other than
bilateral thyroid adenomatous hyperplasia.
Eight out of 10 cats vomited during the trial,
five of which were presented for vomiting as
part of their previous history.
The data for heart rates of the 10 cats in group
B are summarised in Table 2.
Heart rates were well controlled during the
treatment period and fell significantly from days
1 to 20 (p = 0.0060), from days 1 to 11 (p =
0.0060) and from days 11 to 20 (p = 0.0210).
Thyroid Hormone Concentrations
Fig. 3 shows the serum TT4 concentrations of
the 10 cats in group B over the study period
and the data are summarised in Table 3.
Of the 10 cats in this group, all had elevated
serum TT4 concentrations on day 1 of the
study. Of these, one (10 per cent) had a
normal serum TT4 concentration on day 20 of
the study, although a further three cats were
transiently euthyroid (during days 4 to 15
inclusive [two cats] and days 16 and 17 [one]).
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The serum TT4 concentrations on day 20 were
not significantly lower than those on day 1 (p =
0.2340), although there was a significant
difference between the days over the treatment
period (p = 0.002). TT4 concentrations fell
significantly between the first and last days of
potassium iodate treatment alone (day 1
compared to day 11) (p = 0.041), but not
between the first and last days of combined
propranolol and potassium iodate treatment
(day 11 compared to day 20) (p = 0.2800).
Fig. 4 shows the serum TT3 concentrations of
the cats in group B over the study period and
the data are summarised in Table 3.
Of the 10 cats in group B, four (forty per cent)
had elevated TT3 concentrations on day 1 of
the study. Of these four cats,, three (75 per
cent) had normal T3 concentrations at the time
of surgery. The serum TT3 concentrations on
day 20 were not significantly lower than those
on day 1 (p = 0.1240), although there was a
significant difference between days over the
treatment period (p = 0.002). There was no
significant fall in TT3 concentrations from days
I to 11 (p = 0.1390) or from days 11 to 20 (p =
0.7220).
The data for serum rT3 concentrations of cats
in group B are summarised in Table 3.
The serum rT3 concentrations were not
significantly different between days 1 and 20 (p
= 0.6360), between days 1 and 11 (p =
0.4760) or 11 and 20 (p = 0.2860).
Complete Blood Counts
No significant abnormalities attributable to
repeated blood sampling were seen in any
parameter in any cat in the study.
Serum Potassium Concentrations
The three anorexic cats which had serum
potassium concentrations determined all
showed values within the reference range
(4.00 - 5.00 nmol/l).
Comparison Of Group A And Group B Cats
Heart Rates
The data comparing the heart rates of the cats
in Groups A and B are summarised in Table 3.
There was no significant difference in heart
rates between group A and B cats at days 1,
II or 20 (p = 0.9439, 0.1809 and 0.3981
respectively).
Thyroid Hormone Concentrations
The data comparing the serum TT4, TT3 and
rT3 concentrations of the cats in Groups A and
B are summarised in Table 3.
For serum TT4 concentrations, there was no
significant difference between group A and B
cats at days 1, 11 or 20 (p = 0.3418, 0.6472
and 0.3069 respectively).
For serum TT3 concentrations, there was no
significant differences between group A and B
cats at days 1, 11 or 20 (p = 0.5035, 0.1300
and 0.3823 respectively).
For serum rT3 concentrations, there was no
significant difference between group A and B
cats at days 1, 11 or 20 (p = 1.000, 0.3847,
and 0.4033 respectively).
Liver Pathology
Histological examination of the liver was
carried out on three cats, identified by the
numbers in Table 1. All were taking 42.5mg of
potassium iodate three times daily. Cat 3 was
in Group A and was the sole cat taking 7.5 mg
propranolol three times daily from day 7 of the
study. The cat died on anaesthetic induction.
Liver pathology showed hepatocellular
necrosis, with minimal periportal lymphocyte
and neutrophil infiltration, indicative of mild
cholangitis. The liver changes were not
considered severe enough to have contributed
to the cat's death.
Two (cats 14 and 15) were in Group B and
were taking 5mg propranolol three times daily
when they developed jaundice. Cat 14 was
improving at the end of the trial when it had an
ultrasound-guided needle liver biospy. Liver
histology from this cat showed mild fatty
degeneration together with acute cholangitis.
Cat 15 had a liver biopsy at the time of
thyroidectomy. The biopsy results showed
focal fatty nodules and areas of fatty
degeneration of cytoplasm indicative of hepatic
lipidosis. However, at post-mortem
examination, histological examination showed
more chronic degenerative changes without
significant associated fatty abnormalities.
DISCUSSION
Feline hyperthyroidism (thyrotoxicosis) is the
most commonly diagnosed endocrine disease
of cats (Thoday and Mooney, 1992). Despite a
number of treatment options, the most reliable
in the medium to long-term for the practitioner
is surgical thyroidectomy. As hyperthyroid cats
are poor anaesthetic risks (Peterson and
others, 1983) it is recommended that
euthyroidism is induced prior to surgery
(Birchard and others, 1984). The drugs of
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choice are the thioglyoxalines carbimazole
(NeoMercazole, Roche) available in Europe
and methimazole (Tapazole, Eli Lilly) available
in the U.S.A.
Mild clinical adverse reactions (anorexia,
vomiting and lethargy) requiring drug
withdrawal occur in approximately 8 per cent
and 15 per cent of cats treated carbimazole
and methimazole respectively (Peterson and
others, 1988; Mooney and others, 1992).
Serious adverse effects, such as
thrombocytopenia and agranulocytosis, have
been reported in up to 3 per cent of cats
treated with methimazole (Peterson and
others, 1988) but not in cats treated with
carbimazole.
Other drugs that have been used to treat feline
hyperthyroidism include stable iodine (127l) and
the beta-adrenoceptor blocking agents.
Stable iodine was the earliest agent used
effectively to treat human thyrotoxicosis. Large
doses dramatically decrease thyroid hormone
synthesis (the Wolff-Chaikoff effect) by
reducing peroxidase-catalysed organification of
iodide (Wolff and Chaikoff, 1948). Thyroid
hormone release is also decreased as a result
of inhibition of thyroglobulin endocytosis.
Unfortunately, the failure of thyroid function of
most human patients to normalise (Emerson
and others, 1975) and rapid escape from its
inhibitory control (Cooper, 1991) mean that
iodine cannot be used as sole therapy for long
term management of thyrotoxicosis.
It is currently believed that an excess of thyroid
hormones causes an increase in the number of
beta-adrenoceptors or an amplification of the
adrenergic signal at the cell membrane level
(Trepanier, 1990) and that many of the signs of
hyperthyroidism are due to subsequently
enhanced catecholamine activity with
increased sympathetic drive. Thus, the beta-
adrenoceptor blocking drugs very effectively
ameliorate many of these signs and some
studies (Feely and Peden, 1984; Lennquist
and others, 1985; Alderberth and others, 1987)
have reported them to be as effective as the
thioureylenes in the pre-surgical management
of human patients awaiting thyroidectomy.
However, the negative nitrogen balance,
increased cardiac output and elevated rate of
oxygen consumption of thyrotoxicosis are
seldom normalised (O'Malley and others,
1982) and patients remain hyperthyroid.
Propranolol, the beta-adrenoceptor blocking
drug most frequently used in hyperthyroid cats,
has been employed as the sole agent for
presurgical stabilisation (Carlson, 1986). It is a
non-selective beta,- and beta2-adrenoceptor
blocking agent with no direct effects on the
thyroid gland. However, like some other beta-
adrenoreceptor blockers, propranolol
decreases peripheral monodeiodination of T4
to T3 (Feely and Peden, 1984). However,
serum TT3 concentrations fall by a maximum
of 30 per cent, serum TT4 concentrations are
usually unaffected and euthyroidism is not
restored (Lotti and others, 1977; Wiersinga and
Touber, 1977).
It is clear, therefore, that an alternative method
of preparation for surgery is required for a
relatively small percentage, but, because of the
high incidence of the disease, a very significant
number, of hyperthyroid cats.
Feek and others (1980) showed that a
combination of propranolol and potassium
iodide (as a source of stable iodine) induced
clinical and biochemical euthyroidism in all and
nine of 10, human Grave's patients
respectively prior to thyroidectomy. In
successfully treated patients, both the serum
TT3 and TT4 concentrations fell to their
reference ranges within means of 5 and 8 days
respectively. There was also a significant fall
before surgery, and a transient rise after
surgery, of rT3. A secondary rise or 'escape' of
thyroid hormones was seen in only two (20 per
cent) of patients. The authors suggested that
there may be a previously unrecognised
synergism between the drugs and that the
combination may be the optimal preoperative
preparation for patients with Grave's disease.
Pharmaceutical preparations of both potassium
iodide and iodine are currently unavailable in
the UK. Potassium iodate is now used as the
source of stable iodine in human medicine.
A condition comparable to Grave's disease has
not been recorded in cats. The causal
pathological change is commonly termed
thyroid adenoma (adenomatous hyperplasia),
which closely resembles that seen in human
toxic nodular goitre. Apart from a pilot study by
one of us (Thoday, 1986), to our knowledge
there are no previous reports of the use of
propranolol and stable iodine to reduce plasma
thyroid hormone concentrations prior to
surgery in feline toxic nodular goitre.
In the human Grave's disease study, patients
were treated with 60mg potassium iodide
(yielding 33mg free iodine) three times daily. A
proportionately higher dose of free iodine
(25mg three times daily) was initially
administered to the cats in this study to ensure
that any potential effect would definitely be
induced. Although this dose was subsequently
reduced to 12.5mg three times daily, this is
unlikely to have had any effect on the outcome
of the study as 3.3mg free iodine three times
daily has previously been shown to have
significant inhibitory effects on thyroid hormone
production in cats (Thoday, 1986). The dose of
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propranolol used (2.5 to 7.5 mg per cat three
times daily) has been shown to be effective in
blocking the increased sympathetic effects of
hyperthyroidism in most affected cats. Efficacy
was determined by reduction of heart rate to
below 200 beats per minute. This has been
reported to be an appropriate clinical method of
determining adequate B-adrenergic blockade in
cats (Jacobs and others, 1997).
In this study two groups were chosen to
examine initially the independent action of
propranolol and potassium iodate and then to
investigate their combined effect. As thyroid
hormone concentrations may fluctuate
markedly in hyperthyroid cats not receiving any
form of therapy (Peterson and others, 1987)
and, in some cats, TT3 concentrations may fall
rapidly when treated with potassium iodate and
propranolol (Thoday, 1986) blood sampling
was carried out daily. No adverse effects on
haematoiogicai parameters from this protocol
were noted.
The cases included in the trial comprised a
combination of Domestic Short and Longhaired
cats, with a median age in the two groups of
12.5 and 13 years. This part of the signalment
is highly comparable to previously reported
series of hyperthyroid cats (Peterson and
others, 1983; Thoday and Mooney, 1992).
There were 2.5 times the number of
ovariectomised females than castrated males.
However, this is likely to have arisen by
chance as there is no reported sex
predisposition for feline hyperthyroidism, either
in our clinic (Thoday and Mooney, 1992) or
elsewhere (Hoenig and others, 1982; Peterson
and others, 1983). As the study was designed
to evaluate the effect of the drugs on serum
thyroid hormone concentrations and as
concurrent diseases may affect these, animals
with any identified non-thyroidal diseases were
excluded from the study.
At the beginning of the trial, all cats had
elevated TT4 concentrations, while a number
in both groups had reference range TT3
concentrations. The latter has been well
recorded in hyperthyroid cats and may result
from within or between day variations in mildly
affected animals or the effects- of non-thyroidal
illness (Peterson and others, 1987; Peterson &
Gamble, 1988). As cats with non-thyroidal
illness were, as far as could be determined,
excluded from the study, the reference range
TT3 values in this study probably resulted from
intra or inter-daily variations which is the far
commoner cause in feline thyrotoxicosis
(Thoday and Mooney, 1992). No cat that had a
TT4 concentration at diagnosis of more than
190nmol/l developed a reference range value
during the trial. Although three cats in Group A
and two cats in Group B with serum TT4
concentrations less than 190nmol/l also failed
to develop reference range values, it appears
that cats with biochemically more severe
hyperthyroidism are less likely to benefit from
this regimen than those with lower TT4
concentrations.
Some animals in both groups developed
variable anorexia or depression. No adverse
effects were noted in Group A cats when on
the propranolol alone and the number affected
was greater and the degree of the adverse
effects were worse on the higher dosage of
potassium iodate and in Group B where the
drug was given for the full length of the trial.
This strongly suggests that these adverse
effects were associated with the potassium
iodate and were dose and time related.
Concentrated aqueous solutions of potassium
iodide may cause salivation, inappetance or
anorexia, proportedly as a result of its
unpleasant, brassy taste and administration in
gelatin capsules has been recommended to
prevent this (Thoday and Mooney, 1992).
Despite this method of administration, variable
anorexia or depression still occurred in some
cats suggesting that the effect may be
systemic rather than local.
Although a number of cats vomited
occassionally during treatment, this occurred
with almost equal frequency when comparing
those on propranolol or potassium iodate
alone. Vomiting occurs in approximately 30 per
cent of untreated hyperthyroid cats (Thoday
and Mooney, 1992) and may result from a
direct action of thyroid hormones on the
chemoreceptor trigger zone (Rosenthal and
others, 1976), gastric stasis (Parkin and
others, 1982) or rapid overeating (Bernstein,
1984). It is therefore difficult to attribute the
vomiting to the potassium iodate therapy.
The cause of the liver disease in the three
affected cats was not determined. As well as
the adverse effects described above,
administration of iodine to cats has been
reported to cause muscle spasms,
hypothermia, cardiovascular collapse and
death (Wilkinson, 1990). We have been
unable to trace reports of any direct
hepatotoxic effects in either cats or humans.
The clinical, and particularly the
histopathological changes were very different
between the three affected cats also making a
direct toxic effect less likely. One possible
explanation is that the well-recognised liver
abnormalities of hyperthyroid cats (Mooney
and others, 1992) may have been exacerbated
by anorexia resulting from iodine
administration, leading to hepatic lipidosis and
hepatopathy. Hepatic lipidosis has been
reported in a hyperthyroid cat (Center, 1994).
Another is the development of thyrotoxic storm
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as described in humans. This is usually of
unknown cause but may be associated with
increased iodine intake. Thyrotoxic storm
results in systolic hypertension and variable
gastrointestinal abnormalities including
splenomegaly, hepatomegaly, abnormalities in
liver function tests and jaundice, leading to
high mortality (Wartofsky, 1996). Survival is
improved by the administration of propranolol
although some workers have reported that
standard doses may not prevent storm
(Eriksson and others, 1977). Thyrotoxic storm
has not been reported in cats. To the authors'
knowledge, propranolol has not been reported
as causing liver abnormalities in either humans
or cats.
Group A cats showed no significant fall in TT4
concentrations whilst on propranolol alone.
However, there was a significant fall after
potassium iodate was introduced. By contrast,
TT3 concentrations fell significantly over the
first 10 day period of treatment in this group
and fell significantly further once potassium
iodate therapy was begun. The fall in TT3
concentrations after beginning propranolol was
presumably due to decreased peripheral
conversion of T4 to T3, as in humans so
managed (Cooper and others, 1982) whilst the
fall in both the TT4 and TT3 concentrations
after the addition of potassium iodate therapy
is likely to have been due to the Wolff-Chaikoff
effect. Four (36 per cent) cats in this group had
TT4 concentrations within the reference range
at the time of surgery. A further cat developed
reference range serum TT4 concentrations on
day 15, but showed a secondary rise on day
16. Eighty two per cent of cats in this group
had reference range TT3 concentrations at the
time of surgery compared with only 37.5 per
cent prior to drug administration.
Reverse T3, a metabolicaily inactive product,
results from deiodination of T4 in its inner ring.
In humans, rT3 is almost entirely derived from
extrathyroidal deiodination of T4 (Chopra,
1976), the remainder being synthesised de
novo in the thyroid gland. The situation in cats
is unknown. The reduction in rT3 that occurred
in this group during the study is likely to have
been a consequence of the fall in serum TT4
concentrations.
Group B cats failed to show a significant
reduction in serum TT4 concentrations
between days 1 and day 20, although there
was a significant difference between the days
over the treatment period. This was probably
due to the rapid fall in TT4 concentrations at
the beginning of potassium iodate therapy with
no further significant fall following this. Only
one cat had a reference range serum TT4
concentration at the time of surgery. Although
there was a significant difference in TT3
concentrations in Group B cats over the entire
treatment period, there was no significant fall
during the first 10 days of potassium iodate
therapy or combination therapy. This suggests
that the reduced serum TT3 concentrations
could not be further lowered by inhibition of
TT4 to TT3 conversion as propranolol therapy
alone significantly reduced TT3 concentrations
in group A. However, 75 per cent of the cats
with elevated serum TT3 concentrations in
group B on day 1 of the study had reference
range TT3 concentrations at the time of
surgery and there was no secondary rise in
serum TT3 concentrations in the remainder.
Interestingly, serum rT3 concentrations were
not significantly reduced at any time in this
group which had potassium iodate
administered for the whole study period,
compared with a signigicant reduction in the
cats in group A which only had the potassium
iodate for 10 days. The reasons for this are
unknown.
The clinical features of thyrotoxicosis improved
in all cats in both groups in this study, even in
the cat in which serum thyroid hormone
concentrations increased during therapy.
Although there was no significant difference
between the groups, the reduction in heart
rates in the group A and B cats in the first
halves of the trial respectively will have
resulted from different mechanisms. In group A
cats, it would have been the result of both p-
adrenoceptor blockade and a reduction in
serum TT3 concentrations due to the
propranolol. In group B cats, heart rates would
have been controlled by the rapid reduction of
serum thyroid hormone concentrations caused
by iodine released from potassium iodate.
These drug combinations induced reference
range TT4 concentrations in only five of the 21
cats (23.8 per cent) in this study (four in group
A [36.4 per cent] and one in group B [10 per
cent]. However, the reduction to reference
range TT3 concentrations was far higher (89
and 75 per cent of those with initially elevated
serum concentrations in groups A and B
respectively). In the cats which did not achieve
the respective reference ranges, TT4 and TT3
concentrations were markedly reduced in all
but one which became more thyrotoxic when
given potassium iodate. it has long been
recognised that in some humans, the use of
iodides exacerbates thyrotoxicosis, both alone
(Thompson and others, 1930) and rarely in
combination with propranolol (Linger and
others, 1981). Whilst this cat had uneventful
surgery and outcome it would be unwise to
proceed with potassium iodate treatment if the
signs of thyrotoxicosis were clearly worsening.
Another alternative regimen for the medical
management of hyperthyroidism in cats, using
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calcium ipodate, was recently published
(Murray and Peterson, 1997). The results are
difficult to compare with the present report but
33 per cent of their cats failed to respond and
the serum TT4 concentration remained high in
all cats, although the serum TT3 concentration
fell into the reference range in 66 per cent of
the cases. From these parameters, as a group,
the animals in the present study responded
more satisfactorily. However, no adverse
effects attributable to ipodate therapy were
reported in that study.
As previous studies had been carried out on
the two drugs individually in humans, it was
proposed that the combination of propranolol
and potassium iodide may be synergistic in
lowering serum thyroid hormone
concentrations of patients with Grave's disease
(Feek and others, 1980). The separate effects
of the two drugs have not been determined in
cats and no such conclusions can be made
from this study.
Cats in group A appeared to tolerate this
regimen better and more cats in this group had
reference range TT4 and TT3 concentrations
at the time of surgery.. Furthermore, Group A
cats had a significant reduction in TT3
concentrations over the treatment period whilst
Group B cats did not suggesting this is the
preferred treatment for clinical cases. As three
cats developed liver pathology, biochemical
monitoring of indices of hepatic damage should
be undertaken regularly, particularly during the
potassium iodate administration phase of the
treatment regimen.
In summary, the use of propranolol and
potassium iodate offer an alternative to
presurgical treatment with carbimazole in cats
that cannot tolerate this drug. The regimen
used in group A (propranolol for 20 days and
potassium iodate for the last 10 days) was both
the most effective in lowering serum thyroid
hormone concentrations and associated with
the least adverse effects and this is protocol
that we would recommend. Further studies are
required to determine whether the drug
combination has any additive or synergistic
effects. Longer term studies would be required
to assess the possibility of using these drugs
for long term medical control and to see
whether the cats' serum thyroid hormone
concentrations would eventually 'escape' from
the effects of the potassium iodate.
ACKNOWLEDGEMENTS
This study was funded by an award from
BSAVA's Petsavers. The authors are grateful
to Drs. G. J. Beckett and A. F. Howie of the
Department of Clinical Biochemistry, The
University of Edinburgh, for their advice
regarding the radioimmunoassays, Professor J.
I. Mason, Dr A. F. Smith and the staff of the
same department for allowing DJF access to
laboratory facilities, Ms Helen Evans of SCL
Biosciences for providing data on the validation
of the TT4 and TT3 radioimmunoassays for
use with cat serum, Dr. R. W. Else of the
Department of Veterinary Pathology, The
University of Edinburgh, for post-mortem and
histological examinations and Professor G. D.
Murray of the Medical Statistics Unit, The
University of Edinburgh, for statistical advice.
We should also like to thank the nurses of the
Small Animal Clinic, The Department of
Veterinary Clinical Studies, The University of
Edinburgh for their care of the cases while
hospitalised. During this study, DJF was
supported by the Feline Advisory Bureau and




Alderberth, A., Stenstrom, G., & Hasselgren, P.
(1987) The selective B-| - blocking agent
metoprolol compared with antithyroid drugs
and thyroxine as preoperative treatment of
patients with hyperthyroidism. Annals of
Surgery 205, 182 - 188.
Bernstein, M. (1984). Endocrine and urogenital
diseases of cats. Proceedings of the 51"
Meeting of the American Animal Hospital
Association, 139-140.
Birchard, S. J., Peterson, M. E. & Jacobson, A.
(1984) Surgical treatment of feline
hyperthyroidism. Journal of the American
Animal Hospital Association 20, 705 - 709.
Carlson, R. A. (1986) Presurgical management
and treatment of hyperthyroidism in two cats.
The Compendium of Continuing Education for
the Practicing Veterinarian. 8, 521 - 530.
Center, S.A. (1994) Hepatic lipidosis In :
Consultations In Feline Internal Medicine 2. Ed.
J.R. August. W.B. Saunders Co. Philadelphia,
pp. 87-101.
Chopra, I.J. (1976) An assessment of daily
turnover and significance of thyroidal secretion
of reverse T3. Journal of Clinical Investigation
58, 32 - 40.
Cooper, D. S. (1991) Treatment of
thyrotoxicosis. In: Werner and Ingbads The
Thyroid. A Fundamental and Clinical Text,
Sixth edn. Eds L. E. Braverman and R. D.
Utiger. J. B. Lippincott, Philadelphia, pp. 887-
916.
Cooper D.S., Daniels, G.H., Ladenson, P.W. &
Ridgway, E.C. (1982) Hyperthyroxinaemia in
patients treated with high - dose propranolol.
American Journal of Medicine 73, 867 - 871.
Emerson, E., Anderson, A.J., Howard, W.J. &
Utiger, R.D. (1975) Serum thyroxine and
triiodothyronine concentrations during iodide
treatment of hyperthyroidism. Journal of
Clinical Endocrinology and Metabolism 40, 33-
36.
Erikson, M.A., Rubenfeld, S., Garber, A.J. &
Kohler, P.O. (1977) Propranolol does not
prevent thyroid storm. New England Journal of
Medicine 296, 263 - 264.
Feek, C.M., Sawers, J.S.A., Irvine, W.J.,
Beckett, G.J., Ratciiffe, W. & Toft, A.D. (1980)
Combination of potassium iodide and
propranolol in preparation of patients with
Graves' disease for thyroid surgery. New
England Journal of Medicine 16, 883 - 885.
Feely, J. & Peden, N. (1984) Use of B -
adrenoreceptor blocking drugs in
hyperthyroidism. Drugs 27, 425 - 446.
Hoenig, M., Goldschmidt, M.H., Ferguson,
D.C., Koch, K, & Eymontt, M.J. (1982) Toxic
nodular goitre in the cat. Journal of Small
Animal Practice 23, 1-12.
Jacobs, G., Whittem, T., Sama, R., Calvert, C.
& Ferguson, D. (1997) Pharmokinetics of
propranolol in healthy cats during euthyroid
and hyperthyroid states. American Journal of
Veterinary Research. 58, 398 - 403.
Lennquist, S., Jorsto, E., Anderberg, B. &
Smeds, S. (1985) Betablockers compared to
antithyroid drugs as preoperative treatment in
hyperthyroidism: drug tolerance, complications
and postoperative thyroid function. Surgery
98,1141 - 1146.
Lotti, G„ Deiitala, G. & Devilla, L. (1977)
Reduction of plasma triiodothyronine (T3) by
propranolol. Clinical Endocrinology 6, 405-410.
Mooney, C.T., Thoday, K.L. & Doxey, D.L.
(1992) Carbimazole therapy of feline
hyperthyroidism. Journal of Small Animal
Practice 33, 228 - 235.
Murray, L.A.S. & Peterson, M.E. (1997) Ipodate
treatment of hyperthyroidism in cats. Journal of
the American Medical Association 211, 63 - 67.
O'Malley, B. P., Abbott, R.J., Barnett, D. B.,
Northoner, B. J. & Rosenthal, F. D. (1982)
Propranolol versus carbimazole as the sole
treatment for thyrotoxicosis. A consideration of
circulating thyroid hormone levels and tissue
thyroid function. Clinical Endocrinology
(Oxford), 16, 545- 552.
Parkin, A.J., Nisbet, A.P. & Bishop, N. (1982)
Vomiting due to gastric stasis as the
presenting feature of thyrotoxicosis.
Postgraduate Medical Journal 57, 405.
Peterson, M.E. & Gamble, D.A. (1988) Effect of
nonthyroidal illness on serum thyroxine
concentrations in cats: 494 cases. Journal of
the American Veterinary Medical Association
197, 1203 - 1208.
V,
Peterson, M.E., Graves, T.K. & Cavanagh, I.
(1987) Serum thyroid hormone concentrations
fluctuate in cats with hyperthyroidism. Journal
of Veterinary Internal Medicine 1, 142 -146.
Peterson, M.E., Kintzer, P.P., Cavanagh, P.G.,
Fox, P.R., Ferguson, D.C., Johnson, G.F. &
Becker, D.V. (1983) Feline hyperthyroidism:
Pretreatment clinical and laboratory evaluation
of 131 cases. Journal of the American
Veterinary Medical Association 183, 103 - 110.
Peterson, M.E., Kintzer, P.P. & Hurvitz, A.I.
(1988) Methimazole treatment of 262 cats with
9
Table 1




















1 13 DSH MN Vaccination 42.50 No No
2 14 DLH FN Vomiting 42.50 No No
3 15 DSH MN Weight loss 42.50 No No
4 14 DSH FN Weight loss 42.50 Yes Yes
5 16 DSH ' FN Vaccination 21.25 No No
6 9 DLH FN
. Weight loss 21.25 Yes No
7 7 DSH FN Weight loss 21.25 No No
8 8 DSH FN Polyphagia 21.25 No No
9 8 DSH FN Heart murmur 21.25 Yes Yes
10 12 DSH MN Weight loss 21.25 Yes Yes




















12 15 DLH MN Vomiting 42.50 No No
13 13 DSH FN PU/PD 42.50 No No
14 10 DSH FN Weight loss 42.50 No No
15 14 DSH MN Weight loss 42.50 • Yes No
16 14 DSH FN Polyphagia 21.25 No No
17 10 DLH FN Weight loss 21.25 Yes Yes
18 9 DSH FN Weight loss 21.25 Yes No
19 15 DLH MN Vaccination 21.25 No No
20 12 DSH FN Matted fur 21.25 No No
21 12 DSH FN Anorexia 21.25 Yes No
DLH - Domestic Long Hair
DSH - Domestic Short Hair
FN - Ovariohysterectomised female
MN - Castrated male
PD- Polydipsia
PU - Polyuria
TID- Three times daily
TT4- Total serum thyroxine concentration
Table 2
Comparison Of Heart Rates Of Cats In Groups A and B Before, During And At The End Of
Treatment Periods With Propranolol And Potassium lodate
Heart Rate (beats per minute)
Cat Group Day Range Median Quartiles
A 1 180 - 280 240 220 260
11 140 - 220 180 178 200
20 140-200 180 160 180
B 1 180-270 250 195 260
11 140-240 200 170 220
20 140-210 180 175 200
Group A cats had propranolol from days 1 to 20 and potassium iodate from days 11 to 20 inclusive.
Group B cats.had potassium iodate from days 1 to 20 and propranolol from days 11 to 20 inclusive
Table 3
Comparison Of Serum Thyroid Hormone Concentrations Of Cats In Groups A And B Before,
During And At the End Of The Treatment Periods With Propranolol And Potassium lodate.
Thyroid Hormone Concentration (nmol/I)
Thyroid Hormone Cat
Group
Day Range Median Quartiles
1 88.8 - 275.6 165.6 104.4 214.6
A 11 62.5 - 275.8 155.7 95.4 173.2
20 45.3-264.1 97.5 46.2 120.1
Thyroxine
1 88.6-313.2 219.7 105.7 285.3
B 11 39.2 - 279.5 120.1 26.3 220.4
20 39.5 - 453.5 120.1 84.0 212.9
—
1 3.16 - 5.26 4.06 3.48 4.37
A 11 2.47 - 4.74 2.84 2.68 3.49
20 1.18-2.60 1.76 1.36 2.38
Triiodothyronine
1 1.95 - 10.63 2.94 2.19 4.61
B 11 0.54 - 5.87 1.91 0.83 3.05
20 1.00-7.85 1.95 1.63 2.31
—
1 0.75 - 9.30 3.70 1.22 4.95
A 11 0.62 - 5.55 3.05 1.21 4.36
20 0.50 - 3.30 1.69 0.72 2.10
reverse Triiodothyronine
1 0.87 - 9.50 2.64 1.21 8.43
B 11 0.54 - 4.90 1.72 0.86 3.88
20 0.31 - 7.45 2.60 1.07 3.13
Group A cats had propranolol from days 1 to 20 and potassium iodate from days 11 to 20 inclusive.










































































































1234567890123415678920 Days BoxplotfGroupcatsshowingerumtotalT3concentra io svert20d ytri l period.Bottomftheboxr presentstfirquartile(Q1),th pfb xt ird quartile(Q3).Whiskersdefint ra geofthata.
